Sample ID 1,Structure 1,Log AC50 (M) 1,Sample Name 1,MOA 1,Sample ID 2,Structure 2,Log AC50 (M) 2,Sample Name 2,MOA 2,Gamma,Label
NCGC00386226-04,NC1=NC(N)=C2N=C(CC(CC#C)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=NC2=N1,-7.274421616144317,Pralatrexate,Dihydrofolate Reductase (DHFR) Inhibitors,NCGC00182868-16,O=C(NCCCCC1CCN(CC1)C(=O)C2=CC=CC=C2)\C=C\C3=CN=CC=C3,-7.531608356085238,Daporinad,NAMPT Inhibitor,0.980325,0
NCGC00345809-03,CC(C)C1=NN(C2=C1C(=O)NC(CC3=CC=C(OCCO)C=C3)=N2)C4=C(Cl)C=CC=C4Cl,-7.18160253455865,RGB-286147,CDK1/2/3/7/9 Inhibitor,NCGC00182868-16,O=C(NCCCCC1CCN(CC1)C(=O)C2=CC=CC=C2)\C=C\C3=CN=CC=C3,-7.531608356085238,Daporinad,NAMPT Inhibitor,0.970045,0
NCGC00345782-02,ClC1=CC=C(OCCCCCCN\C(NC2=CC=NC=C2)=N/C#N)C=C1,-8.331614083309999,GMX-1778,IKK beta Inhibitor,NCGC00182868-16,O=C(NCCCCC1CCN(CC1)C(=O)C2=CC=CC=C2)\C=C\C3=CN=CC=C3,-7.531608356085238,Daporinad,NAMPT Inhibitor,0.60559,1
NCGC00346644-04,O=C(CC1=CC=C(C=N1)C2=CC=C(OCCN3CCOCC3)C=C2)NCC4=CC=CC=C4,-7.43161051350816,KX-01,Src Kinase Inhibitor,NCGC00182868-16,O=C(NCCCCC1CCN(CC1)C(=O)C2=CC=CC=C2)\C=C\C3=CN=CC=C3,-7.531608356085238,Daporinad,NAMPT Inhibitor,0.90619,1
NCGC00242506-13,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)B(O)O,-7.43161051350816,Bortezomib,Proteasome Inhibitor,NCGC00182868-16,O=C(NCCCCC1CCN(CC1)C(=O)C2=CC=CC=C2)\C=C\C3=CN=CC=C3,-7.531608356085238,Daporinad,NAMPT Inhibitor,0.870655,1
NCGC00242514-13,COCCN1C(C)=[N+](CC2=NC=CN=C2)C3=C1C(=O)C4=CC=CC=C4C3=O,-8.381638068890123,Sepantronium bromide,Survivin Inhibitor,NCGC00182868-16,O=C(NCCCCC1CCN(CC1)C(=O)C2=CC=CC=C2)\C=C\C3=CN=CC=C3,-7.531608356085238,Daporinad,NAMPT Inhibitor,1.032325,0
NCGC00263017-01,COC1=C(OC)C=C2C(NCCN3CCOCC3)=NC(=NC2=C1)C4=CC=C(C=C4)N5CCN(C)CC5,-7.731609264370069,CPG-52364,"TLR 7, 8 and 9 Antagonist",NCGC00182868-16,O=C(NCCCCC1CCN(CC1)C(=O)C2=CC=CC=C2)\C=C\C3=CN=CC=C3,-7.531608356085238,Daporinad,NAMPT Inhibitor,1.06726,0
NCGC00346962-02,CN1C=C(C=N1)C2=CC=C3N=CC4=C(N(C(=O)C=C4)C5=CC6=C(CCN6C(=O)C=C)C=C5)C3=C2,-6.031605320261941,HMSL10077,BTK Inhibitor,NCGC00182868-16,O=C(NCCCCC1CCN(CC1)C(=O)C2=CC=CC=C2)\C=C\C3=CN=CC=C3,-7.531608356085238,Daporinad,NAMPT Inhibitor,0.953735,0
NCGC00346656-03,CCC1=C2N=C(C=C(NCC3=CC=C[N+]([O-])=C3)N2N=C1)N4CCCC[C@H]4CCO,-7.18160253455865,Dinaciclib (SCH727965),CDK1/2/5/9 Inhibitor,NCGC00182868-16,O=C(NCCCCC1CCN(CC1)C(=O)C2=CC=CC=C2)\C=C\C3=CN=CC=C3,-7.531608356085238,Daporinad,NAMPT Inhibitor,1.0484149999999999,0
NCGC00263183-11,CN1CCN(CC1)C2=CC=C(NC3=NC=C4C(=O)N(CC=C)N(C4=N3)C5=CC=CC(=N5)C(C)(C)O)C=C2,-5.881605633370822,MK-1775,Wee1 Kinase Inhibitor,NCGC00182868-16,O=C(NCCCCC1CCN(CC1)C(=O)C2=CC=CC=C2)\C=C\C3=CN=CC=C3,-7.531608356085238,Daporinad,NAMPT Inhibitor,0.9798600000000001,0
NCGC00263117-17,CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C3=CC=CC=C3N1,-6.231605379060391,Panobinostat,HDAC Inhibitor,NCGC00182868-16,O=C(NCCCCC1CCN(CC1)C(=O)C2=CC=CC=C2)\C=C\C3=CN=CC=C3,-7.531608356085238,Daporinad,NAMPT Inhibitor,0.647755,1
NCGC00249613-10,CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN2CCOCC2)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]4(C)CO4,-7.4816045202261074,Carfilzomib,Proteasome Inhibitor,NCGC00182868-16,O=C(NCCCCC1CCN(CC1)C(=O)C2=CC=CC=C2)\C=C\C3=CN=CC=C3,-7.531608356085238,Daporinad,NAMPT Inhibitor,0.363185,1
NCGC00346951-03,O=C1C2=CC=CC=C2[N+]3=C1C4=C(C=C3)C5=CC=CC=C5N4,-5.931605578511759,Fascaplysin,CDK4/6 Inhibitor,NCGC00182868-16,O=C(NCCCCC1CCN(CC1)C(=O)C2=CC=CC=C2)\C=C\C3=CN=CC=C3,-7.531608356085238,Daporinad,NAMPT Inhibitor,0.754665,1
NCGC00345799-07,COC[C@H](NC(=O)[C@H](COC)NC(=O)C1=CN=C(C)S1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)[C@@]3(C)CO3,-6.8316056515638195,Oprozomib,Proteasome Inhibitor,NCGC00182868-16,O=C(NCCCCC1CCN(CC1)C(=O)C2=CC=CC=C2)\C=C\C3=CN=CC=C3,-7.531608356085238,Daporinad,NAMPT Inhibitor,0.7344999999999999,1
NCGC00263222-02,CC1(C)OC2=C([C@H](NCC3=CC=CC=C3)[C@@H]1O)C(=O)C4=CC=CC=C4C2=O,-5.481605573349707,CAY-10581,IDO Inhibitor,NCGC00182868-16,O=C(NCCCCC1CCN(CC1)C(=O)C2=CC=CC=C2)\C=C\C3=CN=CC=C3,-7.531608356085238,Daporinad,NAMPT Inhibitor,0.868555,1
NCGC00242217-07,COC1=CC2=C(C=C1OC)N(C=N2)C3=CC(OCC4=C(C=CC=C4)C(F)(F)F)=C(S3)C(N)=O,-5.83160565156382,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00182868-16,O=C(NCCCCC1CCN(CC1)C(=O)C2=CC=CC=C2)\C=C\C3=CN=CC=C3,-7.531608356085238,Daporinad,NAMPT Inhibitor,0.850025,1
NCGC00347952-11,C\C(=N/NC(=S)N1CCC1)C2=NC=CC=C2,-8.731656086048936,NSC-319726,Mutant p53 Activator,NCGC00182868-16,O=C(NCCCCC1CCN(CC1)C(=O)C2=CC=CC=C2)\C=C\C3=CN=CC=C3,-7.531608356085238,Daporinad,NAMPT Inhibitor,0.9822,0
NCGC00346535-01,COC1=CC=C(C=C1)[S+]([O-])(=O)N(C(C)=O)C2=C(\C=C\C3=CC=N(=O)C=C3)C=CC=C2,-6.081605805570835,IVX-214,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00182868-16,O=C(NCCCCC1CCN(CC1)C(=O)C2=CC=CC=C2)\C=C\C3=CN=CC=C3,-7.531608356085238,Daporinad,NAMPT Inhibitor,0.97896,0
NCGC00345825-01,FC(F)C1=NN(C(=C1)C2=CN=C(NC(=O)C3CC3)S2)C4=C(Cl)C=CC=C4Cl,-5.931605578511759,BMS-3,LIMK Inhibitor,NCGC00182868-16,O=C(NCCCCC1CCN(CC1)C(=O)C2=CC=CC=C2)\C=C\C3=CN=CC=C3,-7.531608356085238,Daporinad,NAMPT Inhibitor,0.86819,1
NCGC00188382-05,CC(NCC1=CC=C2N(CC(C)(C)O)\C(NC2=C1)=N\C(=O)C3=CC=C(S3)C4=CNN=C4)C(C)(C)C,-6.131605396855363,NCGC00188382-01,ITK inhibitor,NCGC00182868-16,O=C(NCCCCC1CCN(CC1)C(=O)C2=CC=CC=C2)\C=C\C3=CN=CC=C3,-7.531608356085238,Daporinad,NAMPT Inhibitor,1.0901,0
NCGC00345852-02,CC(C)C1=C2N=C(N[C@@H](CO)[C@H](O)CO)C=C(NCC3=CC=CC=C3)N2N=C1,-6.231605379060391,BS-194,CDK1/2/5/9 Inhibitor,NCGC00182868-16,O=C(NCCCCC1CCN(CC1)C(=O)C2=CC=CC=C2)\C=C\C3=CN=CC=C3,-7.531608356085238,Daporinad,NAMPT Inhibitor,1.0646149999999999,0
NCGC00345823-01,CC(C)(N)C1=CC=C(C=C1)C2=NC3=C(C=CC=C3)N=C2C4=CC=CC=C4,-6.531605402012491,"Akt-I-1,2",AKT Inhibitor,NCGC00182868-16,O=C(NCCCCC1CCN(CC1)C(=O)C2=CC=CC=C2)\C=C\C3=CN=CC=C3,-7.531608356085238,Daporinad,NAMPT Inhibitor,1.06765,0
NCGC00263087-15,CC[C@H]1N(C(C)C)C2=NC(NC3=CC=C(C=C3OC)C(=O)NC4CCC(CC4)N5CCN(CC6CC6)CC5)=NC=C2N(C)C1=O,-6.981607443736785,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00182868-16,O=C(NCCCCC1CCN(CC1)C(=O)C2=CC=CC=C2)\C=C\C3=CN=CC=C3,-7.531608356085238,Daporinad,NAMPT Inhibitor,0.995335,0
NCGC00346969-01,CCOC(=O)N1CCN(CC1)[N+](\[O-])=N\OC2=CC=C(C=C2C#N)[N+]([O-])=O,-5.981605362312015,JS-59-4,nitric oxide donors,NCGC00182868-16,O=C(NCCCCC1CCN(CC1)C(=O)C2=CC=CC=C2)\C=C\C3=CN=CC=C3,-7.531608356085238,Daporinad,NAMPT Inhibitor,0.9937750000000001,0
NCGC00253438-01,CC[C@H]1N(C2CCCC2)C3=NC(NC4=CC=C(C=C4OC)C(=O)NC5CCN(C)CC5)=NC=C3N(C)C1=O,-7.4816045202261074,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00182868-16,O=C(NCCCCC1CCN(CC1)C(=O)C2=CC=CC=C2)\C=C\C3=CN=CC=C3,-7.531608356085238,Daporinad,NAMPT Inhibitor,0.9102300000000001,1
NCGC00346449-01,ClC1=CC=C(CCCOC2=NNC(=O)C(Br)=C2NCC3=CN=CC=C3)C=C1,-6.231605379060391,Parogrelil,Phosphodiesterase III/Va (PDE) Inhibitor,NCGC00182868-16,O=C(NCCCCC1CCN(CC1)C(=O)C2=CC=CC=C2)\C=C\C3=CN=CC=C3,-7.531608356085238,Daporinad,NAMPT Inhibitor,0.7792749999999999,1
NCGC00263112-06,C[C@@H](OC1=C(SC(=C1)N2C=NC3=C2C=C(CN4CCN(C)CC4)C=C3)C(N)=O)C5=CC=CC=C5C(F)(F)F,-7.281606275378642,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00182868-16,O=C(NCCCCC1CCN(CC1)C(=O)C2=CC=CC=C2)\C=C\C3=CN=CC=C3,-7.531608356085238,Daporinad,NAMPT Inhibitor,0.870115,1
NCGC00263110-02,CN(C(C)=O)C1(CCN(CCC[C@@]2(CCCN(C2)C(=O)C3=CC=CC=C3)C4=CC=C(Cl)C(Cl)=C4)CC1)C5=CC=CC=C5,-7.031605787340429,Osanetant,Tachykinin NK3 Antagonist,NCGC00182868-16,O=C(NCCCCC1CCN(CC1)C(=O)C2=CC=CC=C2)\C=C\C3=CN=CC=C3,-7.531608356085238,Daporinad,NAMPT Inhibitor,0.827245,1
NCGC00386226-04,NC1=NC(N)=C2N=C(CC(CC#C)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=NC2=N1,-7.274421616144317,Pralatrexate,Dihydrofolate Reductase (DHFR) Inhibitors,NCGC00345809-03,CC(C)C1=NN(C2=C1C(=O)NC(CC3=CC=C(OCCO)C=C3)=N2)C4=C(Cl)C=CC=C4Cl,-7.18160253455865,RGB-286147,CDK1/2/3/7/9 Inhibitor,1.0121099999999998,0
NCGC00346644-04,O=C(CC1=CC=C(C=N1)C2=CC=C(OCCN3CCOCC3)C=C2)NCC4=CC=CC=C4,-7.43161051350816,KX-01,Src Kinase Inhibitor,NCGC00345809-03,CC(C)C1=NN(C2=C1C(=O)NC(CC3=CC=C(OCCO)C=C3)=N2)C4=C(Cl)C=CC=C4Cl,-7.18160253455865,RGB-286147,CDK1/2/3/7/9 Inhibitor,0.8942649999999999,1
NCGC00346962-02,CN1C=C(C=N1)C2=CC=C3N=CC4=C(N(C(=O)C=C4)C5=CC6=C(CCN6C(=O)C=C)C=C5)C3=C2,-6.031605320261941,HMSL10077,BTK Inhibitor,NCGC00345809-03,CC(C)C1=NN(C2=C1C(=O)NC(CC3=CC=C(OCCO)C=C3)=N2)C4=C(Cl)C=CC=C4Cl,-7.18160253455865,RGB-286147,CDK1/2/3/7/9 Inhibitor,0.806735,1
NCGC00346656-03,CCC1=C2N=C(C=C(NCC3=CC=C[N+]([O-])=C3)N2N=C1)N4CCCC[C@H]4CCO,-7.18160253455865,Dinaciclib (SCH727965),CDK1/2/5/9 Inhibitor,NCGC00345809-03,CC(C)C1=NN(C2=C1C(=O)NC(CC3=CC=C(OCCO)C=C3)=N2)C4=C(Cl)C=CC=C4Cl,-7.18160253455865,RGB-286147,CDK1/2/3/7/9 Inhibitor,0.818225,1
NCGC00346951-03,O=C1C2=CC=CC=C2[N+]3=C1C4=C(C=C3)C5=CC=CC=C5N4,-5.931605578511759,Fascaplysin,CDK4/6 Inhibitor,NCGC00345809-03,CC(C)C1=NN(C2=C1C(=O)NC(CC3=CC=C(OCCO)C=C3)=N2)C4=C(Cl)C=CC=C4Cl,-7.18160253455865,RGB-286147,CDK1/2/3/7/9 Inhibitor,0.8144750000000001,1
NCGC00347952-11,C\C(=N/NC(=S)N1CCC1)C2=NC=CC=C2,-8.731656086048936,NSC-319726,Mutant p53 Activator,NCGC00345809-03,CC(C)C1=NN(C2=C1C(=O)NC(CC3=CC=C(OCCO)C=C3)=N2)C4=C(Cl)C=CC=C4Cl,-7.18160253455865,RGB-286147,CDK1/2/3/7/9 Inhibitor,0.8843749999999999,1
NCGC00346535-01,COC1=CC=C(C=C1)[S+]([O-])(=O)N(C(C)=O)C2=C(\C=C\C3=CC=N(=O)C=C3)C=CC=C2,-6.081605805570835,IVX-214,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00345809-03,CC(C)C1=NN(C2=C1C(=O)NC(CC3=CC=C(OCCO)C=C3)=N2)C4=C(Cl)C=CC=C4Cl,-7.18160253455865,RGB-286147,CDK1/2/3/7/9 Inhibitor,0.879775,1
NCGC00345825-01,FC(F)C1=NN(C(=C1)C2=CN=C(NC(=O)C3CC3)S2)C4=C(Cl)C=CC=C4Cl,-5.931605578511759,BMS-3,LIMK Inhibitor,NCGC00345809-03,CC(C)C1=NN(C2=C1C(=O)NC(CC3=CC=C(OCCO)C=C3)=N2)C4=C(Cl)C=CC=C4Cl,-7.18160253455865,RGB-286147,CDK1/2/3/7/9 Inhibitor,0.9132849999999999,1
NCGC00345852-02,CC(C)C1=C2N=C(N[C@@H](CO)[C@H](O)CO)C=C(NCC3=CC=CC=C3)N2N=C1,-6.231605379060391,BS-194,CDK1/2/5/9 Inhibitor,NCGC00345809-03,CC(C)C1=NN(C2=C1C(=O)NC(CC3=CC=C(OCCO)C=C3)=N2)C4=C(Cl)C=CC=C4Cl,-7.18160253455865,RGB-286147,CDK1/2/3/7/9 Inhibitor,0.7811300000000001,1
NCGC00345823-01,CC(C)(N)C1=CC=C(C=C1)C2=NC3=C(C=CC=C3)N=C2C4=CC=CC=C4,-6.531605402012491,"Akt-I-1,2",AKT Inhibitor,NCGC00345809-03,CC(C)C1=NN(C2=C1C(=O)NC(CC3=CC=C(OCCO)C=C3)=N2)C4=C(Cl)C=CC=C4Cl,-7.18160253455865,RGB-286147,CDK1/2/3/7/9 Inhibitor,0.826355,1
NCGC00346969-01,CCOC(=O)N1CCN(CC1)[N+](\[O-])=N\OC2=CC=C(C=C2C#N)[N+]([O-])=O,-5.981605362312015,JS-59-4,nitric oxide donors,NCGC00345809-03,CC(C)C1=NN(C2=C1C(=O)NC(CC3=CC=C(OCCO)C=C3)=N2)C4=C(Cl)C=CC=C4Cl,-7.18160253455865,RGB-286147,CDK1/2/3/7/9 Inhibitor,0.811085,1
NCGC00346449-01,ClC1=CC=C(CCCOC2=NNC(=O)C(Br)=C2NCC3=CN=CC=C3)C=C1,-6.231605379060391,Parogrelil,Phosphodiesterase III/Va (PDE) Inhibitor,NCGC00345809-03,CC(C)C1=NN(C2=C1C(=O)NC(CC3=CC=C(OCCO)C=C3)=N2)C4=C(Cl)C=CC=C4Cl,-7.18160253455865,RGB-286147,CDK1/2/3/7/9 Inhibitor,0.8405800000000001,1
NCGC00386226-04,NC1=NC(N)=C2N=C(CC(CC#C)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=NC2=N1,-7.274421616144317,Pralatrexate,Dihydrofolate Reductase (DHFR) Inhibitors,NCGC00345782-02,ClC1=CC=C(OCCCCCCN\C(NC2=CC=NC=C2)=N/C#N)C=C1,-8.331614083309999,GMX-1778,IKK beta Inhibitor,0.98488,0
NCGC00345809-03,CC(C)C1=NN(C2=C1C(=O)NC(CC3=CC=C(OCCO)C=C3)=N2)C4=C(Cl)C=CC=C4Cl,-7.18160253455865,RGB-286147,CDK1/2/3/7/9 Inhibitor,NCGC00345782-02,ClC1=CC=C(OCCCCCCN\C(NC2=CC=NC=C2)=N/C#N)C=C1,-8.331614083309999,GMX-1778,IKK beta Inhibitor,1.104005,0
NCGC00346644-04,O=C(CC1=CC=C(C=N1)C2=CC=C(OCCN3CCOCC3)C=C2)NCC4=CC=CC=C4,-7.43161051350816,KX-01,Src Kinase Inhibitor,NCGC00345782-02,ClC1=CC=C(OCCCCCCN\C(NC2=CC=NC=C2)=N/C#N)C=C1,-8.331614083309999,GMX-1778,IKK beta Inhibitor,1.02792,0
NCGC00346962-02,CN1C=C(C=N1)C2=CC=C3N=CC4=C(N(C(=O)C=C4)C5=CC6=C(CCN6C(=O)C=C)C=C5)C3=C2,-6.031605320261941,HMSL10077,BTK Inhibitor,NCGC00345782-02,ClC1=CC=C(OCCCCCCN\C(NC2=CC=NC=C2)=N/C#N)C=C1,-8.331614083309999,GMX-1778,IKK beta Inhibitor,0.9684899999999999,0
NCGC00346656-03,CCC1=C2N=C(C=C(NCC3=CC=C[N+]([O-])=C3)N2N=C1)N4CCCC[C@H]4CCO,-7.18160253455865,Dinaciclib (SCH727965),CDK1/2/5/9 Inhibitor,NCGC00345782-02,ClC1=CC=C(OCCCCCCN\C(NC2=CC=NC=C2)=N/C#N)C=C1,-8.331614083309999,GMX-1778,IKK beta Inhibitor,1.193215,0
NCGC00346951-03,O=C1C2=CC=CC=C2[N+]3=C1C4=C(C=C3)C5=CC=CC=C5N4,-5.931605578511759,Fascaplysin,CDK4/6 Inhibitor,NCGC00345782-02,ClC1=CC=C(OCCCCCCN\C(NC2=CC=NC=C2)=N/C#N)C=C1,-8.331614083309999,GMX-1778,IKK beta Inhibitor,0.8026899999999999,1
NCGC00345799-07,COC[C@H](NC(=O)[C@H](COC)NC(=O)C1=CN=C(C)S1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)[C@@]3(C)CO3,-6.8316056515638195,Oprozomib,Proteasome Inhibitor,NCGC00345782-02,ClC1=CC=C(OCCCCCCN\C(NC2=CC=NC=C2)=N/C#N)C=C1,-8.331614083309999,GMX-1778,IKK beta Inhibitor,0.673875,1
NCGC00347952-11,C\C(=N/NC(=S)N1CCC1)C2=NC=CC=C2,-8.731656086048936,NSC-319726,Mutant p53 Activator,NCGC00345782-02,ClC1=CC=C(OCCCCCCN\C(NC2=CC=NC=C2)=N/C#N)C=C1,-8.331614083309999,GMX-1778,IKK beta Inhibitor,0.9032,1
NCGC00346535-01,COC1=CC=C(C=C1)[S+]([O-])(=O)N(C(C)=O)C2=C(\C=C\C3=CC=N(=O)C=C3)C=CC=C2,-6.081605805570835,IVX-214,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00345782-02,ClC1=CC=C(OCCCCCCN\C(NC2=CC=NC=C2)=N/C#N)C=C1,-8.331614083309999,GMX-1778,IKK beta Inhibitor,0.95602,0
NCGC00345825-01,FC(F)C1=NN(C(=C1)C2=CN=C(NC(=O)C3CC3)S2)C4=C(Cl)C=CC=C4Cl,-5.931605578511759,BMS-3,LIMK Inhibitor,NCGC00345782-02,ClC1=CC=C(OCCCCCCN\C(NC2=CC=NC=C2)=N/C#N)C=C1,-8.331614083309999,GMX-1778,IKK beta Inhibitor,0.9461400000000001,1
NCGC00345852-02,CC(C)C1=C2N=C(N[C@@H](CO)[C@H](O)CO)C=C(NCC3=CC=CC=C3)N2N=C1,-6.231605379060391,BS-194,CDK1/2/5/9 Inhibitor,NCGC00345782-02,ClC1=CC=C(OCCCCCCN\C(NC2=CC=NC=C2)=N/C#N)C=C1,-8.331614083309999,GMX-1778,IKK beta Inhibitor,1.0287000000000002,0
NCGC00345823-01,CC(C)(N)C1=CC=C(C=C1)C2=NC3=C(C=CC=C3)N=C2C4=CC=CC=C4,-6.531605402012491,"Akt-I-1,2",AKT Inhibitor,NCGC00345782-02,ClC1=CC=C(OCCCCCCN\C(NC2=CC=NC=C2)=N/C#N)C=C1,-8.331614083309999,GMX-1778,IKK beta Inhibitor,0.898695,1
NCGC00346969-01,CCOC(=O)N1CCN(CC1)[N+](\[O-])=N\OC2=CC=C(C=C2C#N)[N+]([O-])=O,-5.981605362312015,JS-59-4,nitric oxide donors,NCGC00345782-02,ClC1=CC=C(OCCCCCCN\C(NC2=CC=NC=C2)=N/C#N)C=C1,-8.331614083309999,GMX-1778,IKK beta Inhibitor,0.940215,1
NCGC00346449-01,ClC1=CC=C(CCCOC2=NNC(=O)C(Br)=C2NCC3=CN=CC=C3)C=C1,-6.231605379060391,Parogrelil,Phosphodiesterase III/Va (PDE) Inhibitor,NCGC00345782-02,ClC1=CC=C(OCCCCCCN\C(NC2=CC=NC=C2)=N/C#N)C=C1,-8.331614083309999,GMX-1778,IKK beta Inhibitor,0.7721199999999999,1
NCGC00386226-04,NC1=NC(N)=C2N=C(CC(CC#C)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=NC2=N1,-7.274421616144317,Pralatrexate,Dihydrofolate Reductase (DHFR) Inhibitors,NCGC00346644-04,O=C(CC1=CC=C(C=N1)C2=CC=C(OCCN3CCOCC3)C=C2)NCC4=CC=CC=C4,-7.43161051350816,KX-01,Src Kinase Inhibitor,1.0975350000000001,0
NCGC00346962-02,CN1C=C(C=N1)C2=CC=C3N=CC4=C(N(C(=O)C=C4)C5=CC6=C(CCN6C(=O)C=C)C=C5)C3=C2,-6.031605320261941,HMSL10077,BTK Inhibitor,NCGC00346644-04,O=C(CC1=CC=C(C=N1)C2=CC=C(OCCN3CCOCC3)C=C2)NCC4=CC=CC=C4,-7.43161051350816,KX-01,Src Kinase Inhibitor,0.92041,1
NCGC00346656-03,CCC1=C2N=C(C=C(NCC3=CC=C[N+]([O-])=C3)N2N=C1)N4CCCC[C@H]4CCO,-7.18160253455865,Dinaciclib (SCH727965),CDK1/2/5/9 Inhibitor,NCGC00346644-04,O=C(CC1=CC=C(C=N1)C2=CC=C(OCCN3CCOCC3)C=C2)NCC4=CC=CC=C4,-7.43161051350816,KX-01,Src Kinase Inhibitor,0.901095,1
NCGC00346951-03,O=C1C2=CC=CC=C2[N+]3=C1C4=C(C=C3)C5=CC=CC=C5N4,-5.931605578511759,Fascaplysin,CDK4/6 Inhibitor,NCGC00346644-04,O=C(CC1=CC=C(C=N1)C2=CC=C(OCCN3CCOCC3)C=C2)NCC4=CC=CC=C4,-7.43161051350816,KX-01,Src Kinase Inhibitor,1.017665,0
NCGC00347952-11,C\C(=N/NC(=S)N1CCC1)C2=NC=CC=C2,-8.731656086048936,NSC-319726,Mutant p53 Activator,NCGC00346644-04,O=C(CC1=CC=C(C=N1)C2=CC=C(OCCN3CCOCC3)C=C2)NCC4=CC=CC=C4,-7.43161051350816,KX-01,Src Kinase Inhibitor,0.8888199999999999,1
NCGC00346969-01,CCOC(=O)N1CCN(CC1)[N+](\[O-])=N\OC2=CC=C(C=C2C#N)[N+]([O-])=O,-5.981605362312015,JS-59-4,nitric oxide donors,NCGC00346644-04,O=C(CC1=CC=C(C=N1)C2=CC=C(OCCN3CCOCC3)C=C2)NCC4=CC=CC=C4,-7.43161051350816,KX-01,Src Kinase Inhibitor,1.028235,0
NCGC00386226-04,NC1=NC(N)=C2N=C(CC(CC#C)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=NC2=N1,-7.274421616144317,Pralatrexate,Dihydrofolate Reductase (DHFR) Inhibitors,NCGC00242506-13,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)B(O)O,-7.43161051350816,Bortezomib,Proteasome Inhibitor,0.9956499999999999,0
NCGC00345809-03,CC(C)C1=NN(C2=C1C(=O)NC(CC3=CC=C(OCCO)C=C3)=N2)C4=C(Cl)C=CC=C4Cl,-7.18160253455865,RGB-286147,CDK1/2/3/7/9 Inhibitor,NCGC00242506-13,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)B(O)O,-7.43161051350816,Bortezomib,Proteasome Inhibitor,0.818285,1
NCGC00345782-02,ClC1=CC=C(OCCCCCCN\C(NC2=CC=NC=C2)=N/C#N)C=C1,-8.331614083309999,GMX-1778,IKK beta Inhibitor,NCGC00242506-13,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)B(O)O,-7.43161051350816,Bortezomib,Proteasome Inhibitor,0.828125,1
NCGC00346644-04,O=C(CC1=CC=C(C=N1)C2=CC=C(OCCN3CCOCC3)C=C2)NCC4=CC=CC=C4,-7.43161051350816,KX-01,Src Kinase Inhibitor,NCGC00242506-13,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)B(O)O,-7.43161051350816,Bortezomib,Proteasome Inhibitor,0.89331,1
NCGC00242514-13,COCCN1C(C)=[N+](CC2=NC=CN=C2)C3=C1C(=O)C4=CC=CC=C4C3=O,-8.381638068890123,Sepantronium bromide,Survivin Inhibitor,NCGC00242506-13,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)B(O)O,-7.43161051350816,Bortezomib,Proteasome Inhibitor,0.860355,1
NCGC00263017-01,COC1=C(OC)C=C2C(NCCN3CCOCC3)=NC(=NC2=C1)C4=CC=C(C=C4)N5CCN(C)CC5,-7.731609264370069,CPG-52364,"TLR 7, 8 and 9 Antagonist",NCGC00242506-13,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)B(O)O,-7.43161051350816,Bortezomib,Proteasome Inhibitor,0.9226300000000001,1
NCGC00346962-02,CN1C=C(C=N1)C2=CC=C3N=CC4=C(N(C(=O)C=C4)C5=CC6=C(CCN6C(=O)C=C)C=C5)C3=C2,-6.031605320261941,HMSL10077,BTK Inhibitor,NCGC00242506-13,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)B(O)O,-7.43161051350816,Bortezomib,Proteasome Inhibitor,0.911865,1
NCGC00346656-03,CCC1=C2N=C(C=C(NCC3=CC=C[N+]([O-])=C3)N2N=C1)N4CCCC[C@H]4CCO,-7.18160253455865,Dinaciclib (SCH727965),CDK1/2/5/9 Inhibitor,NCGC00242506-13,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)B(O)O,-7.43161051350816,Bortezomib,Proteasome Inhibitor,0.90078,1
NCGC00263183-11,CN1CCN(CC1)C2=CC=C(NC3=NC=C4C(=O)N(CC=C)N(C4=N3)C5=CC=CC(=N5)C(C)(C)O)C=C2,-5.881605633370822,MK-1775,Wee1 Kinase Inhibitor,NCGC00242506-13,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)B(O)O,-7.43161051350816,Bortezomib,Proteasome Inhibitor,1.02378,0
NCGC00263117-17,CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C3=CC=CC=C3N1,-6.231605379060391,Panobinostat,HDAC Inhibitor,NCGC00242506-13,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)B(O)O,-7.43161051350816,Bortezomib,Proteasome Inhibitor,0.354935,1
NCGC00249613-10,CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN2CCOCC2)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]4(C)CO4,-7.4816045202261074,Carfilzomib,Proteasome Inhibitor,NCGC00242506-13,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)B(O)O,-7.43161051350816,Bortezomib,Proteasome Inhibitor,0.38017999999999996,1
NCGC00346951-03,O=C1C2=CC=CC=C2[N+]3=C1C4=C(C=C3)C5=CC=CC=C5N4,-5.931605578511759,Fascaplysin,CDK4/6 Inhibitor,NCGC00242506-13,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)B(O)O,-7.43161051350816,Bortezomib,Proteasome Inhibitor,1.000365,0
NCGC00345799-07,COC[C@H](NC(=O)[C@H](COC)NC(=O)C1=CN=C(C)S1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)[C@@]3(C)CO3,-6.8316056515638195,Oprozomib,Proteasome Inhibitor,NCGC00242506-13,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)B(O)O,-7.43161051350816,Bortezomib,Proteasome Inhibitor,0.52598,1
NCGC00263222-02,CC1(C)OC2=C([C@H](NCC3=CC=CC=C3)[C@@H]1O)C(=O)C4=CC=CC=C4C2=O,-5.481605573349707,CAY-10581,IDO Inhibitor,NCGC00242506-13,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)B(O)O,-7.43161051350816,Bortezomib,Proteasome Inhibitor,0.8627849999999999,1
NCGC00347952-11,C\C(=N/NC(=S)N1CCC1)C2=NC=CC=C2,-8.731656086048936,NSC-319726,Mutant p53 Activator,NCGC00242506-13,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)B(O)O,-7.43161051350816,Bortezomib,Proteasome Inhibitor,0.9251,1
NCGC00346535-01,COC1=CC=C(C=C1)[S+]([O-])(=O)N(C(C)=O)C2=C(\C=C\C3=CC=N(=O)C=C3)C=CC=C2,-6.081605805570835,IVX-214,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00242506-13,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)B(O)O,-7.43161051350816,Bortezomib,Proteasome Inhibitor,0.91414,1
NCGC00345825-01,FC(F)C1=NN(C(=C1)C2=CN=C(NC(=O)C3CC3)S2)C4=C(Cl)C=CC=C4Cl,-5.931605578511759,BMS-3,LIMK Inhibitor,NCGC00242506-13,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)B(O)O,-7.43161051350816,Bortezomib,Proteasome Inhibitor,0.913135,1
NCGC00345852-02,CC(C)C1=C2N=C(N[C@@H](CO)[C@H](O)CO)C=C(NCC3=CC=CC=C3)N2N=C1,-6.231605379060391,BS-194,CDK1/2/5/9 Inhibitor,NCGC00242506-13,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)B(O)O,-7.43161051350816,Bortezomib,Proteasome Inhibitor,0.8810150000000001,1
NCGC00345823-01,CC(C)(N)C1=CC=C(C=C1)C2=NC3=C(C=CC=C3)N=C2C4=CC=CC=C4,-6.531605402012491,"Akt-I-1,2",AKT Inhibitor,NCGC00242506-13,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)B(O)O,-7.43161051350816,Bortezomib,Proteasome Inhibitor,0.940175,1
NCGC00263087-15,CC[C@H]1N(C(C)C)C2=NC(NC3=CC=C(C=C3OC)C(=O)NC4CCC(CC4)N5CCN(CC6CC6)CC5)=NC=C2N(C)C1=O,-6.981607443736785,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00242506-13,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)B(O)O,-7.43161051350816,Bortezomib,Proteasome Inhibitor,1.135255,0
NCGC00346969-01,CCOC(=O)N1CCN(CC1)[N+](\[O-])=N\OC2=CC=C(C=C2C#N)[N+]([O-])=O,-5.981605362312015,JS-59-4,nitric oxide donors,NCGC00242506-13,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)B(O)O,-7.43161051350816,Bortezomib,Proteasome Inhibitor,0.934335,1
NCGC00253438-01,CC[C@H]1N(C2CCCC2)C3=NC(NC4=CC=C(C=C4OC)C(=O)NC5CCN(C)CC5)=NC=C3N(C)C1=O,-7.4816045202261074,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00242506-13,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)B(O)O,-7.43161051350816,Bortezomib,Proteasome Inhibitor,1.1232199999999999,0
NCGC00346449-01,ClC1=CC=C(CCCOC2=NNC(=O)C(Br)=C2NCC3=CN=CC=C3)C=C1,-6.231605379060391,Parogrelil,Phosphodiesterase III/Va (PDE) Inhibitor,NCGC00242506-13,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)B(O)O,-7.43161051350816,Bortezomib,Proteasome Inhibitor,1.0060049999999998,0
NCGC00263112-06,C[C@@H](OC1=C(SC(=C1)N2C=NC3=C2C=C(CN4CCN(C)CC4)C=C3)C(N)=O)C5=CC=CC=C5C(F)(F)F,-7.281606275378642,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00242506-13,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)B(O)O,-7.43161051350816,Bortezomib,Proteasome Inhibitor,1.1360350000000001,0
NCGC00263110-02,CN(C(C)=O)C1(CCN(CCC[C@@]2(CCCN(C2)C(=O)C3=CC=CC=C3)C4=CC=C(Cl)C(Cl)=C4)CC1)C5=CC=CC=C5,-7.031605787340429,Osanetant,Tachykinin NK3 Antagonist,NCGC00242506-13,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)B(O)O,-7.43161051350816,Bortezomib,Proteasome Inhibitor,0.8852549999999999,1
NCGC00386226-04,NC1=NC(N)=C2N=C(CC(CC#C)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=NC2=N1,-7.274421616144317,Pralatrexate,Dihydrofolate Reductase (DHFR) Inhibitors,NCGC00242514-13,COCCN1C(C)=[N+](CC2=NC=CN=C2)C3=C1C(=O)C4=CC=CC=C4C3=O,-8.381638068890123,Sepantronium bromide,Survivin Inhibitor,0.9108400000000001,1
NCGC00345809-03,CC(C)C1=NN(C2=C1C(=O)NC(CC3=CC=C(OCCO)C=C3)=N2)C4=C(Cl)C=CC=C4Cl,-7.18160253455865,RGB-286147,CDK1/2/3/7/9 Inhibitor,NCGC00242514-13,COCCN1C(C)=[N+](CC2=NC=CN=C2)C3=C1C(=O)C4=CC=CC=C4C3=O,-8.381638068890123,Sepantronium bromide,Survivin Inhibitor,0.732275,1
NCGC00345782-02,ClC1=CC=C(OCCCCCCN\C(NC2=CC=NC=C2)=N/C#N)C=C1,-8.331614083309999,GMX-1778,IKK beta Inhibitor,NCGC00242514-13,COCCN1C(C)=[N+](CC2=NC=CN=C2)C3=C1C(=O)C4=CC=CC=C4C3=O,-8.381638068890123,Sepantronium bromide,Survivin Inhibitor,0.857205,1
NCGC00346644-04,O=C(CC1=CC=C(C=N1)C2=CC=C(OCCN3CCOCC3)C=C2)NCC4=CC=CC=C4,-7.43161051350816,KX-01,Src Kinase Inhibitor,NCGC00242514-13,COCCN1C(C)=[N+](CC2=NC=CN=C2)C3=C1C(=O)C4=CC=CC=C4C3=O,-8.381638068890123,Sepantronium bromide,Survivin Inhibitor,0.87887,1
NCGC00263017-01,COC1=C(OC)C=C2C(NCCN3CCOCC3)=NC(=NC2=C1)C4=CC=C(C=C4)N5CCN(C)CC5,-7.731609264370069,CPG-52364,"TLR 7, 8 and 9 Antagonist",NCGC00242514-13,COCCN1C(C)=[N+](CC2=NC=CN=C2)C3=C1C(=O)C4=CC=CC=C4C3=O,-8.381638068890123,Sepantronium bromide,Survivin Inhibitor,1.081345,0
NCGC00346962-02,CN1C=C(C=N1)C2=CC=C3N=CC4=C(N(C(=O)C=C4)C5=CC6=C(CCN6C(=O)C=C)C=C5)C3=C2,-6.031605320261941,HMSL10077,BTK Inhibitor,NCGC00242514-13,COCCN1C(C)=[N+](CC2=NC=CN=C2)C3=C1C(=O)C4=CC=CC=C4C3=O,-8.381638068890123,Sepantronium bromide,Survivin Inhibitor,0.862125,1
NCGC00346656-03,CCC1=C2N=C(C=C(NCC3=CC=C[N+]([O-])=C3)N2N=C1)N4CCCC[C@H]4CCO,-7.18160253455865,Dinaciclib (SCH727965),CDK1/2/5/9 Inhibitor,NCGC00242514-13,COCCN1C(C)=[N+](CC2=NC=CN=C2)C3=C1C(=O)C4=CC=CC=C4C3=O,-8.381638068890123,Sepantronium bromide,Survivin Inhibitor,0.77239,1
NCGC00263183-11,CN1CCN(CC1)C2=CC=C(NC3=NC=C4C(=O)N(CC=C)N(C4=N3)C5=CC=CC(=N5)C(C)(C)O)C=C2,-5.881605633370822,MK-1775,Wee1 Kinase Inhibitor,NCGC00242514-13,COCCN1C(C)=[N+](CC2=NC=CN=C2)C3=C1C(=O)C4=CC=CC=C4C3=O,-8.381638068890123,Sepantronium bromide,Survivin Inhibitor,1.00779,0
NCGC00263117-17,CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C3=CC=CC=C3N1,-6.231605379060391,Panobinostat,HDAC Inhibitor,NCGC00242514-13,COCCN1C(C)=[N+](CC2=NC=CN=C2)C3=C1C(=O)C4=CC=CC=C4C3=O,-8.381638068890123,Sepantronium bromide,Survivin Inhibitor,0.745895,1
NCGC00249613-10,CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN2CCOCC2)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]4(C)CO4,-7.4816045202261074,Carfilzomib,Proteasome Inhibitor,NCGC00242514-13,COCCN1C(C)=[N+](CC2=NC=CN=C2)C3=C1C(=O)C4=CC=CC=C4C3=O,-8.381638068890123,Sepantronium bromide,Survivin Inhibitor,0.65496,1
NCGC00346951-03,O=C1C2=CC=CC=C2[N+]3=C1C4=C(C=C3)C5=CC=CC=C5N4,-5.931605578511759,Fascaplysin,CDK4/6 Inhibitor,NCGC00242514-13,COCCN1C(C)=[N+](CC2=NC=CN=C2)C3=C1C(=O)C4=CC=CC=C4C3=O,-8.381638068890123,Sepantronium bromide,Survivin Inhibitor,0.857175,1
NCGC00345799-07,COC[C@H](NC(=O)[C@H](COC)NC(=O)C1=CN=C(C)S1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)[C@@]3(C)CO3,-6.8316056515638195,Oprozomib,Proteasome Inhibitor,NCGC00242514-13,COCCN1C(C)=[N+](CC2=NC=CN=C2)C3=C1C(=O)C4=CC=CC=C4C3=O,-8.381638068890123,Sepantronium bromide,Survivin Inhibitor,0.880405,1
NCGC00263222-02,CC1(C)OC2=C([C@H](NCC3=CC=CC=C3)[C@@H]1O)C(=O)C4=CC=CC=C4C2=O,-5.481605573349707,CAY-10581,IDO Inhibitor,NCGC00242514-13,COCCN1C(C)=[N+](CC2=NC=CN=C2)C3=C1C(=O)C4=CC=CC=C4C3=O,-8.381638068890123,Sepantronium bromide,Survivin Inhibitor,0.6710499999999999,1
NCGC00347952-11,C\C(=N/NC(=S)N1CCC1)C2=NC=CC=C2,-8.731656086048936,NSC-319726,Mutant p53 Activator,NCGC00242514-13,COCCN1C(C)=[N+](CC2=NC=CN=C2)C3=C1C(=O)C4=CC=CC=C4C3=O,-8.381638068890123,Sepantronium bromide,Survivin Inhibitor,0.575,1
NCGC00346535-01,COC1=CC=C(C=C1)[S+]([O-])(=O)N(C(C)=O)C2=C(\C=C\C3=CC=N(=O)C=C3)C=CC=C2,-6.081605805570835,IVX-214,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00242514-13,COCCN1C(C)=[N+](CC2=NC=CN=C2)C3=C1C(=O)C4=CC=CC=C4C3=O,-8.381638068890123,Sepantronium bromide,Survivin Inhibitor,0.768165,1
NCGC00345825-01,FC(F)C1=NN(C(=C1)C2=CN=C(NC(=O)C3CC3)S2)C4=C(Cl)C=CC=C4Cl,-5.931605578511759,BMS-3,LIMK Inhibitor,NCGC00242514-13,COCCN1C(C)=[N+](CC2=NC=CN=C2)C3=C1C(=O)C4=CC=CC=C4C3=O,-8.381638068890123,Sepantronium bromide,Survivin Inhibitor,0.8381350000000001,1
NCGC00345852-02,CC(C)C1=C2N=C(N[C@@H](CO)[C@H](O)CO)C=C(NCC3=CC=CC=C3)N2N=C1,-6.231605379060391,BS-194,CDK1/2/5/9 Inhibitor,NCGC00242514-13,COCCN1C(C)=[N+](CC2=NC=CN=C2)C3=C1C(=O)C4=CC=CC=C4C3=O,-8.381638068890123,Sepantronium bromide,Survivin Inhibitor,0.903565,1
NCGC00345823-01,CC(C)(N)C1=CC=C(C=C1)C2=NC3=C(C=CC=C3)N=C2C4=CC=CC=C4,-6.531605402012491,"Akt-I-1,2",AKT Inhibitor,NCGC00242514-13,COCCN1C(C)=[N+](CC2=NC=CN=C2)C3=C1C(=O)C4=CC=CC=C4C3=O,-8.381638068890123,Sepantronium bromide,Survivin Inhibitor,0.989525,0
NCGC00263087-15,CC[C@H]1N(C(C)C)C2=NC(NC3=CC=C(C=C3OC)C(=O)NC4CCC(CC4)N5CCN(CC6CC6)CC5)=NC=C2N(C)C1=O,-6.981607443736785,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00242514-13,COCCN1C(C)=[N+](CC2=NC=CN=C2)C3=C1C(=O)C4=CC=CC=C4C3=O,-8.381638068890123,Sepantronium bromide,Survivin Inhibitor,0.81177,1
NCGC00346969-01,CCOC(=O)N1CCN(CC1)[N+](\[O-])=N\OC2=CC=C(C=C2C#N)[N+]([O-])=O,-5.981605362312015,JS-59-4,nitric oxide donors,NCGC00242514-13,COCCN1C(C)=[N+](CC2=NC=CN=C2)C3=C1C(=O)C4=CC=CC=C4C3=O,-8.381638068890123,Sepantronium bromide,Survivin Inhibitor,0.94253,1
NCGC00253438-01,CC[C@H]1N(C2CCCC2)C3=NC(NC4=CC=C(C=C4OC)C(=O)NC5CCN(C)CC5)=NC=C3N(C)C1=O,-7.4816045202261074,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00242514-13,COCCN1C(C)=[N+](CC2=NC=CN=C2)C3=C1C(=O)C4=CC=CC=C4C3=O,-8.381638068890123,Sepantronium bromide,Survivin Inhibitor,0.872995,1
NCGC00346449-01,ClC1=CC=C(CCCOC2=NNC(=O)C(Br)=C2NCC3=CN=CC=C3)C=C1,-6.231605379060391,Parogrelil,Phosphodiesterase III/Va (PDE) Inhibitor,NCGC00242514-13,COCCN1C(C)=[N+](CC2=NC=CN=C2)C3=C1C(=O)C4=CC=CC=C4C3=O,-8.381638068890123,Sepantronium bromide,Survivin Inhibitor,1.139235,0
NCGC00263112-06,C[C@@H](OC1=C(SC(=C1)N2C=NC3=C2C=C(CN4CCN(C)CC4)C=C3)C(N)=O)C5=CC=CC=C5C(F)(F)F,-7.281606275378642,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00242514-13,COCCN1C(C)=[N+](CC2=NC=CN=C2)C3=C1C(=O)C4=CC=CC=C4C3=O,-8.381638068890123,Sepantronium bromide,Survivin Inhibitor,1.00962,0
NCGC00263110-02,CN(C(C)=O)C1(CCN(CCC[C@@]2(CCCN(C2)C(=O)C3=CC=CC=C3)C4=CC=C(Cl)C(Cl)=C4)CC1)C5=CC=CC=C5,-7.031605787340429,Osanetant,Tachykinin NK3 Antagonist,NCGC00242514-13,COCCN1C(C)=[N+](CC2=NC=CN=C2)C3=C1C(=O)C4=CC=CC=C4C3=O,-8.381638068890123,Sepantronium bromide,Survivin Inhibitor,0.849465,1
NCGC00182868-16,O=C(NCCCCC1CCN(CC1)C(=O)C2=CC=CC=C2)\C=C\C3=CN=CC=C3,-7.531608356085238,Daporinad,NAMPT Inhibitor,NCGC00025060-04,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O,-6.681604807136856,Methotrexate,Dihydrofolate Reductase (DHFR) Inhibitor,0.8902350000000001,1
NCGC00386226-04,NC1=NC(N)=C2N=C(CC(CC#C)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=NC2=N1,-7.274421616144317,Pralatrexate,Dihydrofolate Reductase (DHFR) Inhibitors,NCGC00025060-04,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O,-6.681604807136856,Methotrexate,Dihydrofolate Reductase (DHFR) Inhibitor,0.765185,1
NCGC00345809-03,CC(C)C1=NN(C2=C1C(=O)NC(CC3=CC=C(OCCO)C=C3)=N2)C4=C(Cl)C=CC=C4Cl,-7.18160253455865,RGB-286147,CDK1/2/3/7/9 Inhibitor,NCGC00025060-04,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O,-6.681604807136856,Methotrexate,Dihydrofolate Reductase (DHFR) Inhibitor,0.976075,0
NCGC00345782-02,ClC1=CC=C(OCCCCCCN\C(NC2=CC=NC=C2)=N/C#N)C=C1,-8.331614083309999,GMX-1778,IKK beta Inhibitor,NCGC00025060-04,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O,-6.681604807136856,Methotrexate,Dihydrofolate Reductase (DHFR) Inhibitor,0.97002,0
NCGC00346644-04,O=C(CC1=CC=C(C=N1)C2=CC=C(OCCN3CCOCC3)C=C2)NCC4=CC=CC=C4,-7.43161051350816,KX-01,Src Kinase Inhibitor,NCGC00025060-04,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O,-6.681604807136856,Methotrexate,Dihydrofolate Reductase (DHFR) Inhibitor,1.09971,0
NCGC00242506-13,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)B(O)O,-7.43161051350816,Bortezomib,Proteasome Inhibitor,NCGC00025060-04,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O,-6.681604807136856,Methotrexate,Dihydrofolate Reductase (DHFR) Inhibitor,1.1596449999999998,0
NCGC00242514-13,COCCN1C(C)=[N+](CC2=NC=CN=C2)C3=C1C(=O)C4=CC=CC=C4C3=O,-8.381638068890123,Sepantronium bromide,Survivin Inhibitor,NCGC00025060-04,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O,-6.681604807136856,Methotrexate,Dihydrofolate Reductase (DHFR) Inhibitor,1.14319,0
NCGC00263017-01,COC1=C(OC)C=C2C(NCCN3CCOCC3)=NC(=NC2=C1)C4=CC=C(C=C4)N5CCN(C)CC5,-7.731609264370069,CPG-52364,"TLR 7, 8 and 9 Antagonist",NCGC00025060-04,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O,-6.681604807136856,Methotrexate,Dihydrofolate Reductase (DHFR) Inhibitor,1.1182400000000001,0
NCGC00346962-02,CN1C=C(C=N1)C2=CC=C3N=CC4=C(N(C(=O)C=C4)C5=CC6=C(CCN6C(=O)C=C)C=C5)C3=C2,-6.031605320261941,HMSL10077,BTK Inhibitor,NCGC00025060-04,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O,-6.681604807136856,Methotrexate,Dihydrofolate Reductase (DHFR) Inhibitor,1.1014399999999998,0
NCGC00346656-03,CCC1=C2N=C(C=C(NCC3=CC=C[N+]([O-])=C3)N2N=C1)N4CCCC[C@H]4CCO,-7.18160253455865,Dinaciclib (SCH727965),CDK1/2/5/9 Inhibitor,NCGC00025060-04,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O,-6.681604807136856,Methotrexate,Dihydrofolate Reductase (DHFR) Inhibitor,1.02456,0
NCGC00263183-11,CN1CCN(CC1)C2=CC=C(NC3=NC=C4C(=O)N(CC=C)N(C4=N3)C5=CC=CC(=N5)C(C)(C)O)C=C2,-5.881605633370822,MK-1775,Wee1 Kinase Inhibitor,NCGC00025060-04,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O,-6.681604807136856,Methotrexate,Dihydrofolate Reductase (DHFR) Inhibitor,1.2679200000000002,0
NCGC00263117-17,CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C3=CC=CC=C3N1,-6.231605379060391,Panobinostat,HDAC Inhibitor,NCGC00025060-04,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O,-6.681604807136856,Methotrexate,Dihydrofolate Reductase (DHFR) Inhibitor,1.14089,0
NCGC00249613-10,CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN2CCOCC2)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]4(C)CO4,-7.4816045202261074,Carfilzomib,Proteasome Inhibitor,NCGC00025060-04,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O,-6.681604807136856,Methotrexate,Dihydrofolate Reductase (DHFR) Inhibitor,0.9638199999999999,0
NCGC00346951-03,O=C1C2=CC=CC=C2[N+]3=C1C4=C(C=C3)C5=CC=CC=C5N4,-5.931605578511759,Fascaplysin,CDK4/6 Inhibitor,NCGC00025060-04,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O,-6.681604807136856,Methotrexate,Dihydrofolate Reductase (DHFR) Inhibitor,1.020045,0
NCGC00345799-07,COC[C@H](NC(=O)[C@H](COC)NC(=O)C1=CN=C(C)S1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)[C@@]3(C)CO3,-6.8316056515638195,Oprozomib,Proteasome Inhibitor,NCGC00025060-04,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O,-6.681604807136856,Methotrexate,Dihydrofolate Reductase (DHFR) Inhibitor,1.2285149999999998,0
NCGC00263222-02,CC1(C)OC2=C([C@H](NCC3=CC=CC=C3)[C@@H]1O)C(=O)C4=CC=CC=C4C2=O,-5.481605573349707,CAY-10581,IDO Inhibitor,NCGC00025060-04,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O,-6.681604807136856,Methotrexate,Dihydrofolate Reductase (DHFR) Inhibitor,1.03599,0
NCGC00242217-07,COC1=CC2=C(C=C1OC)N(C=N2)C3=CC(OCC4=C(C=CC=C4)C(F)(F)F)=C(S3)C(N)=O,-5.83160565156382,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00025060-04,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O,-6.681604807136856,Methotrexate,Dihydrofolate Reductase (DHFR) Inhibitor,1.0374050000000001,0
NCGC00347952-11,C\C(=N/NC(=S)N1CCC1)C2=NC=CC=C2,-8.731656086048936,NSC-319726,Mutant p53 Activator,NCGC00025060-04,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O,-6.681604807136856,Methotrexate,Dihydrofolate Reductase (DHFR) Inhibitor,1.2105000000000001,0
NCGC00346535-01,COC1=CC=C(C=C1)[S+]([O-])(=O)N(C(C)=O)C2=C(\C=C\C3=CC=N(=O)C=C3)C=CC=C2,-6.081605805570835,IVX-214,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00025060-04,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O,-6.681604807136856,Methotrexate,Dihydrofolate Reductase (DHFR) Inhibitor,1.1420400000000002,0
NCGC00345825-01,FC(F)C1=NN(C(=C1)C2=CN=C(NC(=O)C3CC3)S2)C4=C(Cl)C=CC=C4Cl,-5.931605578511759,BMS-3,LIMK Inhibitor,NCGC00025060-04,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O,-6.681604807136856,Methotrexate,Dihydrofolate Reductase (DHFR) Inhibitor,1.11802,0
NCGC00188382-05,CC(NCC1=CC=C2N(CC(C)(C)O)\C(NC2=C1)=N\C(=O)C3=CC=C(S3)C4=CNN=C4)C(C)(C)C,-6.131605396855363,NCGC00188382-01,ITK inhibitor,NCGC00025060-04,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O,-6.681604807136856,Methotrexate,Dihydrofolate Reductase (DHFR) Inhibitor,1.151955,0
NCGC00345852-02,CC(C)C1=C2N=C(N[C@@H](CO)[C@H](O)CO)C=C(NCC3=CC=CC=C3)N2N=C1,-6.231605379060391,BS-194,CDK1/2/5/9 Inhibitor,NCGC00025060-04,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O,-6.681604807136856,Methotrexate,Dihydrofolate Reductase (DHFR) Inhibitor,1.07261,0
NCGC00345823-01,CC(C)(N)C1=CC=C(C=C1)C2=NC3=C(C=CC=C3)N=C2C4=CC=CC=C4,-6.531605402012491,"Akt-I-1,2",AKT Inhibitor,NCGC00025060-04,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O,-6.681604807136856,Methotrexate,Dihydrofolate Reductase (DHFR) Inhibitor,1.0429650000000001,0
NCGC00263087-15,CC[C@H]1N(C(C)C)C2=NC(NC3=CC=C(C=C3OC)C(=O)NC4CCC(CC4)N5CCN(CC6CC6)CC5)=NC=C2N(C)C1=O,-6.981607443736785,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00025060-04,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O,-6.681604807136856,Methotrexate,Dihydrofolate Reductase (DHFR) Inhibitor,1.211915,0
NCGC00346969-01,CCOC(=O)N1CCN(CC1)[N+](\[O-])=N\OC2=CC=C(C=C2C#N)[N+]([O-])=O,-5.981605362312015,JS-59-4,nitric oxide donors,NCGC00025060-04,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O,-6.681604807136856,Methotrexate,Dihydrofolate Reductase (DHFR) Inhibitor,1.055835,0
NCGC00253438-01,CC[C@H]1N(C2CCCC2)C3=NC(NC4=CC=C(C=C4OC)C(=O)NC5CCN(C)CC5)=NC=C3N(C)C1=O,-7.4816045202261074,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00025060-04,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O,-6.681604807136856,Methotrexate,Dihydrofolate Reductase (DHFR) Inhibitor,1.243945,0
NCGC00346449-01,ClC1=CC=C(CCCOC2=NNC(=O)C(Br)=C2NCC3=CN=CC=C3)C=C1,-6.231605379060391,Parogrelil,Phosphodiesterase III/Va (PDE) Inhibitor,NCGC00025060-04,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O,-6.681604807136856,Methotrexate,Dihydrofolate Reductase (DHFR) Inhibitor,0.9272099999999999,1
NCGC00263112-06,C[C@@H](OC1=C(SC(=C1)N2C=NC3=C2C=C(CN4CCN(C)CC4)C=C3)C(N)=O)C5=CC=CC=C5C(F)(F)F,-7.281606275378642,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00025060-04,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O,-6.681604807136856,Methotrexate,Dihydrofolate Reductase (DHFR) Inhibitor,1.2485849999999998,0
NCGC00263110-02,CN(C(C)=O)C1(CCN(CCC[C@@]2(CCCN(C2)C(=O)C3=CC=CC=C3)C4=CC=C(Cl)C(Cl)=C4)CC1)C5=CC=CC=C5,-7.031605787340429,Osanetant,Tachykinin NK3 Antagonist,NCGC00025060-04,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O,-6.681604807136856,Methotrexate,Dihydrofolate Reductase (DHFR) Inhibitor,1.0028299999999999,0
NCGC00386226-04,NC1=NC(N)=C2N=C(CC(CC#C)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=NC2=N1,-7.274421616144317,Pralatrexate,Dihydrofolate Reductase (DHFR) Inhibitors,NCGC00263017-01,COC1=C(OC)C=C2C(NCCN3CCOCC3)=NC(=NC2=C1)C4=CC=C(C=C4)N5CCN(C)CC5,-7.731609264370069,CPG-52364,"TLR 7, 8 and 9 Antagonist",1.066795,0
NCGC00345809-03,CC(C)C1=NN(C2=C1C(=O)NC(CC3=CC=C(OCCO)C=C3)=N2)C4=C(Cl)C=CC=C4Cl,-7.18160253455865,RGB-286147,CDK1/2/3/7/9 Inhibitor,NCGC00263017-01,COC1=C(OC)C=C2C(NCCN3CCOCC3)=NC(=NC2=C1)C4=CC=C(C=C4)N5CCN(C)CC5,-7.731609264370069,CPG-52364,"TLR 7, 8 and 9 Antagonist",0.9233899999999999,1
NCGC00345782-02,ClC1=CC=C(OCCCCCCN\C(NC2=CC=NC=C2)=N/C#N)C=C1,-8.331614083309999,GMX-1778,IKK beta Inhibitor,NCGC00263017-01,COC1=C(OC)C=C2C(NCCN3CCOCC3)=NC(=NC2=C1)C4=CC=C(C=C4)N5CCN(C)CC5,-7.731609264370069,CPG-52364,"TLR 7, 8 and 9 Antagonist",1.0218500000000001,0
NCGC00346644-04,O=C(CC1=CC=C(C=N1)C2=CC=C(OCCN3CCOCC3)C=C2)NCC4=CC=CC=C4,-7.43161051350816,KX-01,Src Kinase Inhibitor,NCGC00263017-01,COC1=C(OC)C=C2C(NCCN3CCOCC3)=NC(=NC2=C1)C4=CC=C(C=C4)N5CCN(C)CC5,-7.731609264370069,CPG-52364,"TLR 7, 8 and 9 Antagonist",1.0635050000000001,0
NCGC00346962-02,CN1C=C(C=N1)C2=CC=C3N=CC4=C(N(C(=O)C=C4)C5=CC6=C(CCN6C(=O)C=C)C=C5)C3=C2,-6.031605320261941,HMSL10077,BTK Inhibitor,NCGC00263017-01,COC1=C(OC)C=C2C(NCCN3CCOCC3)=NC(=NC2=C1)C4=CC=C(C=C4)N5CCN(C)CC5,-7.731609264370069,CPG-52364,"TLR 7, 8 and 9 Antagonist",1.00271,0
NCGC00346656-03,CCC1=C2N=C(C=C(NCC3=CC=C[N+]([O-])=C3)N2N=C1)N4CCCC[C@H]4CCO,-7.18160253455865,Dinaciclib (SCH727965),CDK1/2/5/9 Inhibitor,NCGC00263017-01,COC1=C(OC)C=C2C(NCCN3CCOCC3)=NC(=NC2=C1)C4=CC=C(C=C4)N5CCN(C)CC5,-7.731609264370069,CPG-52364,"TLR 7, 8 and 9 Antagonist",0.945705,1
NCGC00263183-11,CN1CCN(CC1)C2=CC=C(NC3=NC=C4C(=O)N(CC=C)N(C4=N3)C5=CC=CC(=N5)C(C)(C)O)C=C2,-5.881605633370822,MK-1775,Wee1 Kinase Inhibitor,NCGC00263017-01,COC1=C(OC)C=C2C(NCCN3CCOCC3)=NC(=NC2=C1)C4=CC=C(C=C4)N5CCN(C)CC5,-7.731609264370069,CPG-52364,"TLR 7, 8 and 9 Antagonist",0.9178,1
NCGC00263117-17,CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C3=CC=CC=C3N1,-6.231605379060391,Panobinostat,HDAC Inhibitor,NCGC00263017-01,COC1=C(OC)C=C2C(NCCN3CCOCC3)=NC(=NC2=C1)C4=CC=C(C=C4)N5CCN(C)CC5,-7.731609264370069,CPG-52364,"TLR 7, 8 and 9 Antagonist",0.9038600000000001,1
NCGC00346951-03,O=C1C2=CC=CC=C2[N+]3=C1C4=C(C=C3)C5=CC=CC=C5N4,-5.931605578511759,Fascaplysin,CDK4/6 Inhibitor,NCGC00263017-01,COC1=C(OC)C=C2C(NCCN3CCOCC3)=NC(=NC2=C1)C4=CC=C(C=C4)N5CCN(C)CC5,-7.731609264370069,CPG-52364,"TLR 7, 8 and 9 Antagonist",0.909155,1
NCGC00345799-07,COC[C@H](NC(=O)[C@H](COC)NC(=O)C1=CN=C(C)S1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)[C@@]3(C)CO3,-6.8316056515638195,Oprozomib,Proteasome Inhibitor,NCGC00263017-01,COC1=C(OC)C=C2C(NCCN3CCOCC3)=NC(=NC2=C1)C4=CC=C(C=C4)N5CCN(C)CC5,-7.731609264370069,CPG-52364,"TLR 7, 8 and 9 Antagonist",0.955265,0
NCGC00263222-02,CC1(C)OC2=C([C@H](NCC3=CC=CC=C3)[C@@H]1O)C(=O)C4=CC=CC=C4C2=O,-5.481605573349707,CAY-10581,IDO Inhibitor,NCGC00263017-01,COC1=C(OC)C=C2C(NCCN3CCOCC3)=NC(=NC2=C1)C4=CC=C(C=C4)N5CCN(C)CC5,-7.731609264370069,CPG-52364,"TLR 7, 8 and 9 Antagonist",0.920425,1
NCGC00347952-11,C\C(=N/NC(=S)N1CCC1)C2=NC=CC=C2,-8.731656086048936,NSC-319726,Mutant p53 Activator,NCGC00263017-01,COC1=C(OC)C=C2C(NCCN3CCOCC3)=NC(=NC2=C1)C4=CC=C(C=C4)N5CCN(C)CC5,-7.731609264370069,CPG-52364,"TLR 7, 8 and 9 Antagonist",0.86963,1
NCGC00346535-01,COC1=CC=C(C=C1)[S+]([O-])(=O)N(C(C)=O)C2=C(\C=C\C3=CC=N(=O)C=C3)C=CC=C2,-6.081605805570835,IVX-214,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00263017-01,COC1=C(OC)C=C2C(NCCN3CCOCC3)=NC(=NC2=C1)C4=CC=C(C=C4)N5CCN(C)CC5,-7.731609264370069,CPG-52364,"TLR 7, 8 and 9 Antagonist",0.98979,0
NCGC00345825-01,FC(F)C1=NN(C(=C1)C2=CN=C(NC(=O)C3CC3)S2)C4=C(Cl)C=CC=C4Cl,-5.931605578511759,BMS-3,LIMK Inhibitor,NCGC00263017-01,COC1=C(OC)C=C2C(NCCN3CCOCC3)=NC(=NC2=C1)C4=CC=C(C=C4)N5CCN(C)CC5,-7.731609264370069,CPG-52364,"TLR 7, 8 and 9 Antagonist",0.9113,1
NCGC00345852-02,CC(C)C1=C2N=C(N[C@@H](CO)[C@H](O)CO)C=C(NCC3=CC=CC=C3)N2N=C1,-6.231605379060391,BS-194,CDK1/2/5/9 Inhibitor,NCGC00263017-01,COC1=C(OC)C=C2C(NCCN3CCOCC3)=NC(=NC2=C1)C4=CC=C(C=C4)N5CCN(C)CC5,-7.731609264370069,CPG-52364,"TLR 7, 8 and 9 Antagonist",1.036475,0
NCGC00345823-01,CC(C)(N)C1=CC=C(C=C1)C2=NC3=C(C=CC=C3)N=C2C4=CC=CC=C4,-6.531605402012491,"Akt-I-1,2",AKT Inhibitor,NCGC00263017-01,COC1=C(OC)C=C2C(NCCN3CCOCC3)=NC(=NC2=C1)C4=CC=C(C=C4)N5CCN(C)CC5,-7.731609264370069,CPG-52364,"TLR 7, 8 and 9 Antagonist",1.02753,0
NCGC00263087-15,CC[C@H]1N(C(C)C)C2=NC(NC3=CC=C(C=C3OC)C(=O)NC4CCC(CC4)N5CCN(CC6CC6)CC5)=NC=C2N(C)C1=O,-6.981607443736785,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00263017-01,COC1=C(OC)C=C2C(NCCN3CCOCC3)=NC(=NC2=C1)C4=CC=C(C=C4)N5CCN(C)CC5,-7.731609264370069,CPG-52364,"TLR 7, 8 and 9 Antagonist",1.1267800000000001,0
NCGC00346969-01,CCOC(=O)N1CCN(CC1)[N+](\[O-])=N\OC2=CC=C(C=C2C#N)[N+]([O-])=O,-5.981605362312015,JS-59-4,nitric oxide donors,NCGC00263017-01,COC1=C(OC)C=C2C(NCCN3CCOCC3)=NC(=NC2=C1)C4=CC=C(C=C4)N5CCN(C)CC5,-7.731609264370069,CPG-52364,"TLR 7, 8 and 9 Antagonist",1.03784,0
NCGC00346449-01,ClC1=CC=C(CCCOC2=NNC(=O)C(Br)=C2NCC3=CN=CC=C3)C=C1,-6.231605379060391,Parogrelil,Phosphodiesterase III/Va (PDE) Inhibitor,NCGC00263017-01,COC1=C(OC)C=C2C(NCCN3CCOCC3)=NC(=NC2=C1)C4=CC=C(C=C4)N5CCN(C)CC5,-7.731609264370069,CPG-52364,"TLR 7, 8 and 9 Antagonist",0.898255,1
NCGC00263112-06,C[C@@H](OC1=C(SC(=C1)N2C=NC3=C2C=C(CN4CCN(C)CC4)C=C3)C(N)=O)C5=CC=CC=C5C(F)(F)F,-7.281606275378642,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00263017-01,COC1=C(OC)C=C2C(NCCN3CCOCC3)=NC(=NC2=C1)C4=CC=C(C=C4)N5CCN(C)CC5,-7.731609264370069,CPG-52364,"TLR 7, 8 and 9 Antagonist",1.081105,0
NCGC00263110-02,CN(C(C)=O)C1(CCN(CCC[C@@]2(CCCN(C2)C(=O)C3=CC=CC=C3)C4=CC=C(Cl)C(Cl)=C4)CC1)C5=CC=CC=C5,-7.031605787340429,Osanetant,Tachykinin NK3 Antagonist,NCGC00263017-01,COC1=C(OC)C=C2C(NCCN3CCOCC3)=NC(=NC2=C1)C4=CC=C(C=C4)N5CCN(C)CC5,-7.731609264370069,CPG-52364,"TLR 7, 8 and 9 Antagonist",0.9253899999999999,1
NCGC00386226-04,NC1=NC(N)=C2N=C(CC(CC#C)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=NC2=N1,-7.274421616144317,Pralatrexate,Dihydrofolate Reductase (DHFR) Inhibitors,NCGC00346962-02,CN1C=C(C=N1)C2=CC=C3N=CC4=C(N(C(=O)C=C4)C5=CC6=C(CCN6C(=O)C=C)C=C5)C3=C2,-6.031605320261941,HMSL10077,BTK Inhibitor,0.9734349999999999,0
NCGC00347952-11,C\C(=N/NC(=S)N1CCC1)C2=NC=CC=C2,-8.731656086048936,NSC-319726,Mutant p53 Activator,NCGC00346962-02,CN1C=C(C=N1)C2=CC=C3N=CC4=C(N(C(=O)C=C4)C5=CC6=C(CCN6C(=O)C=C)C=C5)C3=C2,-6.031605320261941,HMSL10077,BTK Inhibitor,0.9475100000000001,1
NCGC00346969-01,CCOC(=O)N1CCN(CC1)[N+](\[O-])=N\OC2=CC=C(C=C2C#N)[N+]([O-])=O,-5.981605362312015,JS-59-4,nitric oxide donors,NCGC00346962-02,CN1C=C(C=N1)C2=CC=C3N=CC4=C(N(C(=O)C=C4)C5=CC6=C(CCN6C(=O)C=C)C=C5)C3=C2,-6.031605320261941,HMSL10077,BTK Inhibitor,0.9662949999999999,0
NCGC00386226-04,NC1=NC(N)=C2N=C(CC(CC#C)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=NC2=N1,-7.274421616144317,Pralatrexate,Dihydrofolate Reductase (DHFR) Inhibitors,NCGC00346656-03,CCC1=C2N=C(C=C(NCC3=CC=C[N+]([O-])=C3)N2N=C1)N4CCCC[C@H]4CCO,-7.18160253455865,Dinaciclib (SCH727965),CDK1/2/5/9 Inhibitor,0.93477,1
NCGC00346962-02,CN1C=C(C=N1)C2=CC=C3N=CC4=C(N(C(=O)C=C4)C5=CC6=C(CCN6C(=O)C=C)C=C5)C3=C2,-6.031605320261941,HMSL10077,BTK Inhibitor,NCGC00346656-03,CCC1=C2N=C(C=C(NCC3=CC=C[N+]([O-])=C3)N2N=C1)N4CCCC[C@H]4CCO,-7.18160253455865,Dinaciclib (SCH727965),CDK1/2/5/9 Inhibitor,0.8917949999999999,1
NCGC00346951-03,O=C1C2=CC=CC=C2[N+]3=C1C4=C(C=C3)C5=CC=CC=C5N4,-5.931605578511759,Fascaplysin,CDK4/6 Inhibitor,NCGC00346656-03,CCC1=C2N=C(C=C(NCC3=CC=C[N+]([O-])=C3)N2N=C1)N4CCCC[C@H]4CCO,-7.18160253455865,Dinaciclib (SCH727965),CDK1/2/5/9 Inhibitor,0.945535,1
NCGC00347952-11,C\C(=N/NC(=S)N1CCC1)C2=NC=CC=C2,-8.731656086048936,NSC-319726,Mutant p53 Activator,NCGC00346656-03,CCC1=C2N=C(C=C(NCC3=CC=C[N+]([O-])=C3)N2N=C1)N4CCCC[C@H]4CCO,-7.18160253455865,Dinaciclib (SCH727965),CDK1/2/5/9 Inhibitor,0.7949200000000001,1
NCGC00346969-01,CCOC(=O)N1CCN(CC1)[N+](\[O-])=N\OC2=CC=C(C=C2C#N)[N+]([O-])=O,-5.981605362312015,JS-59-4,nitric oxide donors,NCGC00346656-03,CCC1=C2N=C(C=C(NCC3=CC=C[N+]([O-])=C3)N2N=C1)N4CCCC[C@H]4CCO,-7.18160253455865,Dinaciclib (SCH727965),CDK1/2/5/9 Inhibitor,0.90188,1
NCGC00386226-04,NC1=NC(N)=C2N=C(CC(CC#C)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=NC2=N1,-7.274421616144317,Pralatrexate,Dihydrofolate Reductase (DHFR) Inhibitors,NCGC00263183-11,CN1CCN(CC1)C2=CC=C(NC3=NC=C4C(=O)N(CC=C)N(C4=N3)C5=CC=CC(=N5)C(C)(C)O)C=C2,-5.881605633370822,MK-1775,Wee1 Kinase Inhibitor,1.0729250000000001,0
NCGC00345809-03,CC(C)C1=NN(C2=C1C(=O)NC(CC3=CC=C(OCCO)C=C3)=N2)C4=C(Cl)C=CC=C4Cl,-7.18160253455865,RGB-286147,CDK1/2/3/7/9 Inhibitor,NCGC00263183-11,CN1CCN(CC1)C2=CC=C(NC3=NC=C4C(=O)N(CC=C)N(C4=N3)C5=CC=CC(=N5)C(C)(C)O)C=C2,-5.881605633370822,MK-1775,Wee1 Kinase Inhibitor,0.857425,1
NCGC00345782-02,ClC1=CC=C(OCCCCCCN\C(NC2=CC=NC=C2)=N/C#N)C=C1,-8.331614083309999,GMX-1778,IKK beta Inhibitor,NCGC00263183-11,CN1CCN(CC1)C2=CC=C(NC3=NC=C4C(=O)N(CC=C)N(C4=N3)C5=CC=CC(=N5)C(C)(C)O)C=C2,-5.881605633370822,MK-1775,Wee1 Kinase Inhibitor,0.89839,1
NCGC00346644-04,O=C(CC1=CC=C(C=N1)C2=CC=C(OCCN3CCOCC3)C=C2)NCC4=CC=CC=C4,-7.43161051350816,KX-01,Src Kinase Inhibitor,NCGC00263183-11,CN1CCN(CC1)C2=CC=C(NC3=NC=C4C(=O)N(CC=C)N(C4=N3)C5=CC=CC(=N5)C(C)(C)O)C=C2,-5.881605633370822,MK-1775,Wee1 Kinase Inhibitor,0.9210200000000001,1
NCGC00346962-02,CN1C=C(C=N1)C2=CC=C3N=CC4=C(N(C(=O)C=C4)C5=CC6=C(CCN6C(=O)C=C)C=C5)C3=C2,-6.031605320261941,HMSL10077,BTK Inhibitor,NCGC00263183-11,CN1CCN(CC1)C2=CC=C(NC3=NC=C4C(=O)N(CC=C)N(C4=N3)C5=CC=CC(=N5)C(C)(C)O)C=C2,-5.881605633370822,MK-1775,Wee1 Kinase Inhibitor,0.895105,1
NCGC00346656-03,CCC1=C2N=C(C=C(NCC3=CC=C[N+]([O-])=C3)N2N=C1)N4CCCC[C@H]4CCO,-7.18160253455865,Dinaciclib (SCH727965),CDK1/2/5/9 Inhibitor,NCGC00263183-11,CN1CCN(CC1)C2=CC=C(NC3=NC=C4C(=O)N(CC=C)N(C4=N3)C5=CC=CC(=N5)C(C)(C)O)C=C2,-5.881605633370822,MK-1775,Wee1 Kinase Inhibitor,0.90704,1
NCGC00346951-03,O=C1C2=CC=CC=C2[N+]3=C1C4=C(C=C3)C5=CC=CC=C5N4,-5.931605578511759,Fascaplysin,CDK4/6 Inhibitor,NCGC00263183-11,CN1CCN(CC1)C2=CC=C(NC3=NC=C4C(=O)N(CC=C)N(C4=N3)C5=CC=CC(=N5)C(C)(C)O)C=C2,-5.881605633370822,MK-1775,Wee1 Kinase Inhibitor,0.8801749999999999,1
NCGC00345799-07,COC[C@H](NC(=O)[C@H](COC)NC(=O)C1=CN=C(C)S1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)[C@@]3(C)CO3,-6.8316056515638195,Oprozomib,Proteasome Inhibitor,NCGC00263183-11,CN1CCN(CC1)C2=CC=C(NC3=NC=C4C(=O)N(CC=C)N(C4=N3)C5=CC=CC(=N5)C(C)(C)O)C=C2,-5.881605633370822,MK-1775,Wee1 Kinase Inhibitor,0.9222899999999999,1
NCGC00263222-02,CC1(C)OC2=C([C@H](NCC3=CC=CC=C3)[C@@H]1O)C(=O)C4=CC=CC=C4C2=O,-5.481605573349707,CAY-10581,IDO Inhibitor,NCGC00263183-11,CN1CCN(CC1)C2=CC=C(NC3=NC=C4C(=O)N(CC=C)N(C4=N3)C5=CC=CC(=N5)C(C)(C)O)C=C2,-5.881605633370822,MK-1775,Wee1 Kinase Inhibitor,0.88733,1
NCGC00347952-11,C\C(=N/NC(=S)N1CCC1)C2=NC=CC=C2,-8.731656086048936,NSC-319726,Mutant p53 Activator,NCGC00263183-11,CN1CCN(CC1)C2=CC=C(NC3=NC=C4C(=O)N(CC=C)N(C4=N3)C5=CC=CC(=N5)C(C)(C)O)C=C2,-5.881605633370822,MK-1775,Wee1 Kinase Inhibitor,0.848755,1
NCGC00346535-01,COC1=CC=C(C=C1)[S+]([O-])(=O)N(C(C)=O)C2=C(\C=C\C3=CC=N(=O)C=C3)C=CC=C2,-6.081605805570835,IVX-214,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00263183-11,CN1CCN(CC1)C2=CC=C(NC3=NC=C4C(=O)N(CC=C)N(C4=N3)C5=CC=CC(=N5)C(C)(C)O)C=C2,-5.881605633370822,MK-1775,Wee1 Kinase Inhibitor,0.943175,1
NCGC00345825-01,FC(F)C1=NN(C(=C1)C2=CN=C(NC(=O)C3CC3)S2)C4=C(Cl)C=CC=C4Cl,-5.931605578511759,BMS-3,LIMK Inhibitor,NCGC00263183-11,CN1CCN(CC1)C2=CC=C(NC3=NC=C4C(=O)N(CC=C)N(C4=N3)C5=CC=CC(=N5)C(C)(C)O)C=C2,-5.881605633370822,MK-1775,Wee1 Kinase Inhibitor,0.96195,0
NCGC00345852-02,CC(C)C1=C2N=C(N[C@@H](CO)[C@H](O)CO)C=C(NCC3=CC=CC=C3)N2N=C1,-6.231605379060391,BS-194,CDK1/2/5/9 Inhibitor,NCGC00263183-11,CN1CCN(CC1)C2=CC=C(NC3=NC=C4C(=O)N(CC=C)N(C4=N3)C5=CC=CC(=N5)C(C)(C)O)C=C2,-5.881605633370822,MK-1775,Wee1 Kinase Inhibitor,1.07898,0
NCGC00345823-01,CC(C)(N)C1=CC=C(C=C1)C2=NC3=C(C=CC=C3)N=C2C4=CC=CC=C4,-6.531605402012491,"Akt-I-1,2",AKT Inhibitor,NCGC00263183-11,CN1CCN(CC1)C2=CC=C(NC3=NC=C4C(=O)N(CC=C)N(C4=N3)C5=CC=CC(=N5)C(C)(C)O)C=C2,-5.881605633370822,MK-1775,Wee1 Kinase Inhibitor,0.8536250000000001,1
NCGC00346969-01,CCOC(=O)N1CCN(CC1)[N+](\[O-])=N\OC2=CC=C(C=C2C#N)[N+]([O-])=O,-5.981605362312015,JS-59-4,nitric oxide donors,NCGC00263183-11,CN1CCN(CC1)C2=CC=C(NC3=NC=C4C(=O)N(CC=C)N(C4=N3)C5=CC=CC(=N5)C(C)(C)O)C=C2,-5.881605633370822,MK-1775,Wee1 Kinase Inhibitor,0.8451150000000001,1
NCGC00346449-01,ClC1=CC=C(CCCOC2=NNC(=O)C(Br)=C2NCC3=CN=CC=C3)C=C1,-6.231605379060391,Parogrelil,Phosphodiesterase III/Va (PDE) Inhibitor,NCGC00263183-11,CN1CCN(CC1)C2=CC=C(NC3=NC=C4C(=O)N(CC=C)N(C4=N3)C5=CC=CC(=N5)C(C)(C)O)C=C2,-5.881605633370822,MK-1775,Wee1 Kinase Inhibitor,0.893725,1
NCGC00386226-04,NC1=NC(N)=C2N=C(CC(CC#C)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=NC2=N1,-7.274421616144317,Pralatrexate,Dihydrofolate Reductase (DHFR) Inhibitors,NCGC00263117-17,CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C3=CC=CC=C3N1,-6.231605379060391,Panobinostat,HDAC Inhibitor,0.957005,0
NCGC00345809-03,CC(C)C1=NN(C2=C1C(=O)NC(CC3=CC=C(OCCO)C=C3)=N2)C4=C(Cl)C=CC=C4Cl,-7.18160253455865,RGB-286147,CDK1/2/3/7/9 Inhibitor,NCGC00263117-17,CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C3=CC=CC=C3N1,-6.231605379060391,Panobinostat,HDAC Inhibitor,0.92595,1
NCGC00345782-02,ClC1=CC=C(OCCCCCCN\C(NC2=CC=NC=C2)=N/C#N)C=C1,-8.331614083309999,GMX-1778,IKK beta Inhibitor,NCGC00263117-17,CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C3=CC=CC=C3N1,-6.231605379060391,Panobinostat,HDAC Inhibitor,0.609105,1
NCGC00346644-04,O=C(CC1=CC=C(C=N1)C2=CC=C(OCCN3CCOCC3)C=C2)NCC4=CC=CC=C4,-7.43161051350816,KX-01,Src Kinase Inhibitor,NCGC00263117-17,CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C3=CC=CC=C3N1,-6.231605379060391,Panobinostat,HDAC Inhibitor,0.9606950000000001,0
NCGC00346962-02,CN1C=C(C=N1)C2=CC=C3N=CC4=C(N(C(=O)C=C4)C5=CC6=C(CCN6C(=O)C=C)C=C5)C3=C2,-6.031605320261941,HMSL10077,BTK Inhibitor,NCGC00263117-17,CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C3=CC=CC=C3N1,-6.231605379060391,Panobinostat,HDAC Inhibitor,0.837375,1
NCGC00346656-03,CCC1=C2N=C(C=C(NCC3=CC=C[N+]([O-])=C3)N2N=C1)N4CCCC[C@H]4CCO,-7.18160253455865,Dinaciclib (SCH727965),CDK1/2/5/9 Inhibitor,NCGC00263117-17,CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C3=CC=CC=C3N1,-6.231605379060391,Panobinostat,HDAC Inhibitor,0.9884999999999999,0
NCGC00263183-11,CN1CCN(CC1)C2=CC=C(NC3=NC=C4C(=O)N(CC=C)N(C4=N3)C5=CC=CC(=N5)C(C)(C)O)C=C2,-5.881605633370822,MK-1775,Wee1 Kinase Inhibitor,NCGC00263117-17,CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C3=CC=CC=C3N1,-6.231605379060391,Panobinostat,HDAC Inhibitor,0.94889,1
NCGC00346951-03,O=C1C2=CC=CC=C2[N+]3=C1C4=C(C=C3)C5=CC=CC=C5N4,-5.931605578511759,Fascaplysin,CDK4/6 Inhibitor,NCGC00263117-17,CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C3=CC=CC=C3N1,-6.231605379060391,Panobinostat,HDAC Inhibitor,0.7877449999999999,1
NCGC00345799-07,COC[C@H](NC(=O)[C@H](COC)NC(=O)C1=CN=C(C)S1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)[C@@]3(C)CO3,-6.8316056515638195,Oprozomib,Proteasome Inhibitor,NCGC00263117-17,CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C3=CC=CC=C3N1,-6.231605379060391,Panobinostat,HDAC Inhibitor,0.10762000000000001,1
NCGC00263222-02,CC1(C)OC2=C([C@H](NCC3=CC=CC=C3)[C@@H]1O)C(=O)C4=CC=CC=C4C2=O,-5.481605573349707,CAY-10581,IDO Inhibitor,NCGC00263117-17,CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C3=CC=CC=C3N1,-6.231605379060391,Panobinostat,HDAC Inhibitor,0.7392350000000001,1
NCGC00347952-11,C\C(=N/NC(=S)N1CCC1)C2=NC=CC=C2,-8.731656086048936,NSC-319726,Mutant p53 Activator,NCGC00263117-17,CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C3=CC=CC=C3N1,-6.231605379060391,Panobinostat,HDAC Inhibitor,0.298825,1
NCGC00346535-01,COC1=CC=C(C=C1)[S+]([O-])(=O)N(C(C)=O)C2=C(\C=C\C3=CC=N(=O)C=C3)C=CC=C2,-6.081605805570835,IVX-214,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00263117-17,CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C3=CC=CC=C3N1,-6.231605379060391,Panobinostat,HDAC Inhibitor,0.7625500000000001,1
NCGC00345825-01,FC(F)C1=NN(C(=C1)C2=CN=C(NC(=O)C3CC3)S2)C4=C(Cl)C=CC=C4Cl,-5.931605578511759,BMS-3,LIMK Inhibitor,NCGC00263117-17,CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C3=CC=CC=C3N1,-6.231605379060391,Panobinostat,HDAC Inhibitor,0.7099150000000001,1
NCGC00345852-02,CC(C)C1=C2N=C(N[C@@H](CO)[C@H](O)CO)C=C(NCC3=CC=CC=C3)N2N=C1,-6.231605379060391,BS-194,CDK1/2/5/9 Inhibitor,NCGC00263117-17,CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C3=CC=CC=C3N1,-6.231605379060391,Panobinostat,HDAC Inhibitor,0.8505100000000001,1
NCGC00345823-01,CC(C)(N)C1=CC=C(C=C1)C2=NC3=C(C=CC=C3)N=C2C4=CC=CC=C4,-6.531605402012491,"Akt-I-1,2",AKT Inhibitor,NCGC00263117-17,CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C3=CC=CC=C3N1,-6.231605379060391,Panobinostat,HDAC Inhibitor,0.8630950000000001,1
NCGC00346969-01,CCOC(=O)N1CCN(CC1)[N+](\[O-])=N\OC2=CC=C(C=C2C#N)[N+]([O-])=O,-5.981605362312015,JS-59-4,nitric oxide donors,NCGC00263117-17,CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C3=CC=CC=C3N1,-6.231605379060391,Panobinostat,HDAC Inhibitor,0.92672,1
NCGC00346449-01,ClC1=CC=C(CCCOC2=NNC(=O)C(Br)=C2NCC3=CN=CC=C3)C=C1,-6.231605379060391,Parogrelil,Phosphodiesterase III/Va (PDE) Inhibitor,NCGC00263117-17,CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C3=CC=CC=C3N1,-6.231605379060391,Panobinostat,HDAC Inhibitor,0.924695,1
NCGC00386226-04,NC1=NC(N)=C2N=C(CC(CC#C)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=NC2=N1,-7.274421616144317,Pralatrexate,Dihydrofolate Reductase (DHFR) Inhibitors,NCGC00249613-10,CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN2CCOCC2)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]4(C)CO4,-7.4816045202261074,Carfilzomib,Proteasome Inhibitor,1.124905,0
NCGC00345809-03,CC(C)C1=NN(C2=C1C(=O)NC(CC3=CC=C(OCCO)C=C3)=N2)C4=C(Cl)C=CC=C4Cl,-7.18160253455865,RGB-286147,CDK1/2/3/7/9 Inhibitor,NCGC00249613-10,CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN2CCOCC2)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]4(C)CO4,-7.4816045202261074,Carfilzomib,Proteasome Inhibitor,0.72434,1
NCGC00345782-02,ClC1=CC=C(OCCCCCCN\C(NC2=CC=NC=C2)=N/C#N)C=C1,-8.331614083309999,GMX-1778,IKK beta Inhibitor,NCGC00249613-10,CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN2CCOCC2)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]4(C)CO4,-7.4816045202261074,Carfilzomib,Proteasome Inhibitor,0.36724,1
NCGC00346644-04,O=C(CC1=CC=C(C=N1)C2=CC=C(OCCN3CCOCC3)C=C2)NCC4=CC=CC=C4,-7.43161051350816,KX-01,Src Kinase Inhibitor,NCGC00249613-10,CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN2CCOCC2)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]4(C)CO4,-7.4816045202261074,Carfilzomib,Proteasome Inhibitor,0.82898,1
NCGC00263017-01,COC1=C(OC)C=C2C(NCCN3CCOCC3)=NC(=NC2=C1)C4=CC=C(C=C4)N5CCN(C)CC5,-7.731609264370069,CPG-52364,"TLR 7, 8 and 9 Antagonist",NCGC00249613-10,CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN2CCOCC2)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]4(C)CO4,-7.4816045202261074,Carfilzomib,Proteasome Inhibitor,0.5996100000000001,1
NCGC00346962-02,CN1C=C(C=N1)C2=CC=C3N=CC4=C(N(C(=O)C=C4)C5=CC6=C(CCN6C(=O)C=C)C=C5)C3=C2,-6.031605320261941,HMSL10077,BTK Inhibitor,NCGC00249613-10,CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN2CCOCC2)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]4(C)CO4,-7.4816045202261074,Carfilzomib,Proteasome Inhibitor,0.588745,1
NCGC00346656-03,CCC1=C2N=C(C=C(NCC3=CC=C[N+]([O-])=C3)N2N=C1)N4CCCC[C@H]4CCO,-7.18160253455865,Dinaciclib (SCH727965),CDK1/2/5/9 Inhibitor,NCGC00249613-10,CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN2CCOCC2)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]4(C)CO4,-7.4816045202261074,Carfilzomib,Proteasome Inhibitor,0.720505,1
NCGC00263183-11,CN1CCN(CC1)C2=CC=C(NC3=NC=C4C(=O)N(CC=C)N(C4=N3)C5=CC=CC(=N5)C(C)(C)O)C=C2,-5.881605633370822,MK-1775,Wee1 Kinase Inhibitor,NCGC00249613-10,CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN2CCOCC2)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]4(C)CO4,-7.4816045202261074,Carfilzomib,Proteasome Inhibitor,0.582425,1
NCGC00263117-17,CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C3=CC=CC=C3N1,-6.231605379060391,Panobinostat,HDAC Inhibitor,NCGC00249613-10,CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN2CCOCC2)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]4(C)CO4,-7.4816045202261074,Carfilzomib,Proteasome Inhibitor,0.04141,1
NCGC00346951-03,O=C1C2=CC=CC=C2[N+]3=C1C4=C(C=C3)C5=CC=CC=C5N4,-5.931605578511759,Fascaplysin,CDK4/6 Inhibitor,NCGC00249613-10,CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN2CCOCC2)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]4(C)CO4,-7.4816045202261074,Carfilzomib,Proteasome Inhibitor,0.66201,1
NCGC00345799-07,COC[C@H](NC(=O)[C@H](COC)NC(=O)C1=CN=C(C)S1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)[C@@]3(C)CO3,-6.8316056515638195,Oprozomib,Proteasome Inhibitor,NCGC00249613-10,CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN2CCOCC2)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]4(C)CO4,-7.4816045202261074,Carfilzomib,Proteasome Inhibitor,0.498045,1
NCGC00263222-02,CC1(C)OC2=C([C@H](NCC3=CC=CC=C3)[C@@H]1O)C(=O)C4=CC=CC=C4C2=O,-5.481605573349707,CAY-10581,IDO Inhibitor,NCGC00249613-10,CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN2CCOCC2)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]4(C)CO4,-7.4816045202261074,Carfilzomib,Proteasome Inhibitor,0.63887,1
NCGC00347952-11,C\C(=N/NC(=S)N1CCC1)C2=NC=CC=C2,-8.731656086048936,NSC-319726,Mutant p53 Activator,NCGC00249613-10,CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN2CCOCC2)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]4(C)CO4,-7.4816045202261074,Carfilzomib,Proteasome Inhibitor,0.85151,1
NCGC00346535-01,COC1=CC=C(C=C1)[S+]([O-])(=O)N(C(C)=O)C2=C(\C=C\C3=CC=N(=O)C=C3)C=CC=C2,-6.081605805570835,IVX-214,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00249613-10,CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN2CCOCC2)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]4(C)CO4,-7.4816045202261074,Carfilzomib,Proteasome Inhibitor,0.7385299999999999,1
NCGC00345825-01,FC(F)C1=NN(C(=C1)C2=CN=C(NC(=O)C3CC3)S2)C4=C(Cl)C=CC=C4Cl,-5.931605578511759,BMS-3,LIMK Inhibitor,NCGC00249613-10,CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN2CCOCC2)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]4(C)CO4,-7.4816045202261074,Carfilzomib,Proteasome Inhibitor,0.6125,1
NCGC00345852-02,CC(C)C1=C2N=C(N[C@@H](CO)[C@H](O)CO)C=C(NCC3=CC=CC=C3)N2N=C1,-6.231605379060391,BS-194,CDK1/2/5/9 Inhibitor,NCGC00249613-10,CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN2CCOCC2)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]4(C)CO4,-7.4816045202261074,Carfilzomib,Proteasome Inhibitor,0.8383799999999999,1
NCGC00345823-01,CC(C)(N)C1=CC=C(C=C1)C2=NC3=C(C=CC=C3)N=C2C4=CC=CC=C4,-6.531605402012491,"Akt-I-1,2",AKT Inhibitor,NCGC00249613-10,CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN2CCOCC2)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]4(C)CO4,-7.4816045202261074,Carfilzomib,Proteasome Inhibitor,0.76399,1
NCGC00263087-15,CC[C@H]1N(C(C)C)C2=NC(NC3=CC=C(C=C3OC)C(=O)NC4CCC(CC4)N5CCN(CC6CC6)CC5)=NC=C2N(C)C1=O,-6.981607443736785,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00249613-10,CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN2CCOCC2)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]4(C)CO4,-7.4816045202261074,Carfilzomib,Proteasome Inhibitor,0.56377,1
NCGC00346969-01,CCOC(=O)N1CCN(CC1)[N+](\[O-])=N\OC2=CC=C(C=C2C#N)[N+]([O-])=O,-5.981605362312015,JS-59-4,nitric oxide donors,NCGC00249613-10,CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN2CCOCC2)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]4(C)CO4,-7.4816045202261074,Carfilzomib,Proteasome Inhibitor,0.5519499999999999,1
NCGC00253438-01,CC[C@H]1N(C2CCCC2)C3=NC(NC4=CC=C(C=C4OC)C(=O)NC5CCN(C)CC5)=NC=C3N(C)C1=O,-7.4816045202261074,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00249613-10,CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN2CCOCC2)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]4(C)CO4,-7.4816045202261074,Carfilzomib,Proteasome Inhibitor,0.6414550000000001,1
NCGC00346449-01,ClC1=CC=C(CCCOC2=NNC(=O)C(Br)=C2NCC3=CN=CC=C3)C=C1,-6.231605379060391,Parogrelil,Phosphodiesterase III/Va (PDE) Inhibitor,NCGC00249613-10,CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN2CCOCC2)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]4(C)CO4,-7.4816045202261074,Carfilzomib,Proteasome Inhibitor,0.8537600000000001,1
NCGC00263112-06,C[C@@H](OC1=C(SC(=C1)N2C=NC3=C2C=C(CN4CCN(C)CC4)C=C3)C(N)=O)C5=CC=CC=C5C(F)(F)F,-7.281606275378642,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00249613-10,CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN2CCOCC2)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]4(C)CO4,-7.4816045202261074,Carfilzomib,Proteasome Inhibitor,0.6855249999999999,1
NCGC00263110-02,CN(C(C)=O)C1(CCN(CCC[C@@]2(CCCN(C2)C(=O)C3=CC=CC=C3)C4=CC=C(Cl)C(Cl)=C4)CC1)C5=CC=CC=C5,-7.031605787340429,Osanetant,Tachykinin NK3 Antagonist,NCGC00249613-10,CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN2CCOCC2)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]4(C)CO4,-7.4816045202261074,Carfilzomib,Proteasome Inhibitor,0.53115,1
NCGC00386226-04,NC1=NC(N)=C2N=C(CC(CC#C)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=NC2=N1,-7.274421616144317,Pralatrexate,Dihydrofolate Reductase (DHFR) Inhibitors,NCGC00346951-03,O=C1C2=CC=CC=C2[N+]3=C1C4=C(C=C3)C5=CC=CC=C5N4,-5.931605578511759,Fascaplysin,CDK4/6 Inhibitor,0.9873049999999999,0
NCGC00346962-02,CN1C=C(C=N1)C2=CC=C3N=CC4=C(N(C(=O)C=C4)C5=CC6=C(CCN6C(=O)C=C)C=C5)C3=C2,-6.031605320261941,HMSL10077,BTK Inhibitor,NCGC00346951-03,O=C1C2=CC=CC=C2[N+]3=C1C4=C(C=C3)C5=CC=CC=C5N4,-5.931605578511759,Fascaplysin,CDK4/6 Inhibitor,0.954405,0
NCGC00347952-11,C\C(=N/NC(=S)N1CCC1)C2=NC=CC=C2,-8.731656086048936,NSC-319726,Mutant p53 Activator,NCGC00346951-03,O=C1C2=CC=CC=C2[N+]3=C1C4=C(C=C3)C5=CC=CC=C5N4,-5.931605578511759,Fascaplysin,CDK4/6 Inhibitor,0.7242149999999999,1
NCGC00346969-01,CCOC(=O)N1CCN(CC1)[N+](\[O-])=N\OC2=CC=C(C=C2C#N)[N+]([O-])=O,-5.981605362312015,JS-59-4,nitric oxide donors,NCGC00346951-03,O=C1C2=CC=CC=C2[N+]3=C1C4=C(C=C3)C5=CC=CC=C5N4,-5.931605578511759,Fascaplysin,CDK4/6 Inhibitor,0.97621,0
NCGC00386226-04,NC1=NC(N)=C2N=C(CC(CC#C)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=NC2=N1,-7.274421616144317,Pralatrexate,Dihydrofolate Reductase (DHFR) Inhibitors,NCGC00345799-07,COC[C@H](NC(=O)[C@H](COC)NC(=O)C1=CN=C(C)S1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)[C@@]3(C)CO3,-6.8316056515638195,Oprozomib,Proteasome Inhibitor,1.2643049999999998,0
NCGC00345809-03,CC(C)C1=NN(C2=C1C(=O)NC(CC3=CC=C(OCCO)C=C3)=N2)C4=C(Cl)C=CC=C4Cl,-7.18160253455865,RGB-286147,CDK1/2/3/7/9 Inhibitor,NCGC00345799-07,COC[C@H](NC(=O)[C@H](COC)NC(=O)C1=CN=C(C)S1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)[C@@]3(C)CO3,-6.8316056515638195,Oprozomib,Proteasome Inhibitor,0.78589,1
NCGC00346644-04,O=C(CC1=CC=C(C=N1)C2=CC=C(OCCN3CCOCC3)C=C2)NCC4=CC=CC=C4,-7.43161051350816,KX-01,Src Kinase Inhibitor,NCGC00345799-07,COC[C@H](NC(=O)[C@H](COC)NC(=O)C1=CN=C(C)S1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)[C@@]3(C)CO3,-6.8316056515638195,Oprozomib,Proteasome Inhibitor,0.86008,1
NCGC00346962-02,CN1C=C(C=N1)C2=CC=C3N=CC4=C(N(C(=O)C=C4)C5=CC6=C(CCN6C(=O)C=C)C=C5)C3=C2,-6.031605320261941,HMSL10077,BTK Inhibitor,NCGC00345799-07,COC[C@H](NC(=O)[C@H](COC)NC(=O)C1=CN=C(C)S1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)[C@@]3(C)CO3,-6.8316056515638195,Oprozomib,Proteasome Inhibitor,0.7822,1
NCGC00346656-03,CCC1=C2N=C(C=C(NCC3=CC=C[N+]([O-])=C3)N2N=C1)N4CCCC[C@H]4CCO,-7.18160253455865,Dinaciclib (SCH727965),CDK1/2/5/9 Inhibitor,NCGC00345799-07,COC[C@H](NC(=O)[C@H](COC)NC(=O)C1=CN=C(C)S1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)[C@@]3(C)CO3,-6.8316056515638195,Oprozomib,Proteasome Inhibitor,0.738135,1
NCGC00346951-03,O=C1C2=CC=CC=C2[N+]3=C1C4=C(C=C3)C5=CC=CC=C5N4,-5.931605578511759,Fascaplysin,CDK4/6 Inhibitor,NCGC00345799-07,COC[C@H](NC(=O)[C@H](COC)NC(=O)C1=CN=C(C)S1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)[C@@]3(C)CO3,-6.8316056515638195,Oprozomib,Proteasome Inhibitor,0.81077,1
NCGC00347952-11,C\C(=N/NC(=S)N1CCC1)C2=NC=CC=C2,-8.731656086048936,NSC-319726,Mutant p53 Activator,NCGC00345799-07,COC[C@H](NC(=O)[C@H](COC)NC(=O)C1=CN=C(C)S1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)[C@@]3(C)CO3,-6.8316056515638195,Oprozomib,Proteasome Inhibitor,0.889945,1
NCGC00346535-01,COC1=CC=C(C=C1)[S+]([O-])(=O)N(C(C)=O)C2=C(\C=C\C3=CC=N(=O)C=C3)C=CC=C2,-6.081605805570835,IVX-214,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00345799-07,COC[C@H](NC(=O)[C@H](COC)NC(=O)C1=CN=C(C)S1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)[C@@]3(C)CO3,-6.8316056515638195,Oprozomib,Proteasome Inhibitor,0.9758549999999999,0
NCGC00345825-01,FC(F)C1=NN(C(=C1)C2=CN=C(NC(=O)C3CC3)S2)C4=C(Cl)C=CC=C4Cl,-5.931605578511759,BMS-3,LIMK Inhibitor,NCGC00345799-07,COC[C@H](NC(=O)[C@H](COC)NC(=O)C1=CN=C(C)S1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)[C@@]3(C)CO3,-6.8316056515638195,Oprozomib,Proteasome Inhibitor,0.869165,1
NCGC00345852-02,CC(C)C1=C2N=C(N[C@@H](CO)[C@H](O)CO)C=C(NCC3=CC=CC=C3)N2N=C1,-6.231605379060391,BS-194,CDK1/2/5/9 Inhibitor,NCGC00345799-07,COC[C@H](NC(=O)[C@H](COC)NC(=O)C1=CN=C(C)S1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)[C@@]3(C)CO3,-6.8316056515638195,Oprozomib,Proteasome Inhibitor,0.950755,0
NCGC00345823-01,CC(C)(N)C1=CC=C(C=C1)C2=NC3=C(C=CC=C3)N=C2C4=CC=CC=C4,-6.531605402012491,"Akt-I-1,2",AKT Inhibitor,NCGC00345799-07,COC[C@H](NC(=O)[C@H](COC)NC(=O)C1=CN=C(C)S1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)[C@@]3(C)CO3,-6.8316056515638195,Oprozomib,Proteasome Inhibitor,0.8739049999999999,1
NCGC00346969-01,CCOC(=O)N1CCN(CC1)[N+](\[O-])=N\OC2=CC=C(C=C2C#N)[N+]([O-])=O,-5.981605362312015,JS-59-4,nitric oxide donors,NCGC00345799-07,COC[C@H](NC(=O)[C@H](COC)NC(=O)C1=CN=C(C)S1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)[C@@]3(C)CO3,-6.8316056515638195,Oprozomib,Proteasome Inhibitor,0.803445,1
NCGC00346449-01,ClC1=CC=C(CCCOC2=NNC(=O)C(Br)=C2NCC3=CN=CC=C3)C=C1,-6.231605379060391,Parogrelil,Phosphodiesterase III/Va (PDE) Inhibitor,NCGC00345799-07,COC[C@H](NC(=O)[C@H](COC)NC(=O)C1=CN=C(C)S1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)[C@@]3(C)CO3,-6.8316056515638195,Oprozomib,Proteasome Inhibitor,1.051785,0
NCGC00386226-04,NC1=NC(N)=C2N=C(CC(CC#C)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=NC2=N1,-7.274421616144317,Pralatrexate,Dihydrofolate Reductase (DHFR) Inhibitors,NCGC00263222-02,CC1(C)OC2=C([C@H](NCC3=CC=CC=C3)[C@@H]1O)C(=O)C4=CC=CC=C4C2=O,-5.481605573349707,CAY-10581,IDO Inhibitor,0.9505600000000001,0
NCGC00345809-03,CC(C)C1=NN(C2=C1C(=O)NC(CC3=CC=C(OCCO)C=C3)=N2)C4=C(Cl)C=CC=C4Cl,-7.18160253455865,RGB-286147,CDK1/2/3/7/9 Inhibitor,NCGC00263222-02,CC1(C)OC2=C([C@H](NCC3=CC=CC=C3)[C@@H]1O)C(=O)C4=CC=CC=C4C2=O,-5.481605573349707,CAY-10581,IDO Inhibitor,0.861815,1
NCGC00345782-02,ClC1=CC=C(OCCCCCCN\C(NC2=CC=NC=C2)=N/C#N)C=C1,-8.331614083309999,GMX-1778,IKK beta Inhibitor,NCGC00263222-02,CC1(C)OC2=C([C@H](NCC3=CC=CC=C3)[C@@H]1O)C(=O)C4=CC=CC=C4C2=O,-5.481605573349707,CAY-10581,IDO Inhibitor,0.916695,1
NCGC00346644-04,O=C(CC1=CC=C(C=N1)C2=CC=C(OCCN3CCOCC3)C=C2)NCC4=CC=CC=C4,-7.43161051350816,KX-01,Src Kinase Inhibitor,NCGC00263222-02,CC1(C)OC2=C([C@H](NCC3=CC=CC=C3)[C@@H]1O)C(=O)C4=CC=CC=C4C2=O,-5.481605573349707,CAY-10581,IDO Inhibitor,0.9293799999999999,1
NCGC00346962-02,CN1C=C(C=N1)C2=CC=C3N=CC4=C(N(C(=O)C=C4)C5=CC6=C(CCN6C(=O)C=C)C=C5)C3=C2,-6.031605320261941,HMSL10077,BTK Inhibitor,NCGC00263222-02,CC1(C)OC2=C([C@H](NCC3=CC=CC=C3)[C@@H]1O)C(=O)C4=CC=CC=C4C2=O,-5.481605573349707,CAY-10581,IDO Inhibitor,1.008085,0
NCGC00346656-03,CCC1=C2N=C(C=C(NCC3=CC=C[N+]([O-])=C3)N2N=C1)N4CCCC[C@H]4CCO,-7.18160253455865,Dinaciclib (SCH727965),CDK1/2/5/9 Inhibitor,NCGC00263222-02,CC1(C)OC2=C([C@H](NCC3=CC=CC=C3)[C@@H]1O)C(=O)C4=CC=CC=C4C2=O,-5.481605573349707,CAY-10581,IDO Inhibitor,0.91404,1
NCGC00346951-03,O=C1C2=CC=CC=C2[N+]3=C1C4=C(C=C3)C5=CC=CC=C5N4,-5.931605578511759,Fascaplysin,CDK4/6 Inhibitor,NCGC00263222-02,CC1(C)OC2=C([C@H](NCC3=CC=CC=C3)[C@@H]1O)C(=O)C4=CC=CC=C4C2=O,-5.481605573349707,CAY-10581,IDO Inhibitor,0.8334250000000001,1
NCGC00345799-07,COC[C@H](NC(=O)[C@H](COC)NC(=O)C1=CN=C(C)S1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)[C@@]3(C)CO3,-6.8316056515638195,Oprozomib,Proteasome Inhibitor,NCGC00263222-02,CC1(C)OC2=C([C@H](NCC3=CC=CC=C3)[C@@H]1O)C(=O)C4=CC=CC=C4C2=O,-5.481605573349707,CAY-10581,IDO Inhibitor,0.838355,1
NCGC00347952-11,C\C(=N/NC(=S)N1CCC1)C2=NC=CC=C2,-8.731656086048936,NSC-319726,Mutant p53 Activator,NCGC00263222-02,CC1(C)OC2=C([C@H](NCC3=CC=CC=C3)[C@@H]1O)C(=O)C4=CC=CC=C4C2=O,-5.481605573349707,CAY-10581,IDO Inhibitor,0.64934,1
NCGC00346535-01,COC1=CC=C(C=C1)[S+]([O-])(=O)N(C(C)=O)C2=C(\C=C\C3=CC=N(=O)C=C3)C=CC=C2,-6.081605805570835,IVX-214,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00263222-02,CC1(C)OC2=C([C@H](NCC3=CC=CC=C3)[C@@H]1O)C(=O)C4=CC=CC=C4C2=O,-5.481605573349707,CAY-10581,IDO Inhibitor,0.97594,0
NCGC00345825-01,FC(F)C1=NN(C(=C1)C2=CN=C(NC(=O)C3CC3)S2)C4=C(Cl)C=CC=C4Cl,-5.931605578511759,BMS-3,LIMK Inhibitor,NCGC00263222-02,CC1(C)OC2=C([C@H](NCC3=CC=CC=C3)[C@@H]1O)C(=O)C4=CC=CC=C4C2=O,-5.481605573349707,CAY-10581,IDO Inhibitor,0.9658450000000001,0
NCGC00345852-02,CC(C)C1=C2N=C(N[C@@H](CO)[C@H](O)CO)C=C(NCC3=CC=CC=C3)N2N=C1,-6.231605379060391,BS-194,CDK1/2/5/9 Inhibitor,NCGC00263222-02,CC1(C)OC2=C([C@H](NCC3=CC=CC=C3)[C@@H]1O)C(=O)C4=CC=CC=C4C2=O,-5.481605573349707,CAY-10581,IDO Inhibitor,0.97003,0
NCGC00345823-01,CC(C)(N)C1=CC=C(C=C1)C2=NC3=C(C=CC=C3)N=C2C4=CC=CC=C4,-6.531605402012491,"Akt-I-1,2",AKT Inhibitor,NCGC00263222-02,CC1(C)OC2=C([C@H](NCC3=CC=CC=C3)[C@@H]1O)C(=O)C4=CC=CC=C4C2=O,-5.481605573349707,CAY-10581,IDO Inhibitor,0.92334,1
NCGC00346969-01,CCOC(=O)N1CCN(CC1)[N+](\[O-])=N\OC2=CC=C(C=C2C#N)[N+]([O-])=O,-5.981605362312015,JS-59-4,nitric oxide donors,NCGC00263222-02,CC1(C)OC2=C([C@H](NCC3=CC=CC=C3)[C@@H]1O)C(=O)C4=CC=CC=C4C2=O,-5.481605573349707,CAY-10581,IDO Inhibitor,0.9318850000000001,1
NCGC00346449-01,ClC1=CC=C(CCCOC2=NNC(=O)C(Br)=C2NCC3=CN=CC=C3)C=C1,-6.231605379060391,Parogrelil,Phosphodiesterase III/Va (PDE) Inhibitor,NCGC00263222-02,CC1(C)OC2=C([C@H](NCC3=CC=CC=C3)[C@@H]1O)C(=O)C4=CC=CC=C4C2=O,-5.481605573349707,CAY-10581,IDO Inhibitor,0.9253899999999999,1
NCGC00386226-04,NC1=NC(N)=C2N=C(CC(CC#C)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=NC2=N1,-7.274421616144317,Pralatrexate,Dihydrofolate Reductase (DHFR) Inhibitors,NCGC00242217-07,COC1=CC2=C(C=C1OC)N(C=N2)C3=CC(OCC4=C(C=CC=C4)C(F)(F)F)=C(S3)C(N)=O,-5.83160565156382,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,1.0280299999999998,0
NCGC00345809-03,CC(C)C1=NN(C2=C1C(=O)NC(CC3=CC=C(OCCO)C=C3)=N2)C4=C(Cl)C=CC=C4Cl,-7.18160253455865,RGB-286147,CDK1/2/3/7/9 Inhibitor,NCGC00242217-07,COC1=CC2=C(C=C1OC)N(C=N2)C3=CC(OCC4=C(C=CC=C4)C(F)(F)F)=C(S3)C(N)=O,-5.83160565156382,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,0.81453,1
NCGC00345782-02,ClC1=CC=C(OCCCCCCN\C(NC2=CC=NC=C2)=N/C#N)C=C1,-8.331614083309999,GMX-1778,IKK beta Inhibitor,NCGC00242217-07,COC1=CC2=C(C=C1OC)N(C=N2)C3=CC(OCC4=C(C=CC=C4)C(F)(F)F)=C(S3)C(N)=O,-5.83160565156382,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,0.94734,1
NCGC00346644-04,O=C(CC1=CC=C(C=N1)C2=CC=C(OCCN3CCOCC3)C=C2)NCC4=CC=CC=C4,-7.43161051350816,KX-01,Src Kinase Inhibitor,NCGC00242217-07,COC1=CC2=C(C=C1OC)N(C=N2)C3=CC(OCC4=C(C=CC=C4)C(F)(F)F)=C(S3)C(N)=O,-5.83160565156382,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,1.0202399999999998,0
NCGC00242506-13,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)B(O)O,-7.43161051350816,Bortezomib,Proteasome Inhibitor,NCGC00242217-07,COC1=CC2=C(C=C1OC)N(C=N2)C3=CC(OCC4=C(C=CC=C4)C(F)(F)F)=C(S3)C(N)=O,-5.83160565156382,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,0.920165,1
NCGC00242514-13,COCCN1C(C)=[N+](CC2=NC=CN=C2)C3=C1C(=O)C4=CC=CC=C4C3=O,-8.381638068890123,Sepantronium bromide,Survivin Inhibitor,NCGC00242217-07,COC1=CC2=C(C=C1OC)N(C=N2)C3=CC(OCC4=C(C=CC=C4)C(F)(F)F)=C(S3)C(N)=O,-5.83160565156382,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,0.859645,1
NCGC00263017-01,COC1=C(OC)C=C2C(NCCN3CCOCC3)=NC(=NC2=C1)C4=CC=C(C=C4)N5CCN(C)CC5,-7.731609264370069,CPG-52364,"TLR 7, 8 and 9 Antagonist",NCGC00242217-07,COC1=CC2=C(C=C1OC)N(C=N2)C3=CC(OCC4=C(C=CC=C4)C(F)(F)F)=C(S3)C(N)=O,-5.83160565156382,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,1.007885,0
NCGC00346962-02,CN1C=C(C=N1)C2=CC=C3N=CC4=C(N(C(=O)C=C4)C5=CC6=C(CCN6C(=O)C=C)C=C5)C3=C2,-6.031605320261941,HMSL10077,BTK Inhibitor,NCGC00242217-07,COC1=CC2=C(C=C1OC)N(C=N2)C3=CC(OCC4=C(C=CC=C4)C(F)(F)F)=C(S3)C(N)=O,-5.83160565156382,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,0.9588000000000001,0
NCGC00346656-03,CCC1=C2N=C(C=C(NCC3=CC=C[N+]([O-])=C3)N2N=C1)N4CCCC[C@H]4CCO,-7.18160253455865,Dinaciclib (SCH727965),CDK1/2/5/9 Inhibitor,NCGC00242217-07,COC1=CC2=C(C=C1OC)N(C=N2)C3=CC(OCC4=C(C=CC=C4)C(F)(F)F)=C(S3)C(N)=O,-5.83160565156382,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,0.943675,1
NCGC00263183-11,CN1CCN(CC1)C2=CC=C(NC3=NC=C4C(=O)N(CC=C)N(C4=N3)C5=CC=CC(=N5)C(C)(C)O)C=C2,-5.881605633370822,MK-1775,Wee1 Kinase Inhibitor,NCGC00242217-07,COC1=CC2=C(C=C1OC)N(C=N2)C3=CC(OCC4=C(C=CC=C4)C(F)(F)F)=C(S3)C(N)=O,-5.83160565156382,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,1.0631849999999998,0
NCGC00263117-17,CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C3=CC=CC=C3N1,-6.231605379060391,Panobinostat,HDAC Inhibitor,NCGC00242217-07,COC1=CC2=C(C=C1OC)N(C=N2)C3=CC(OCC4=C(C=CC=C4)C(F)(F)F)=C(S3)C(N)=O,-5.83160565156382,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,0.9296150000000001,1
NCGC00249613-10,CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN2CCOCC2)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]4(C)CO4,-7.4816045202261074,Carfilzomib,Proteasome Inhibitor,NCGC00242217-07,COC1=CC2=C(C=C1OC)N(C=N2)C3=CC(OCC4=C(C=CC=C4)C(F)(F)F)=C(S3)C(N)=O,-5.83160565156382,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,0.40595499999999995,1
NCGC00346951-03,O=C1C2=CC=CC=C2[N+]3=C1C4=C(C=C3)C5=CC=CC=C5N4,-5.931605578511759,Fascaplysin,CDK4/6 Inhibitor,NCGC00242217-07,COC1=CC2=C(C=C1OC)N(C=N2)C3=CC(OCC4=C(C=CC=C4)C(F)(F)F)=C(S3)C(N)=O,-5.83160565156382,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,1.136275,0
NCGC00345799-07,COC[C@H](NC(=O)[C@H](COC)NC(=O)C1=CN=C(C)S1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)[C@@]3(C)CO3,-6.8316056515638195,Oprozomib,Proteasome Inhibitor,NCGC00242217-07,COC1=CC2=C(C=C1OC)N(C=N2)C3=CC(OCC4=C(C=CC=C4)C(F)(F)F)=C(S3)C(N)=O,-5.83160565156382,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,0.7814749999999999,1
NCGC00263222-02,CC1(C)OC2=C([C@H](NCC3=CC=CC=C3)[C@@H]1O)C(=O)C4=CC=CC=C4C2=O,-5.481605573349707,CAY-10581,IDO Inhibitor,NCGC00242217-07,COC1=CC2=C(C=C1OC)N(C=N2)C3=CC(OCC4=C(C=CC=C4)C(F)(F)F)=C(S3)C(N)=O,-5.83160565156382,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,0.88325,1
NCGC00347952-11,C\C(=N/NC(=S)N1CCC1)C2=NC=CC=C2,-8.731656086048936,NSC-319726,Mutant p53 Activator,NCGC00242217-07,COC1=CC2=C(C=C1OC)N(C=N2)C3=CC(OCC4=C(C=CC=C4)C(F)(F)F)=C(S3)C(N)=O,-5.83160565156382,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,0.860795,1
NCGC00346535-01,COC1=CC=C(C=C1)[S+]([O-])(=O)N(C(C)=O)C2=C(\C=C\C3=CC=N(=O)C=C3)C=CC=C2,-6.081605805570835,IVX-214,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00242217-07,COC1=CC2=C(C=C1OC)N(C=N2)C3=CC(OCC4=C(C=CC=C4)C(F)(F)F)=C(S3)C(N)=O,-5.83160565156382,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,0.992275,0
NCGC00345825-01,FC(F)C1=NN(C(=C1)C2=CN=C(NC(=O)C3CC3)S2)C4=C(Cl)C=CC=C4Cl,-5.931605578511759,BMS-3,LIMK Inhibitor,NCGC00242217-07,COC1=CC2=C(C=C1OC)N(C=N2)C3=CC(OCC4=C(C=CC=C4)C(F)(F)F)=C(S3)C(N)=O,-5.83160565156382,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,0.99673,0
NCGC00345852-02,CC(C)C1=C2N=C(N[C@@H](CO)[C@H](O)CO)C=C(NCC3=CC=CC=C3)N2N=C1,-6.231605379060391,BS-194,CDK1/2/5/9 Inhibitor,NCGC00242217-07,COC1=CC2=C(C=C1OC)N(C=N2)C3=CC(OCC4=C(C=CC=C4)C(F)(F)F)=C(S3)C(N)=O,-5.83160565156382,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,1.0,0
NCGC00345823-01,CC(C)(N)C1=CC=C(C=C1)C2=NC3=C(C=CC=C3)N=C2C4=CC=CC=C4,-6.531605402012491,"Akt-I-1,2",AKT Inhibitor,NCGC00242217-07,COC1=CC2=C(C=C1OC)N(C=N2)C3=CC(OCC4=C(C=CC=C4)C(F)(F)F)=C(S3)C(N)=O,-5.83160565156382,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,0.964035,0
NCGC00263087-15,CC[C@H]1N(C(C)C)C2=NC(NC3=CC=C(C=C3OC)C(=O)NC4CCC(CC4)N5CCN(CC6CC6)CC5)=NC=C2N(C)C1=O,-6.981607443736785,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00242217-07,COC1=CC2=C(C=C1OC)N(C=N2)C3=CC(OCC4=C(C=CC=C4)C(F)(F)F)=C(S3)C(N)=O,-5.83160565156382,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,1.03445,0
NCGC00346969-01,CCOC(=O)N1CCN(CC1)[N+](\[O-])=N\OC2=CC=C(C=C2C#N)[N+]([O-])=O,-5.981605362312015,JS-59-4,nitric oxide donors,NCGC00242217-07,COC1=CC2=C(C=C1OC)N(C=N2)C3=CC(OCC4=C(C=CC=C4)C(F)(F)F)=C(S3)C(N)=O,-5.83160565156382,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,0.964185,0
NCGC00253438-01,CC[C@H]1N(C2CCCC2)C3=NC(NC4=CC=C(C=C4OC)C(=O)NC5CCN(C)CC5)=NC=C3N(C)C1=O,-7.4816045202261074,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00242217-07,COC1=CC2=C(C=C1OC)N(C=N2)C3=CC(OCC4=C(C=CC=C4)C(F)(F)F)=C(S3)C(N)=O,-5.83160565156382,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,0.97448,0
NCGC00346449-01,ClC1=CC=C(CCCOC2=NNC(=O)C(Br)=C2NCC3=CN=CC=C3)C=C1,-6.231605379060391,Parogrelil,Phosphodiesterase III/Va (PDE) Inhibitor,NCGC00242217-07,COC1=CC2=C(C=C1OC)N(C=N2)C3=CC(OCC4=C(C=CC=C4)C(F)(F)F)=C(S3)C(N)=O,-5.83160565156382,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,0.876665,1
NCGC00263112-06,C[C@@H](OC1=C(SC(=C1)N2C=NC3=C2C=C(CN4CCN(C)CC4)C=C3)C(N)=O)C5=CC=CC=C5C(F)(F)F,-7.281606275378642,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00242217-07,COC1=CC2=C(C=C1OC)N(C=N2)C3=CC(OCC4=C(C=CC=C4)C(F)(F)F)=C(S3)C(N)=O,-5.83160565156382,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,1.1314,0
NCGC00263110-02,CN(C(C)=O)C1(CCN(CCC[C@@]2(CCCN(C2)C(=O)C3=CC=CC=C3)C4=CC=C(Cl)C(Cl)=C4)CC1)C5=CC=CC=C5,-7.031605787340429,Osanetant,Tachykinin NK3 Antagonist,NCGC00242217-07,COC1=CC2=C(C=C1OC)N(C=N2)C3=CC(OCC4=C(C=CC=C4)C(F)(F)F)=C(S3)C(N)=O,-5.83160565156382,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,1.00991,0
NCGC00386226-04,NC1=NC(N)=C2N=C(CC(CC#C)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=NC2=N1,-7.274421616144317,Pralatrexate,Dihydrofolate Reductase (DHFR) Inhibitors,NCGC00347952-11,C\C(=N/NC(=S)N1CCC1)C2=NC=CC=C2,-8.731656086048936,NSC-319726,Mutant p53 Activator,1.051835,0
NCGC00386226-04,NC1=NC(N)=C2N=C(CC(CC#C)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=NC2=N1,-7.274421616144317,Pralatrexate,Dihydrofolate Reductase (DHFR) Inhibitors,NCGC00346535-01,COC1=CC=C(C=C1)[S+]([O-])(=O)N(C(C)=O)C2=C(\C=C\C3=CC=N(=O)C=C3)C=CC=C2,-6.081605805570835,IVX-214,Polo-like Kinase-1 (Plk-1) Inhibitor,1.17891,0
NCGC00346644-04,O=C(CC1=CC=C(C=N1)C2=CC=C(OCCN3CCOCC3)C=C2)NCC4=CC=CC=C4,-7.43161051350816,KX-01,Src Kinase Inhibitor,NCGC00346535-01,COC1=CC=C(C=C1)[S+]([O-])(=O)N(C(C)=O)C2=C(\C=C\C3=CC=N(=O)C=C3)C=CC=C2,-6.081605805570835,IVX-214,Polo-like Kinase-1 (Plk-1) Inhibitor,1.0159799999999999,0
NCGC00346962-02,CN1C=C(C=N1)C2=CC=C3N=CC4=C(N(C(=O)C=C4)C5=CC6=C(CCN6C(=O)C=C)C=C5)C3=C2,-6.031605320261941,HMSL10077,BTK Inhibitor,NCGC00346535-01,COC1=CC=C(C=C1)[S+]([O-])(=O)N(C(C)=O)C2=C(\C=C\C3=CC=N(=O)C=C3)C=CC=C2,-6.081605805570835,IVX-214,Polo-like Kinase-1 (Plk-1) Inhibitor,1.0481099999999999,0
NCGC00346656-03,CCC1=C2N=C(C=C(NCC3=CC=C[N+]([O-])=C3)N2N=C1)N4CCCC[C@H]4CCO,-7.18160253455865,Dinaciclib (SCH727965),CDK1/2/5/9 Inhibitor,NCGC00346535-01,COC1=CC=C(C=C1)[S+]([O-])(=O)N(C(C)=O)C2=C(\C=C\C3=CC=N(=O)C=C3)C=CC=C2,-6.081605805570835,IVX-214,Polo-like Kinase-1 (Plk-1) Inhibitor,0.969385,0
NCGC00346951-03,O=C1C2=CC=CC=C2[N+]3=C1C4=C(C=C3)C5=CC=CC=C5N4,-5.931605578511759,Fascaplysin,CDK4/6 Inhibitor,NCGC00346535-01,COC1=CC=C(C=C1)[S+]([O-])(=O)N(C(C)=O)C2=C(\C=C\C3=CC=N(=O)C=C3)C=CC=C2,-6.081605805570835,IVX-214,Polo-like Kinase-1 (Plk-1) Inhibitor,0.913645,1
NCGC00347952-11,C\C(=N/NC(=S)N1CCC1)C2=NC=CC=C2,-8.731656086048936,NSC-319726,Mutant p53 Activator,NCGC00346535-01,COC1=CC=C(C=C1)[S+]([O-])(=O)N(C(C)=O)C2=C(\C=C\C3=CC=N(=O)C=C3)C=CC=C2,-6.081605805570835,IVX-214,Polo-like Kinase-1 (Plk-1) Inhibitor,0.83657,1
NCGC00346969-01,CCOC(=O)N1CCN(CC1)[N+](\[O-])=N\OC2=CC=C(C=C2C#N)[N+]([O-])=O,-5.981605362312015,JS-59-4,nitric oxide donors,NCGC00346535-01,COC1=CC=C(C=C1)[S+]([O-])(=O)N(C(C)=O)C2=C(\C=C\C3=CC=N(=O)C=C3)C=CC=C2,-6.081605805570835,IVX-214,Polo-like Kinase-1 (Plk-1) Inhibitor,0.8985650000000001,1
NCGC00386226-04,NC1=NC(N)=C2N=C(CC(CC#C)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=NC2=N1,-7.274421616144317,Pralatrexate,Dihydrofolate Reductase (DHFR) Inhibitors,NCGC00345825-01,FC(F)C1=NN(C(=C1)C2=CN=C(NC(=O)C3CC3)S2)C4=C(Cl)C=CC=C4Cl,-5.931605578511759,BMS-3,LIMK Inhibitor,1.01248,0
NCGC00346644-04,O=C(CC1=CC=C(C=N1)C2=CC=C(OCCN3CCOCC3)C=C2)NCC4=CC=CC=C4,-7.43161051350816,KX-01,Src Kinase Inhibitor,NCGC00345825-01,FC(F)C1=NN(C(=C1)C2=CN=C(NC(=O)C3CC3)S2)C4=C(Cl)C=CC=C4Cl,-5.931605578511759,BMS-3,LIMK Inhibitor,0.90872,1
NCGC00346962-02,CN1C=C(C=N1)C2=CC=C3N=CC4=C(N(C(=O)C=C4)C5=CC6=C(CCN6C(=O)C=C)C=C5)C3=C2,-6.031605320261941,HMSL10077,BTK Inhibitor,NCGC00345825-01,FC(F)C1=NN(C(=C1)C2=CN=C(NC(=O)C3CC3)S2)C4=C(Cl)C=CC=C4Cl,-5.931605578511759,BMS-3,LIMK Inhibitor,0.8680150000000001,1
NCGC00346656-03,CCC1=C2N=C(C=C(NCC3=CC=C[N+]([O-])=C3)N2N=C1)N4CCCC[C@H]4CCO,-7.18160253455865,Dinaciclib (SCH727965),CDK1/2/5/9 Inhibitor,NCGC00345825-01,FC(F)C1=NN(C(=C1)C2=CN=C(NC(=O)C3CC3)S2)C4=C(Cl)C=CC=C4Cl,-5.931605578511759,BMS-3,LIMK Inhibitor,0.8867799999999999,1
NCGC00346951-03,O=C1C2=CC=CC=C2[N+]3=C1C4=C(C=C3)C5=CC=CC=C5N4,-5.931605578511759,Fascaplysin,CDK4/6 Inhibitor,NCGC00345825-01,FC(F)C1=NN(C(=C1)C2=CN=C(NC(=O)C3CC3)S2)C4=C(Cl)C=CC=C4Cl,-5.931605578511759,BMS-3,LIMK Inhibitor,0.94539,1
NCGC00347952-11,C\C(=N/NC(=S)N1CCC1)C2=NC=CC=C2,-8.731656086048936,NSC-319726,Mutant p53 Activator,NCGC00345825-01,FC(F)C1=NN(C(=C1)C2=CN=C(NC(=O)C3CC3)S2)C4=C(Cl)C=CC=C4Cl,-5.931605578511759,BMS-3,LIMK Inhibitor,0.9379200000000001,1
NCGC00346535-01,COC1=CC=C(C=C1)[S+]([O-])(=O)N(C(C)=O)C2=C(\C=C\C3=CC=N(=O)C=C3)C=CC=C2,-6.081605805570835,IVX-214,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00345825-01,FC(F)C1=NN(C(=C1)C2=CN=C(NC(=O)C3CC3)S2)C4=C(Cl)C=CC=C4Cl,-5.931605578511759,BMS-3,LIMK Inhibitor,1.040685,0
NCGC00345852-02,CC(C)C1=C2N=C(N[C@@H](CO)[C@H](O)CO)C=C(NCC3=CC=CC=C3)N2N=C1,-6.231605379060391,BS-194,CDK1/2/5/9 Inhibitor,NCGC00345825-01,FC(F)C1=NN(C(=C1)C2=CN=C(NC(=O)C3CC3)S2)C4=C(Cl)C=CC=C4Cl,-5.931605578511759,BMS-3,LIMK Inhibitor,1.0044899999999999,0
NCGC00346969-01,CCOC(=O)N1CCN(CC1)[N+](\[O-])=N\OC2=CC=C(C=C2C#N)[N+]([O-])=O,-5.981605362312015,JS-59-4,nitric oxide donors,NCGC00345825-01,FC(F)C1=NN(C(=C1)C2=CN=C(NC(=O)C3CC3)S2)C4=C(Cl)C=CC=C4Cl,-5.931605578511759,BMS-3,LIMK Inhibitor,1.07727,0
NCGC00346449-01,ClC1=CC=C(CCCOC2=NNC(=O)C(Br)=C2NCC3=CN=CC=C3)C=C1,-6.231605379060391,Parogrelil,Phosphodiesterase III/Va (PDE) Inhibitor,NCGC00345825-01,FC(F)C1=NN(C(=C1)C2=CN=C(NC(=O)C3CC3)S2)C4=C(Cl)C=CC=C4Cl,-5.931605578511759,BMS-3,LIMK Inhibitor,0.993325,0
NCGC00182868-16,O=C(NCCCCC1CCN(CC1)C(=O)C2=CC=CC=C2)\C=C\C3=CN=CC=C3,-7.531608356085238,Daporinad,NAMPT Inhibitor,NCGC00015038-08,NC1=NC2=NC=C(CNC3=CC=C(C=C3)C(=O)NC(CCC(O)=O)C(O)=O)N=C2C(N)=N1,-6.931606320539696,Aminopterin,Dihydrofolate Reductase (DHFR) Inhibitor,0.998,0
NCGC00386226-04,NC1=NC(N)=C2N=C(CC(CC#C)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=NC2=N1,-7.274421616144317,Pralatrexate,Dihydrofolate Reductase (DHFR) Inhibitors,NCGC00015038-08,NC1=NC2=NC=C(CNC3=CC=C(C=C3)C(=O)NC(CCC(O)=O)C(O)=O)N=C2C(N)=N1,-6.931606320539696,Aminopterin,Dihydrofolate Reductase (DHFR) Inhibitor,0.75305,1
NCGC00345809-03,CC(C)C1=NN(C2=C1C(=O)NC(CC3=CC=C(OCCO)C=C3)=N2)C4=C(Cl)C=CC=C4Cl,-7.18160253455865,RGB-286147,CDK1/2/3/7/9 Inhibitor,NCGC00015038-08,NC1=NC2=NC=C(CNC3=CC=C(C=C3)C(=O)NC(CCC(O)=O)C(O)=O)N=C2C(N)=N1,-6.931606320539696,Aminopterin,Dihydrofolate Reductase (DHFR) Inhibitor,0.90283,1
NCGC00345782-02,ClC1=CC=C(OCCCCCCN\C(NC2=CC=NC=C2)=N/C#N)C=C1,-8.331614083309999,GMX-1778,IKK beta Inhibitor,NCGC00015038-08,NC1=NC2=NC=C(CNC3=CC=C(C=C3)C(=O)NC(CCC(O)=O)C(O)=O)N=C2C(N)=N1,-6.931606320539696,Aminopterin,Dihydrofolate Reductase (DHFR) Inhibitor,0.9957900000000001,0
NCGC00346644-04,O=C(CC1=CC=C(C=N1)C2=CC=C(OCCN3CCOCC3)C=C2)NCC4=CC=CC=C4,-7.43161051350816,KX-01,Src Kinase Inhibitor,NCGC00015038-08,NC1=NC2=NC=C(CNC3=CC=C(C=C3)C(=O)NC(CCC(O)=O)C(O)=O)N=C2C(N)=N1,-6.931606320539696,Aminopterin,Dihydrofolate Reductase (DHFR) Inhibitor,1.012635,0
NCGC00242506-13,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)B(O)O,-7.43161051350816,Bortezomib,Proteasome Inhibitor,NCGC00015038-08,NC1=NC2=NC=C(CNC3=CC=C(C=C3)C(=O)NC(CCC(O)=O)C(O)=O)N=C2C(N)=N1,-6.931606320539696,Aminopterin,Dihydrofolate Reductase (DHFR) Inhibitor,1.04098,0
NCGC00242514-13,COCCN1C(C)=[N+](CC2=NC=CN=C2)C3=C1C(=O)C4=CC=CC=C4C3=O,-8.381638068890123,Sepantronium bromide,Survivin Inhibitor,NCGC00015038-08,NC1=NC2=NC=C(CNC3=CC=C(C=C3)C(=O)NC(CCC(O)=O)C(O)=O)N=C2C(N)=N1,-6.931606320539696,Aminopterin,Dihydrofolate Reductase (DHFR) Inhibitor,1.05592,0
NCGC00025060-04,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O,-6.681604807136856,Methotrexate,Dihydrofolate Reductase (DHFR) Inhibitor,NCGC00015038-08,NC1=NC2=NC=C(CNC3=CC=C(C=C3)C(=O)NC(CCC(O)=O)C(O)=O)N=C2C(N)=N1,-6.931606320539696,Aminopterin,Dihydrofolate Reductase (DHFR) Inhibitor,0.89763,1
NCGC00263017-01,COC1=C(OC)C=C2C(NCCN3CCOCC3)=NC(=NC2=C1)C4=CC=C(C=C4)N5CCN(C)CC5,-7.731609264370069,CPG-52364,"TLR 7, 8 and 9 Antagonist",NCGC00015038-08,NC1=NC2=NC=C(CNC3=CC=C(C=C3)C(=O)NC(CCC(O)=O)C(O)=O)N=C2C(N)=N1,-6.931606320539696,Aminopterin,Dihydrofolate Reductase (DHFR) Inhibitor,1.091555,0
NCGC00346962-02,CN1C=C(C=N1)C2=CC=C3N=CC4=C(N(C(=O)C=C4)C5=CC6=C(CCN6C(=O)C=C)C=C5)C3=C2,-6.031605320261941,HMSL10077,BTK Inhibitor,NCGC00015038-08,NC1=NC2=NC=C(CNC3=CC=C(C=C3)C(=O)NC(CCC(O)=O)C(O)=O)N=C2C(N)=N1,-6.931606320539696,Aminopterin,Dihydrofolate Reductase (DHFR) Inhibitor,1.049985,0
NCGC00346656-03,CCC1=C2N=C(C=C(NCC3=CC=C[N+]([O-])=C3)N2N=C1)N4CCCC[C@H]4CCO,-7.18160253455865,Dinaciclib (SCH727965),CDK1/2/5/9 Inhibitor,NCGC00015038-08,NC1=NC2=NC=C(CNC3=CC=C(C=C3)C(=O)NC(CCC(O)=O)C(O)=O)N=C2C(N)=N1,-6.931606320539696,Aminopterin,Dihydrofolate Reductase (DHFR) Inhibitor,0.95527,0
NCGC00263183-11,CN1CCN(CC1)C2=CC=C(NC3=NC=C4C(=O)N(CC=C)N(C4=N3)C5=CC=CC(=N5)C(C)(C)O)C=C2,-5.881605633370822,MK-1775,Wee1 Kinase Inhibitor,NCGC00015038-08,NC1=NC2=NC=C(CNC3=CC=C(C=C3)C(=O)NC(CCC(O)=O)C(O)=O)N=C2C(N)=N1,-6.931606320539696,Aminopterin,Dihydrofolate Reductase (DHFR) Inhibitor,1.060095,0
NCGC00263117-17,CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C3=CC=CC=C3N1,-6.231605379060391,Panobinostat,HDAC Inhibitor,NCGC00015038-08,NC1=NC2=NC=C(CNC3=CC=C(C=C3)C(=O)NC(CCC(O)=O)C(O)=O)N=C2C(N)=N1,-6.931606320539696,Aminopterin,Dihydrofolate Reductase (DHFR) Inhibitor,1.035935,0
NCGC00249613-10,CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN2CCOCC2)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]4(C)CO4,-7.4816045202261074,Carfilzomib,Proteasome Inhibitor,NCGC00015038-08,NC1=NC2=NC=C(CNC3=CC=C(C=C3)C(=O)NC(CCC(O)=O)C(O)=O)N=C2C(N)=N1,-6.931606320539696,Aminopterin,Dihydrofolate Reductase (DHFR) Inhibitor,0.74414,1
NCGC00346951-03,O=C1C2=CC=CC=C2[N+]3=C1C4=C(C=C3)C5=CC=CC=C5N4,-5.931605578511759,Fascaplysin,CDK4/6 Inhibitor,NCGC00015038-08,NC1=NC2=NC=C(CNC3=CC=C(C=C3)C(=O)NC(CCC(O)=O)C(O)=O)N=C2C(N)=N1,-6.931606320539696,Aminopterin,Dihydrofolate Reductase (DHFR) Inhibitor,0.955495,0
NCGC00345799-07,COC[C@H](NC(=O)[C@H](COC)NC(=O)C1=CN=C(C)S1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)[C@@]3(C)CO3,-6.8316056515638195,Oprozomib,Proteasome Inhibitor,NCGC00015038-08,NC1=NC2=NC=C(CNC3=CC=C(C=C3)C(=O)NC(CCC(O)=O)C(O)=O)N=C2C(N)=N1,-6.931606320539696,Aminopterin,Dihydrofolate Reductase (DHFR) Inhibitor,1.110205,0
NCGC00263222-02,CC1(C)OC2=C([C@H](NCC3=CC=CC=C3)[C@@H]1O)C(=O)C4=CC=CC=C4C2=O,-5.481605573349707,CAY-10581,IDO Inhibitor,NCGC00015038-08,NC1=NC2=NC=C(CNC3=CC=C(C=C3)C(=O)NC(CCC(O)=O)C(O)=O)N=C2C(N)=N1,-6.931606320539696,Aminopterin,Dihydrofolate Reductase (DHFR) Inhibitor,0.913065,1
NCGC00242217-07,COC1=CC2=C(C=C1OC)N(C=N2)C3=CC(OCC4=C(C=CC=C4)C(F)(F)F)=C(S3)C(N)=O,-5.83160565156382,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00015038-08,NC1=NC2=NC=C(CNC3=CC=C(C=C3)C(=O)NC(CCC(O)=O)C(O)=O)N=C2C(N)=N1,-6.931606320539696,Aminopterin,Dihydrofolate Reductase (DHFR) Inhibitor,0.98352,0
NCGC00347952-11,C\C(=N/NC(=S)N1CCC1)C2=NC=CC=C2,-8.731656086048936,NSC-319726,Mutant p53 Activator,NCGC00015038-08,NC1=NC2=NC=C(CNC3=CC=C(C=C3)C(=O)NC(CCC(O)=O)C(O)=O)N=C2C(N)=N1,-6.931606320539696,Aminopterin,Dihydrofolate Reductase (DHFR) Inhibitor,1.098765,0
NCGC00346535-01,COC1=CC=C(C=C1)[S+]([O-])(=O)N(C(C)=O)C2=C(\C=C\C3=CC=N(=O)C=C3)C=CC=C2,-6.081605805570835,IVX-214,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00015038-08,NC1=NC2=NC=C(CNC3=CC=C(C=C3)C(=O)NC(CCC(O)=O)C(O)=O)N=C2C(N)=N1,-6.931606320539696,Aminopterin,Dihydrofolate Reductase (DHFR) Inhibitor,1.080595,0
NCGC00345825-01,FC(F)C1=NN(C(=C1)C2=CN=C(NC(=O)C3CC3)S2)C4=C(Cl)C=CC=C4Cl,-5.931605578511759,BMS-3,LIMK Inhibitor,NCGC00015038-08,NC1=NC2=NC=C(CNC3=CC=C(C=C3)C(=O)NC(CCC(O)=O)C(O)=O)N=C2C(N)=N1,-6.931606320539696,Aminopterin,Dihydrofolate Reductase (DHFR) Inhibitor,1.102225,0
NCGC00188382-05,CC(NCC1=CC=C2N(CC(C)(C)O)\C(NC2=C1)=N\C(=O)C3=CC=C(S3)C4=CNN=C4)C(C)(C)C,-6.131605396855363,NCGC00188382-01,ITK inhibitor,NCGC00015038-08,NC1=NC2=NC=C(CNC3=CC=C(C=C3)C(=O)NC(CCC(O)=O)C(O)=O)N=C2C(N)=N1,-6.931606320539696,Aminopterin,Dihydrofolate Reductase (DHFR) Inhibitor,1.058985,0
NCGC00345852-02,CC(C)C1=C2N=C(N[C@@H](CO)[C@H](O)CO)C=C(NCC3=CC=CC=C3)N2N=C1,-6.231605379060391,BS-194,CDK1/2/5/9 Inhibitor,NCGC00015038-08,NC1=NC2=NC=C(CNC3=CC=C(C=C3)C(=O)NC(CCC(O)=O)C(O)=O)N=C2C(N)=N1,-6.931606320539696,Aminopterin,Dihydrofolate Reductase (DHFR) Inhibitor,1.05713,0
NCGC00345823-01,CC(C)(N)C1=CC=C(C=C1)C2=NC3=C(C=CC=C3)N=C2C4=CC=CC=C4,-6.531605402012491,"Akt-I-1,2",AKT Inhibitor,NCGC00015038-08,NC1=NC2=NC=C(CNC3=CC=C(C=C3)C(=O)NC(CCC(O)=O)C(O)=O)N=C2C(N)=N1,-6.931606320539696,Aminopterin,Dihydrofolate Reductase (DHFR) Inhibitor,1.0530300000000001,0
NCGC00263087-15,CC[C@H]1N(C(C)C)C2=NC(NC3=CC=C(C=C3OC)C(=O)NC4CCC(CC4)N5CCN(CC6CC6)CC5)=NC=C2N(C)C1=O,-6.981607443736785,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00015038-08,NC1=NC2=NC=C(CNC3=CC=C(C=C3)C(=O)NC(CCC(O)=O)C(O)=O)N=C2C(N)=N1,-6.931606320539696,Aminopterin,Dihydrofolate Reductase (DHFR) Inhibitor,1.1110349999999998,0
NCGC00016268-09,OC(=O)C1=CC=CN=C1,-5.581605560846199,Niacin,Nicotinic acid,NCGC00015038-08,NC1=NC2=NC=C(CNC3=CC=C(C=C3)C(=O)NC(CCC(O)=O)C(O)=O)N=C2C(N)=N1,-6.931606320539696,Aminopterin,Dihydrofolate Reductase (DHFR) Inhibitor,0.936515,1
NCGC00346969-01,CCOC(=O)N1CCN(CC1)[N+](\[O-])=N\OC2=CC=C(C=C2C#N)[N+]([O-])=O,-5.981605362312015,JS-59-4,nitric oxide donors,NCGC00015038-08,NC1=NC2=NC=C(CNC3=CC=C(C=C3)C(=O)NC(CCC(O)=O)C(O)=O)N=C2C(N)=N1,-6.931606320539696,Aminopterin,Dihydrofolate Reductase (DHFR) Inhibitor,1.02715,0
NCGC00253438-01,CC[C@H]1N(C2CCCC2)C3=NC(NC4=CC=C(C=C4OC)C(=O)NC5CCN(C)CC5)=NC=C3N(C)C1=O,-7.4816045202261074,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00015038-08,NC1=NC2=NC=C(CNC3=CC=C(C=C3)C(=O)NC(CCC(O)=O)C(O)=O)N=C2C(N)=N1,-6.931606320539696,Aminopterin,Dihydrofolate Reductase (DHFR) Inhibitor,1.134255,0
NCGC00346449-01,ClC1=CC=C(CCCOC2=NNC(=O)C(Br)=C2NCC3=CN=CC=C3)C=C1,-6.231605379060391,Parogrelil,Phosphodiesterase III/Va (PDE) Inhibitor,NCGC00015038-08,NC1=NC2=NC=C(CNC3=CC=C(C=C3)C(=O)NC(CCC(O)=O)C(O)=O)N=C2C(N)=N1,-6.931606320539696,Aminopterin,Dihydrofolate Reductase (DHFR) Inhibitor,0.9690650000000001,0
NCGC00263112-06,C[C@@H](OC1=C(SC(=C1)N2C=NC3=C2C=C(CN4CCN(C)CC4)C=C3)C(N)=O)C5=CC=CC=C5C(F)(F)F,-7.281606275378642,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00015038-08,NC1=NC2=NC=C(CNC3=CC=C(C=C3)C(=O)NC(CCC(O)=O)C(O)=O)N=C2C(N)=N1,-6.931606320539696,Aminopterin,Dihydrofolate Reductase (DHFR) Inhibitor,1.0562,0
NCGC00263110-02,CN(C(C)=O)C1(CCN(CCC[C@@]2(CCCN(C2)C(=O)C3=CC=CC=C3)C4=CC=C(Cl)C(Cl)=C4)CC1)C5=CC=CC=C5,-7.031605787340429,Osanetant,Tachykinin NK3 Antagonist,NCGC00015038-08,NC1=NC2=NC=C(CNC3=CC=C(C=C3)C(=O)NC(CCC(O)=O)C(O)=O)N=C2C(N)=N1,-6.931606320539696,Aminopterin,Dihydrofolate Reductase (DHFR) Inhibitor,0.98736,0
NCGC00386226-04,NC1=NC(N)=C2N=C(CC(CC#C)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=NC2=N1,-7.274421616144317,Pralatrexate,Dihydrofolate Reductase (DHFR) Inhibitors,NCGC00188382-05,CC(NCC1=CC=C2N(CC(C)(C)O)\C(NC2=C1)=N\C(=O)C3=CC=C(S3)C4=CNN=C4)C(C)(C)C,-6.131605396855363,NCGC00188382-01,ITK inhibitor,1.1778300000000002,0
NCGC00345809-03,CC(C)C1=NN(C2=C1C(=O)NC(CC3=CC=C(OCCO)C=C3)=N2)C4=C(Cl)C=CC=C4Cl,-7.18160253455865,RGB-286147,CDK1/2/3/7/9 Inhibitor,NCGC00188382-05,CC(NCC1=CC=C2N(CC(C)(C)O)\C(NC2=C1)=N\C(=O)C3=CC=C(S3)C4=CNN=C4)C(C)(C)C,-6.131605396855363,NCGC00188382-01,ITK inhibitor,0.792335,1
NCGC00345782-02,ClC1=CC=C(OCCCCCCN\C(NC2=CC=NC=C2)=N/C#N)C=C1,-8.331614083309999,GMX-1778,IKK beta Inhibitor,NCGC00188382-05,CC(NCC1=CC=C2N(CC(C)(C)O)\C(NC2=C1)=N\C(=O)C3=CC=C(S3)C4=CNN=C4)C(C)(C)C,-6.131605396855363,NCGC00188382-01,ITK inhibitor,1.0676,0
NCGC00346644-04,O=C(CC1=CC=C(C=N1)C2=CC=C(OCCN3CCOCC3)C=C2)NCC4=CC=CC=C4,-7.43161051350816,KX-01,Src Kinase Inhibitor,NCGC00188382-05,CC(NCC1=CC=C2N(CC(C)(C)O)\C(NC2=C1)=N\C(=O)C3=CC=C(S3)C4=CNN=C4)C(C)(C)C,-6.131605396855363,NCGC00188382-01,ITK inhibitor,0.9963599999999999,0
NCGC00242506-13,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)B(O)O,-7.43161051350816,Bortezomib,Proteasome Inhibitor,NCGC00188382-05,CC(NCC1=CC=C2N(CC(C)(C)O)\C(NC2=C1)=N\C(=O)C3=CC=C(S3)C4=CNN=C4)C(C)(C)C,-6.131605396855363,NCGC00188382-01,ITK inhibitor,0.7437750000000001,1
NCGC00242514-13,COCCN1C(C)=[N+](CC2=NC=CN=C2)C3=C1C(=O)C4=CC=CC=C4C3=O,-8.381638068890123,Sepantronium bromide,Survivin Inhibitor,NCGC00188382-05,CC(NCC1=CC=C2N(CC(C)(C)O)\C(NC2=C1)=N\C(=O)C3=CC=C(S3)C4=CNN=C4)C(C)(C)C,-6.131605396855363,NCGC00188382-01,ITK inhibitor,0.8251,1
NCGC00263017-01,COC1=C(OC)C=C2C(NCCN3CCOCC3)=NC(=NC2=C1)C4=CC=C(C=C4)N5CCN(C)CC5,-7.731609264370069,CPG-52364,"TLR 7, 8 and 9 Antagonist",NCGC00188382-05,CC(NCC1=CC=C2N(CC(C)(C)O)\C(NC2=C1)=N\C(=O)C3=CC=C(S3)C4=CNN=C4)C(C)(C)C,-6.131605396855363,NCGC00188382-01,ITK inhibitor,0.83596,1
NCGC00346962-02,CN1C=C(C=N1)C2=CC=C3N=CC4=C(N(C(=O)C=C4)C5=CC6=C(CCN6C(=O)C=C)C=C5)C3=C2,-6.031605320261941,HMSL10077,BTK Inhibitor,NCGC00188382-05,CC(NCC1=CC=C2N(CC(C)(C)O)\C(NC2=C1)=N\C(=O)C3=CC=C(S3)C4=CNN=C4)C(C)(C)C,-6.131605396855363,NCGC00188382-01,ITK inhibitor,0.8048550000000001,1
NCGC00346656-03,CCC1=C2N=C(C=C(NCC3=CC=C[N+]([O-])=C3)N2N=C1)N4CCCC[C@H]4CCO,-7.18160253455865,Dinaciclib (SCH727965),CDK1/2/5/9 Inhibitor,NCGC00188382-05,CC(NCC1=CC=C2N(CC(C)(C)O)\C(NC2=C1)=N\C(=O)C3=CC=C(S3)C4=CNN=C4)C(C)(C)C,-6.131605396855363,NCGC00188382-01,ITK inhibitor,0.81144,1
NCGC00263183-11,CN1CCN(CC1)C2=CC=C(NC3=NC=C4C(=O)N(CC=C)N(C4=N3)C5=CC=CC(=N5)C(C)(C)O)C=C2,-5.881605633370822,MK-1775,Wee1 Kinase Inhibitor,NCGC00188382-05,CC(NCC1=CC=C2N(CC(C)(C)O)\C(NC2=C1)=N\C(=O)C3=CC=C(S3)C4=CNN=C4)C(C)(C)C,-6.131605396855363,NCGC00188382-01,ITK inhibitor,0.84788,1
NCGC00263117-17,CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C3=CC=CC=C3N1,-6.231605379060391,Panobinostat,HDAC Inhibitor,NCGC00188382-05,CC(NCC1=CC=C2N(CC(C)(C)O)\C(NC2=C1)=N\C(=O)C3=CC=C(S3)C4=CNN=C4)C(C)(C)C,-6.131605396855363,NCGC00188382-01,ITK inhibitor,0.707475,1
NCGC00249613-10,CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN2CCOCC2)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]4(C)CO4,-7.4816045202261074,Carfilzomib,Proteasome Inhibitor,NCGC00188382-05,CC(NCC1=CC=C2N(CC(C)(C)O)\C(NC2=C1)=N\C(=O)C3=CC=C(S3)C4=CNN=C4)C(C)(C)C,-6.131605396855363,NCGC00188382-01,ITK inhibitor,0.30498000000000003,1
NCGC00346951-03,O=C1C2=CC=CC=C2[N+]3=C1C4=C(C=C3)C5=CC=CC=C5N4,-5.931605578511759,Fascaplysin,CDK4/6 Inhibitor,NCGC00188382-05,CC(NCC1=CC=C2N(CC(C)(C)O)\C(NC2=C1)=N\C(=O)C3=CC=C(S3)C4=CNN=C4)C(C)(C)C,-6.131605396855363,NCGC00188382-01,ITK inhibitor,0.927905,1
NCGC00345799-07,COC[C@H](NC(=O)[C@H](COC)NC(=O)C1=CN=C(C)S1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)[C@@]3(C)CO3,-6.8316056515638195,Oprozomib,Proteasome Inhibitor,NCGC00188382-05,CC(NCC1=CC=C2N(CC(C)(C)O)\C(NC2=C1)=N\C(=O)C3=CC=C(S3)C4=CNN=C4)C(C)(C)C,-6.131605396855363,NCGC00188382-01,ITK inhibitor,0.6157699999999999,1
NCGC00263222-02,CC1(C)OC2=C([C@H](NCC3=CC=CC=C3)[C@@H]1O)C(=O)C4=CC=CC=C4C2=O,-5.481605573349707,CAY-10581,IDO Inhibitor,NCGC00188382-05,CC(NCC1=CC=C2N(CC(C)(C)O)\C(NC2=C1)=N\C(=O)C3=CC=C(S3)C4=CNN=C4)C(C)(C)C,-6.131605396855363,NCGC00188382-01,ITK inhibitor,0.98578,0
NCGC00242217-07,COC1=CC2=C(C=C1OC)N(C=N2)C3=CC(OCC4=C(C=CC=C4)C(F)(F)F)=C(S3)C(N)=O,-5.83160565156382,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00188382-05,CC(NCC1=CC=C2N(CC(C)(C)O)\C(NC2=C1)=N\C(=O)C3=CC=C(S3)C4=CNN=C4)C(C)(C)C,-6.131605396855363,NCGC00188382-01,ITK inhibitor,1.0301399999999998,0
NCGC00347952-11,C\C(=N/NC(=S)N1CCC1)C2=NC=CC=C2,-8.731656086048936,NSC-319726,Mutant p53 Activator,NCGC00188382-05,CC(NCC1=CC=C2N(CC(C)(C)O)\C(NC2=C1)=N\C(=O)C3=CC=C(S3)C4=CNN=C4)C(C)(C)C,-6.131605396855363,NCGC00188382-01,ITK inhibitor,0.92725,1
NCGC00346535-01,COC1=CC=C(C=C1)[S+]([O-])(=O)N(C(C)=O)C2=C(\C=C\C3=CC=N(=O)C=C3)C=CC=C2,-6.081605805570835,IVX-214,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00188382-05,CC(NCC1=CC=C2N(CC(C)(C)O)\C(NC2=C1)=N\C(=O)C3=CC=C(S3)C4=CNN=C4)C(C)(C)C,-6.131605396855363,NCGC00188382-01,ITK inhibitor,1.03898,0
NCGC00345825-01,FC(F)C1=NN(C(=C1)C2=CN=C(NC(=O)C3CC3)S2)C4=C(Cl)C=CC=C4Cl,-5.931605578511759,BMS-3,LIMK Inhibitor,NCGC00188382-05,CC(NCC1=CC=C2N(CC(C)(C)O)\C(NC2=C1)=N\C(=O)C3=CC=C(S3)C4=CNN=C4)C(C)(C)C,-6.131605396855363,NCGC00188382-01,ITK inhibitor,0.78623,1
NCGC00345852-02,CC(C)C1=C2N=C(N[C@@H](CO)[C@H](O)CO)C=C(NCC3=CC=CC=C3)N2N=C1,-6.231605379060391,BS-194,CDK1/2/5/9 Inhibitor,NCGC00188382-05,CC(NCC1=CC=C2N(CC(C)(C)O)\C(NC2=C1)=N\C(=O)C3=CC=C(S3)C4=CNN=C4)C(C)(C)C,-6.131605396855363,NCGC00188382-01,ITK inhibitor,0.77639,1
NCGC00345823-01,CC(C)(N)C1=CC=C(C=C1)C2=NC3=C(C=CC=C3)N=C2C4=CC=CC=C4,-6.531605402012491,"Akt-I-1,2",AKT Inhibitor,NCGC00188382-05,CC(NCC1=CC=C2N(CC(C)(C)O)\C(NC2=C1)=N\C(=O)C3=CC=C(S3)C4=CNN=C4)C(C)(C)C,-6.131605396855363,NCGC00188382-01,ITK inhibitor,0.77461,1
NCGC00263087-15,CC[C@H]1N(C(C)C)C2=NC(NC3=CC=C(C=C3OC)C(=O)NC4CCC(CC4)N5CCN(CC6CC6)CC5)=NC=C2N(C)C1=O,-6.981607443736785,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00188382-05,CC(NCC1=CC=C2N(CC(C)(C)O)\C(NC2=C1)=N\C(=O)C3=CC=C(S3)C4=CNN=C4)C(C)(C)C,-6.131605396855363,NCGC00188382-01,ITK inhibitor,0.78433,1
NCGC00346969-01,CCOC(=O)N1CCN(CC1)[N+](\[O-])=N\OC2=CC=C(C=C2C#N)[N+]([O-])=O,-5.981605362312015,JS-59-4,nitric oxide donors,NCGC00188382-05,CC(NCC1=CC=C2N(CC(C)(C)O)\C(NC2=C1)=N\C(=O)C3=CC=C(S3)C4=CNN=C4)C(C)(C)C,-6.131605396855363,NCGC00188382-01,ITK inhibitor,0.883155,1
NCGC00253438-01,CC[C@H]1N(C2CCCC2)C3=NC(NC4=CC=C(C=C4OC)C(=O)NC5CCN(C)CC5)=NC=C3N(C)C1=O,-7.4816045202261074,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00188382-05,CC(NCC1=CC=C2N(CC(C)(C)O)\C(NC2=C1)=N\C(=O)C3=CC=C(S3)C4=CNN=C4)C(C)(C)C,-6.131605396855363,NCGC00188382-01,ITK inhibitor,0.9393549999999999,1
NCGC00346449-01,ClC1=CC=C(CCCOC2=NNC(=O)C(Br)=C2NCC3=CN=CC=C3)C=C1,-6.231605379060391,Parogrelil,Phosphodiesterase III/Va (PDE) Inhibitor,NCGC00188382-05,CC(NCC1=CC=C2N(CC(C)(C)O)\C(NC2=C1)=N\C(=O)C3=CC=C(S3)C4=CNN=C4)C(C)(C)C,-6.131605396855363,NCGC00188382-01,ITK inhibitor,0.94773,1
NCGC00263112-06,C[C@@H](OC1=C(SC(=C1)N2C=NC3=C2C=C(CN4CCN(C)CC4)C=C3)C(N)=O)C5=CC=CC=C5C(F)(F)F,-7.281606275378642,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00188382-05,CC(NCC1=CC=C2N(CC(C)(C)O)\C(NC2=C1)=N\C(=O)C3=CC=C(S3)C4=CNN=C4)C(C)(C)C,-6.131605396855363,NCGC00188382-01,ITK inhibitor,0.95371,0
NCGC00263110-02,CN(C(C)=O)C1(CCN(CCC[C@@]2(CCCN(C2)C(=O)C3=CC=CC=C3)C4=CC=C(Cl)C(Cl)=C4)CC1)C5=CC=CC=C5,-7.031605787340429,Osanetant,Tachykinin NK3 Antagonist,NCGC00188382-05,CC(NCC1=CC=C2N(CC(C)(C)O)\C(NC2=C1)=N\C(=O)C3=CC=C(S3)C4=CNN=C4)C(C)(C)C,-6.131605396855363,NCGC00188382-01,ITK inhibitor,0.94336,1
NCGC00386226-04,NC1=NC(N)=C2N=C(CC(CC#C)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=NC2=N1,-7.274421616144317,Pralatrexate,Dihydrofolate Reductase (DHFR) Inhibitors,NCGC00345852-02,CC(C)C1=C2N=C(N[C@@H](CO)[C@H](O)CO)C=C(NCC3=CC=CC=C3)N2N=C1,-6.231605379060391,BS-194,CDK1/2/5/9 Inhibitor,1.079175,0
NCGC00346644-04,O=C(CC1=CC=C(C=N1)C2=CC=C(OCCN3CCOCC3)C=C2)NCC4=CC=CC=C4,-7.43161051350816,KX-01,Src Kinase Inhibitor,NCGC00345852-02,CC(C)C1=C2N=C(N[C@@H](CO)[C@H](O)CO)C=C(NCC3=CC=CC=C3)N2N=C1,-6.231605379060391,BS-194,CDK1/2/5/9 Inhibitor,0.9773700000000001,0
NCGC00346962-02,CN1C=C(C=N1)C2=CC=C3N=CC4=C(N(C(=O)C=C4)C5=CC6=C(CCN6C(=O)C=C)C=C5)C3=C2,-6.031605320261941,HMSL10077,BTK Inhibitor,NCGC00345852-02,CC(C)C1=C2N=C(N[C@@H](CO)[C@H](O)CO)C=C(NCC3=CC=CC=C3)N2N=C1,-6.231605379060391,BS-194,CDK1/2/5/9 Inhibitor,0.95841,0
NCGC00346656-03,CCC1=C2N=C(C=C(NCC3=CC=C[N+]([O-])=C3)N2N=C1)N4CCCC[C@H]4CCO,-7.18160253455865,Dinaciclib (SCH727965),CDK1/2/5/9 Inhibitor,NCGC00345852-02,CC(C)C1=C2N=C(N[C@@H](CO)[C@H](O)CO)C=C(NCC3=CC=CC=C3)N2N=C1,-6.231605379060391,BS-194,CDK1/2/5/9 Inhibitor,0.851675,1
NCGC00346951-03,O=C1C2=CC=CC=C2[N+]3=C1C4=C(C=C3)C5=CC=CC=C5N4,-5.931605578511759,Fascaplysin,CDK4/6 Inhibitor,NCGC00345852-02,CC(C)C1=C2N=C(N[C@@H](CO)[C@H](O)CO)C=C(NCC3=CC=CC=C3)N2N=C1,-6.231605379060391,BS-194,CDK1/2/5/9 Inhibitor,0.8775350000000001,1
NCGC00347952-11,C\C(=N/NC(=S)N1CCC1)C2=NC=CC=C2,-8.731656086048936,NSC-319726,Mutant p53 Activator,NCGC00345852-02,CC(C)C1=C2N=C(N[C@@H](CO)[C@H](O)CO)C=C(NCC3=CC=CC=C3)N2N=C1,-6.231605379060391,BS-194,CDK1/2/5/9 Inhibitor,0.9165749999999999,1
NCGC00346535-01,COC1=CC=C(C=C1)[S+]([O-])(=O)N(C(C)=O)C2=C(\C=C\C3=CC=N(=O)C=C3)C=CC=C2,-6.081605805570835,IVX-214,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00345852-02,CC(C)C1=C2N=C(N[C@@H](CO)[C@H](O)CO)C=C(NCC3=CC=CC=C3)N2N=C1,-6.231605379060391,BS-194,CDK1/2/5/9 Inhibitor,0.979075,0
NCGC00346969-01,CCOC(=O)N1CCN(CC1)[N+](\[O-])=N\OC2=CC=C(C=C2C#N)[N+]([O-])=O,-5.981605362312015,JS-59-4,nitric oxide donors,NCGC00345852-02,CC(C)C1=C2N=C(N[C@@H](CO)[C@H](O)CO)C=C(NCC3=CC=CC=C3)N2N=C1,-6.231605379060391,BS-194,CDK1/2/5/9 Inhibitor,0.9756100000000001,0
NCGC00346449-01,ClC1=CC=C(CCCOC2=NNC(=O)C(Br)=C2NCC3=CN=CC=C3)C=C1,-6.231605379060391,Parogrelil,Phosphodiesterase III/Va (PDE) Inhibitor,NCGC00345852-02,CC(C)C1=C2N=C(N[C@@H](CO)[C@H](O)CO)C=C(NCC3=CC=CC=C3)N2N=C1,-6.231605379060391,BS-194,CDK1/2/5/9 Inhibitor,0.95611,0
NCGC00386226-04,NC1=NC(N)=C2N=C(CC(CC#C)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=NC2=N1,-7.274421616144317,Pralatrexate,Dihydrofolate Reductase (DHFR) Inhibitors,NCGC00345823-01,CC(C)(N)C1=CC=C(C=C1)C2=NC3=C(C=CC=C3)N=C2C4=CC=CC=C4,-6.531605402012491,"Akt-I-1,2",AKT Inhibitor,0.9371700000000001,1
NCGC00346644-04,O=C(CC1=CC=C(C=N1)C2=CC=C(OCCN3CCOCC3)C=C2)NCC4=CC=CC=C4,-7.43161051350816,KX-01,Src Kinase Inhibitor,NCGC00345823-01,CC(C)(N)C1=CC=C(C=C1)C2=NC3=C(C=CC=C3)N=C2C4=CC=CC=C4,-6.531605402012491,"Akt-I-1,2",AKT Inhibitor,0.961425,0
NCGC00346962-02,CN1C=C(C=N1)C2=CC=C3N=CC4=C(N(C(=O)C=C4)C5=CC6=C(CCN6C(=O)C=C)C=C5)C3=C2,-6.031605320261941,HMSL10077,BTK Inhibitor,NCGC00345823-01,CC(C)(N)C1=CC=C(C=C1)C2=NC3=C(C=CC=C3)N=C2C4=CC=CC=C4,-6.531605402012491,"Akt-I-1,2",AKT Inhibitor,1.0132249999999998,0
NCGC00346656-03,CCC1=C2N=C(C=C(NCC3=CC=C[N+]([O-])=C3)N2N=C1)N4CCCC[C@H]4CCO,-7.18160253455865,Dinaciclib (SCH727965),CDK1/2/5/9 Inhibitor,NCGC00345823-01,CC(C)(N)C1=CC=C(C=C1)C2=NC3=C(C=CC=C3)N=C2C4=CC=CC=C4,-6.531605402012491,"Akt-I-1,2",AKT Inhibitor,0.94718,1
NCGC00346951-03,O=C1C2=CC=CC=C2[N+]3=C1C4=C(C=C3)C5=CC=CC=C5N4,-5.931605578511759,Fascaplysin,CDK4/6 Inhibitor,NCGC00345823-01,CC(C)(N)C1=CC=C(C=C1)C2=NC3=C(C=CC=C3)N=C2C4=CC=CC=C4,-6.531605402012491,"Akt-I-1,2",AKT Inhibitor,0.99175,0
NCGC00347952-11,C\C(=N/NC(=S)N1CCC1)C2=NC=CC=C2,-8.731656086048936,NSC-319726,Mutant p53 Activator,NCGC00345823-01,CC(C)(N)C1=CC=C(C=C1)C2=NC3=C(C=CC=C3)N=C2C4=CC=CC=C4,-6.531605402012491,"Akt-I-1,2",AKT Inhibitor,0.784375,1
NCGC00346535-01,COC1=CC=C(C=C1)[S+]([O-])(=O)N(C(C)=O)C2=C(\C=C\C3=CC=N(=O)C=C3)C=CC=C2,-6.081605805570835,IVX-214,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00345823-01,CC(C)(N)C1=CC=C(C=C1)C2=NC3=C(C=CC=C3)N=C2C4=CC=CC=C4,-6.531605402012491,"Akt-I-1,2",AKT Inhibitor,0.92079,1
NCGC00345825-01,FC(F)C1=NN(C(=C1)C2=CN=C(NC(=O)C3CC3)S2)C4=C(Cl)C=CC=C4Cl,-5.931605578511759,BMS-3,LIMK Inhibitor,NCGC00345823-01,CC(C)(N)C1=CC=C(C=C1)C2=NC3=C(C=CC=C3)N=C2C4=CC=CC=C4,-6.531605402012491,"Akt-I-1,2",AKT Inhibitor,0.9756450000000001,0
NCGC00345852-02,CC(C)C1=C2N=C(N[C@@H](CO)[C@H](O)CO)C=C(NCC3=CC=CC=C3)N2N=C1,-6.231605379060391,BS-194,CDK1/2/5/9 Inhibitor,NCGC00345823-01,CC(C)(N)C1=CC=C(C=C1)C2=NC3=C(C=CC=C3)N=C2C4=CC=CC=C4,-6.531605402012491,"Akt-I-1,2",AKT Inhibitor,0.947325,1
NCGC00346969-01,CCOC(=O)N1CCN(CC1)[N+](\[O-])=N\OC2=CC=C(C=C2C#N)[N+]([O-])=O,-5.981605362312015,JS-59-4,nitric oxide donors,NCGC00345823-01,CC(C)(N)C1=CC=C(C=C1)C2=NC3=C(C=CC=C3)N=C2C4=CC=CC=C4,-6.531605402012491,"Akt-I-1,2",AKT Inhibitor,0.9571149999999999,0
NCGC00346449-01,ClC1=CC=C(CCCOC2=NNC(=O)C(Br)=C2NCC3=CN=CC=C3)C=C1,-6.231605379060391,Parogrelil,Phosphodiesterase III/Va (PDE) Inhibitor,NCGC00345823-01,CC(C)(N)C1=CC=C(C=C1)C2=NC3=C(C=CC=C3)N=C2C4=CC=CC=C4,-6.531605402012491,"Akt-I-1,2",AKT Inhibitor,0.96702,0
NCGC00386226-04,NC1=NC(N)=C2N=C(CC(CC#C)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=NC2=N1,-7.274421616144317,Pralatrexate,Dihydrofolate Reductase (DHFR) Inhibitors,NCGC00263087-15,CC[C@H]1N(C(C)C)C2=NC(NC3=CC=C(C=C3OC)C(=O)NC4CCC(CC4)N5CCN(CC6CC6)CC5)=NC=C2N(C)C1=O,-6.981607443736785,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,1.2666,0
NCGC00345809-03,CC(C)C1=NN(C2=C1C(=O)NC(CC3=CC=C(OCCO)C=C3)=N2)C4=C(Cl)C=CC=C4Cl,-7.18160253455865,RGB-286147,CDK1/2/3/7/9 Inhibitor,NCGC00263087-15,CC[C@H]1N(C(C)C)C2=NC(NC3=CC=C(C=C3OC)C(=O)NC4CCC(CC4)N5CCN(CC6CC6)CC5)=NC=C2N(C)C1=O,-6.981607443736785,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,0.79314,1
NCGC00345782-02,ClC1=CC=C(OCCCCCCN\C(NC2=CC=NC=C2)=N/C#N)C=C1,-8.331614083309999,GMX-1778,IKK beta Inhibitor,NCGC00263087-15,CC[C@H]1N(C(C)C)C2=NC(NC3=CC=C(C=C3OC)C(=O)NC4CCC(CC4)N5CCN(CC6CC6)CC5)=NC=C2N(C)C1=O,-6.981607443736785,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,0.9290499999999999,1
NCGC00346644-04,O=C(CC1=CC=C(C=N1)C2=CC=C(OCCN3CCOCC3)C=C2)NCC4=CC=CC=C4,-7.43161051350816,KX-01,Src Kinase Inhibitor,NCGC00263087-15,CC[C@H]1N(C(C)C)C2=NC(NC3=CC=C(C=C3OC)C(=O)NC4CCC(CC4)N5CCN(CC6CC6)CC5)=NC=C2N(C)C1=O,-6.981607443736785,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,1.088965,0
NCGC00346962-02,CN1C=C(C=N1)C2=CC=C3N=CC4=C(N(C(=O)C=C4)C5=CC6=C(CCN6C(=O)C=C)C=C5)C3=C2,-6.031605320261941,HMSL10077,BTK Inhibitor,NCGC00263087-15,CC[C@H]1N(C(C)C)C2=NC(NC3=CC=C(C=C3OC)C(=O)NC4CCC(CC4)N5CCN(CC6CC6)CC5)=NC=C2N(C)C1=O,-6.981607443736785,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,1.0983899999999998,0
NCGC00346656-03,CCC1=C2N=C(C=C(NCC3=CC=C[N+]([O-])=C3)N2N=C1)N4CCCC[C@H]4CCO,-7.18160253455865,Dinaciclib (SCH727965),CDK1/2/5/9 Inhibitor,NCGC00263087-15,CC[C@H]1N(C(C)C)C2=NC(NC3=CC=C(C=C3OC)C(=O)NC4CCC(CC4)N5CCN(CC6CC6)CC5)=NC=C2N(C)C1=O,-6.981607443736785,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,0.9566399999999999,0
NCGC00263183-11,CN1CCN(CC1)C2=CC=C(NC3=NC=C4C(=O)N(CC=C)N(C4=N3)C5=CC=CC(=N5)C(C)(C)O)C=C2,-5.881605633370822,MK-1775,Wee1 Kinase Inhibitor,NCGC00263087-15,CC[C@H]1N(C(C)C)C2=NC(NC3=CC=C(C=C3OC)C(=O)NC4CCC(CC4)N5CCN(CC6CC6)CC5)=NC=C2N(C)C1=O,-6.981607443736785,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,0.8800299999999999,1
NCGC00263117-17,CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C3=CC=CC=C3N1,-6.231605379060391,Panobinostat,HDAC Inhibitor,NCGC00263087-15,CC[C@H]1N(C(C)C)C2=NC(NC3=CC=C(C=C3OC)C(=O)NC4CCC(CC4)N5CCN(CC6CC6)CC5)=NC=C2N(C)C1=O,-6.981607443736785,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,0.872165,1
NCGC00346951-03,O=C1C2=CC=CC=C2[N+]3=C1C4=C(C=C3)C5=CC=CC=C5N4,-5.931605578511759,Fascaplysin,CDK4/6 Inhibitor,NCGC00263087-15,CC[C@H]1N(C(C)C)C2=NC(NC3=CC=C(C=C3OC)C(=O)NC4CCC(CC4)N5CCN(CC6CC6)CC5)=NC=C2N(C)C1=O,-6.981607443736785,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,0.72488,1
NCGC00345799-07,COC[C@H](NC(=O)[C@H](COC)NC(=O)C1=CN=C(C)S1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)[C@@]3(C)CO3,-6.8316056515638195,Oprozomib,Proteasome Inhibitor,NCGC00263087-15,CC[C@H]1N(C(C)C)C2=NC(NC3=CC=C(C=C3OC)C(=O)NC4CCC(CC4)N5CCN(CC6CC6)CC5)=NC=C2N(C)C1=O,-6.981607443736785,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,0.92012,1
NCGC00263222-02,CC1(C)OC2=C([C@H](NCC3=CC=CC=C3)[C@@H]1O)C(=O)C4=CC=CC=C4C2=O,-5.481605573349707,CAY-10581,IDO Inhibitor,NCGC00263087-15,CC[C@H]1N(C(C)C)C2=NC(NC3=CC=C(C=C3OC)C(=O)NC4CCC(CC4)N5CCN(CC6CC6)CC5)=NC=C2N(C)C1=O,-6.981607443736785,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,0.6649400000000001,1
NCGC00347952-11,C\C(=N/NC(=S)N1CCC1)C2=NC=CC=C2,-8.731656086048936,NSC-319726,Mutant p53 Activator,NCGC00263087-15,CC[C@H]1N(C(C)C)C2=NC(NC3=CC=C(C=C3OC)C(=O)NC4CCC(CC4)N5CCN(CC6CC6)CC5)=NC=C2N(C)C1=O,-6.981607443736785,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,0.7728550000000001,1
NCGC00346535-01,COC1=CC=C(C=C1)[S+]([O-])(=O)N(C(C)=O)C2=C(\C=C\C3=CC=N(=O)C=C3)C=CC=C2,-6.081605805570835,IVX-214,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00263087-15,CC[C@H]1N(C(C)C)C2=NC(NC3=CC=C(C=C3OC)C(=O)NC4CCC(CC4)N5CCN(CC6CC6)CC5)=NC=C2N(C)C1=O,-6.981607443736785,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,1.14126,0
NCGC00345825-01,FC(F)C1=NN(C(=C1)C2=CN=C(NC(=O)C3CC3)S2)C4=C(Cl)C=CC=C4Cl,-5.931605578511759,BMS-3,LIMK Inhibitor,NCGC00263087-15,CC[C@H]1N(C(C)C)C2=NC(NC3=CC=C(C=C3OC)C(=O)NC4CCC(CC4)N5CCN(CC6CC6)CC5)=NC=C2N(C)C1=O,-6.981607443736785,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,1.19558,0
NCGC00345852-02,CC(C)C1=C2N=C(N[C@@H](CO)[C@H](O)CO)C=C(NCC3=CC=CC=C3)N2N=C1,-6.231605379060391,BS-194,CDK1/2/5/9 Inhibitor,NCGC00263087-15,CC[C@H]1N(C(C)C)C2=NC(NC3=CC=C(C=C3OC)C(=O)NC4CCC(CC4)N5CCN(CC6CC6)CC5)=NC=C2N(C)C1=O,-6.981607443736785,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,0.8725700000000001,1
NCGC00345823-01,CC(C)(N)C1=CC=C(C=C1)C2=NC3=C(C=CC=C3)N=C2C4=CC=CC=C4,-6.531605402012491,"Akt-I-1,2",AKT Inhibitor,NCGC00263087-15,CC[C@H]1N(C(C)C)C2=NC(NC3=CC=C(C=C3OC)C(=O)NC4CCC(CC4)N5CCN(CC6CC6)CC5)=NC=C2N(C)C1=O,-6.981607443736785,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,1.0625,0
NCGC00346969-01,CCOC(=O)N1CCN(CC1)[N+](\[O-])=N\OC2=CC=C(C=C2C#N)[N+]([O-])=O,-5.981605362312015,JS-59-4,nitric oxide donors,NCGC00263087-15,CC[C@H]1N(C(C)C)C2=NC(NC3=CC=C(C=C3OC)C(=O)NC4CCC(CC4)N5CCN(CC6CC6)CC5)=NC=C2N(C)C1=O,-6.981607443736785,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,1.246215,0
NCGC00346449-01,ClC1=CC=C(CCCOC2=NNC(=O)C(Br)=C2NCC3=CN=CC=C3)C=C1,-6.231605379060391,Parogrelil,Phosphodiesterase III/Va (PDE) Inhibitor,NCGC00263087-15,CC[C@H]1N(C(C)C)C2=NC(NC3=CC=C(C=C3OC)C(=O)NC4CCC(CC4)N5CCN(CC6CC6)CC5)=NC=C2N(C)C1=O,-6.981607443736785,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,0.95374,0
NCGC00263112-06,C[C@@H](OC1=C(SC(=C1)N2C=NC3=C2C=C(CN4CCN(C)CC4)C=C3)C(N)=O)C5=CC=CC=C5C(F)(F)F,-7.281606275378642,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00263087-15,CC[C@H]1N(C(C)C)C2=NC(NC3=CC=C(C=C3OC)C(=O)NC4CCC(CC4)N5CCN(CC6CC6)CC5)=NC=C2N(C)C1=O,-6.981607443736785,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,1.0253649999999999,0
NCGC00263110-02,CN(C(C)=O)C1(CCN(CCC[C@@]2(CCCN(C2)C(=O)C3=CC=CC=C3)C4=CC=C(Cl)C(Cl)=C4)CC1)C5=CC=CC=C5,-7.031605787340429,Osanetant,Tachykinin NK3 Antagonist,NCGC00263087-15,CC[C@H]1N(C(C)C)C2=NC(NC3=CC=C(C=C3OC)C(=O)NC4CCC(CC4)N5CCN(CC6CC6)CC5)=NC=C2N(C)C1=O,-6.981607443736785,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,0.69163,1
NCGC00182868-16,O=C(NCCCCC1CCN(CC1)C(=O)C2=CC=CC=C2)\C=C\C3=CN=CC=C3,-7.531608356085238,Daporinad,NAMPT Inhibitor,NCGC00016268-09,OC(=O)C1=CC=CN=C1,-5.581605560846199,Niacin,Nicotinic acid,1.30283,0
NCGC00386226-04,NC1=NC(N)=C2N=C(CC(CC#C)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=NC2=N1,-7.274421616144317,Pralatrexate,Dihydrofolate Reductase (DHFR) Inhibitors,NCGC00016268-09,OC(=O)C1=CC=CN=C1,-5.581605560846199,Niacin,Nicotinic acid,0.9835800000000001,0
NCGC00345809-03,CC(C)C1=NN(C2=C1C(=O)NC(CC3=CC=C(OCCO)C=C3)=N2)C4=C(Cl)C=CC=C4Cl,-7.18160253455865,RGB-286147,CDK1/2/3/7/9 Inhibitor,NCGC00016268-09,OC(=O)C1=CC=CN=C1,-5.581605560846199,Niacin,Nicotinic acid,0.993455,0
NCGC00345782-02,ClC1=CC=C(OCCCCCCN\C(NC2=CC=NC=C2)=N/C#N)C=C1,-8.331614083309999,GMX-1778,IKK beta Inhibitor,NCGC00016268-09,OC(=O)C1=CC=CN=C1,-5.581605560846199,Niacin,Nicotinic acid,1.29497,0
NCGC00346644-04,O=C(CC1=CC=C(C=N1)C2=CC=C(OCCN3CCOCC3)C=C2)NCC4=CC=CC=C4,-7.43161051350816,KX-01,Src Kinase Inhibitor,NCGC00016268-09,OC(=O)C1=CC=CN=C1,-5.581605560846199,Niacin,Nicotinic acid,1.0117500000000001,0
NCGC00242506-13,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)B(O)O,-7.43161051350816,Bortezomib,Proteasome Inhibitor,NCGC00016268-09,OC(=O)C1=CC=CN=C1,-5.581605560846199,Niacin,Nicotinic acid,0.940395,1
NCGC00242514-13,COCCN1C(C)=[N+](CC2=NC=CN=C2)C3=C1C(=O)C4=CC=CC=C4C3=O,-8.381638068890123,Sepantronium bromide,Survivin Inhibitor,NCGC00016268-09,OC(=O)C1=CC=CN=C1,-5.581605560846199,Niacin,Nicotinic acid,0.93533,1
NCGC00025060-04,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O,-6.681604807136856,Methotrexate,Dihydrofolate Reductase (DHFR) Inhibitor,NCGC00016268-09,OC(=O)C1=CC=CN=C1,-5.581605560846199,Niacin,Nicotinic acid,0.98716,0
NCGC00263017-01,COC1=C(OC)C=C2C(NCCN3CCOCC3)=NC(=NC2=C1)C4=CC=C(C=C4)N5CCN(C)CC5,-7.731609264370069,CPG-52364,"TLR 7, 8 and 9 Antagonist",NCGC00016268-09,OC(=O)C1=CC=CN=C1,-5.581605560846199,Niacin,Nicotinic acid,0.9963,0
NCGC00346962-02,CN1C=C(C=N1)C2=CC=C3N=CC4=C(N(C(=O)C=C4)C5=CC6=C(CCN6C(=O)C=C)C=C5)C3=C2,-6.031605320261941,HMSL10077,BTK Inhibitor,NCGC00016268-09,OC(=O)C1=CC=CN=C1,-5.581605560846199,Niacin,Nicotinic acid,1.012545,0
NCGC00346656-03,CCC1=C2N=C(C=C(NCC3=CC=C[N+]([O-])=C3)N2N=C1)N4CCCC[C@H]4CCO,-7.18160253455865,Dinaciclib (SCH727965),CDK1/2/5/9 Inhibitor,NCGC00016268-09,OC(=O)C1=CC=CN=C1,-5.581605560846199,Niacin,Nicotinic acid,0.997115,0
NCGC00263183-11,CN1CCN(CC1)C2=CC=C(NC3=NC=C4C(=O)N(CC=C)N(C4=N3)C5=CC=CC(=N5)C(C)(C)O)C=C2,-5.881605633370822,MK-1775,Wee1 Kinase Inhibitor,NCGC00016268-09,OC(=O)C1=CC=CN=C1,-5.581605560846199,Niacin,Nicotinic acid,1.00614,0
NCGC00263117-17,CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C3=CC=CC=C3N1,-6.231605379060391,Panobinostat,HDAC Inhibitor,NCGC00016268-09,OC(=O)C1=CC=CN=C1,-5.581605560846199,Niacin,Nicotinic acid,0.9759,0
NCGC00249613-10,CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN2CCOCC2)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]4(C)CO4,-7.4816045202261074,Carfilzomib,Proteasome Inhibitor,NCGC00016268-09,OC(=O)C1=CC=CN=C1,-5.581605560846199,Niacin,Nicotinic acid,1.0401,0
NCGC00346951-03,O=C1C2=CC=CC=C2[N+]3=C1C4=C(C=C3)C5=CC=CC=C5N4,-5.931605578511759,Fascaplysin,CDK4/6 Inhibitor,NCGC00016268-09,OC(=O)C1=CC=CN=C1,-5.581605560846199,Niacin,Nicotinic acid,1.0128400000000002,0
NCGC00345799-07,COC[C@H](NC(=O)[C@H](COC)NC(=O)C1=CN=C(C)S1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)[C@@]3(C)CO3,-6.8316056515638195,Oprozomib,Proteasome Inhibitor,NCGC00016268-09,OC(=O)C1=CC=CN=C1,-5.581605560846199,Niacin,Nicotinic acid,0.9549799999999999,0
NCGC00263222-02,CC1(C)OC2=C([C@H](NCC3=CC=CC=C3)[C@@H]1O)C(=O)C4=CC=CC=C4C2=O,-5.481605573349707,CAY-10581,IDO Inhibitor,NCGC00016268-09,OC(=O)C1=CC=CN=C1,-5.581605560846199,Niacin,Nicotinic acid,0.988525,0
NCGC00242217-07,COC1=CC2=C(C=C1OC)N(C=N2)C3=CC(OCC4=C(C=CC=C4)C(F)(F)F)=C(S3)C(N)=O,-5.83160565156382,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00016268-09,OC(=O)C1=CC=CN=C1,-5.581605560846199,Niacin,Nicotinic acid,0.99449,0
NCGC00347952-11,C\C(=N/NC(=S)N1CCC1)C2=NC=CC=C2,-8.731656086048936,NSC-319726,Mutant p53 Activator,NCGC00016268-09,OC(=O)C1=CC=CN=C1,-5.581605560846199,Niacin,Nicotinic acid,0.8542000000000001,1
NCGC00346535-01,COC1=CC=C(C=C1)[S+]([O-])(=O)N(C(C)=O)C2=C(\C=C\C3=CC=N(=O)C=C3)C=CC=C2,-6.081605805570835,IVX-214,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00016268-09,OC(=O)C1=CC=CN=C1,-5.581605560846199,Niacin,Nicotinic acid,0.9674050000000001,0
NCGC00345825-01,FC(F)C1=NN(C(=C1)C2=CN=C(NC(=O)C3CC3)S2)C4=C(Cl)C=CC=C4Cl,-5.931605578511759,BMS-3,LIMK Inhibitor,NCGC00016268-09,OC(=O)C1=CC=CN=C1,-5.581605560846199,Niacin,Nicotinic acid,0.99238,0
NCGC00188382-05,CC(NCC1=CC=C2N(CC(C)(C)O)\C(NC2=C1)=N\C(=O)C3=CC=C(S3)C4=CNN=C4)C(C)(C)C,-6.131605396855363,NCGC00188382-01,ITK inhibitor,NCGC00016268-09,OC(=O)C1=CC=CN=C1,-5.581605560846199,Niacin,Nicotinic acid,1.000505,0
NCGC00345852-02,CC(C)C1=C2N=C(N[C@@H](CO)[C@H](O)CO)C=C(NCC3=CC=CC=C3)N2N=C1,-6.231605379060391,BS-194,CDK1/2/5/9 Inhibitor,NCGC00016268-09,OC(=O)C1=CC=CN=C1,-5.581605560846199,Niacin,Nicotinic acid,1.022605,0
NCGC00345823-01,CC(C)(N)C1=CC=C(C=C1)C2=NC3=C(C=CC=C3)N=C2C4=CC=CC=C4,-6.531605402012491,"Akt-I-1,2",AKT Inhibitor,NCGC00016268-09,OC(=O)C1=CC=CN=C1,-5.581605560846199,Niacin,Nicotinic acid,0.96449,0
NCGC00263087-15,CC[C@H]1N(C(C)C)C2=NC(NC3=CC=C(C=C3OC)C(=O)NC4CCC(CC4)N5CCN(CC6CC6)CC5)=NC=C2N(C)C1=O,-6.981607443736785,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00016268-09,OC(=O)C1=CC=CN=C1,-5.581605560846199,Niacin,Nicotinic acid,0.96079,0
NCGC00346969-01,CCOC(=O)N1CCN(CC1)[N+](\[O-])=N\OC2=CC=C(C=C2C#N)[N+]([O-])=O,-5.981605362312015,JS-59-4,nitric oxide donors,NCGC00016268-09,OC(=O)C1=CC=CN=C1,-5.581605560846199,Niacin,Nicotinic acid,0.982435,0
NCGC00253438-01,CC[C@H]1N(C2CCCC2)C3=NC(NC4=CC=C(C=C4OC)C(=O)NC5CCN(C)CC5)=NC=C3N(C)C1=O,-7.4816045202261074,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00016268-09,OC(=O)C1=CC=CN=C1,-5.581605560846199,Niacin,Nicotinic acid,1.02362,0
NCGC00346449-01,ClC1=CC=C(CCCOC2=NNC(=O)C(Br)=C2NCC3=CN=CC=C3)C=C1,-6.231605379060391,Parogrelil,Phosphodiesterase III/Va (PDE) Inhibitor,NCGC00016268-09,OC(=O)C1=CC=CN=C1,-5.581605560846199,Niacin,Nicotinic acid,1.0054800000000002,0
NCGC00263112-06,C[C@@H](OC1=C(SC(=C1)N2C=NC3=C2C=C(CN4CCN(C)CC4)C=C3)C(N)=O)C5=CC=CC=C5C(F)(F)F,-7.281606275378642,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00016268-09,OC(=O)C1=CC=CN=C1,-5.581605560846199,Niacin,Nicotinic acid,0.962485,0
NCGC00263110-02,CN(C(C)=O)C1(CCN(CCC[C@@]2(CCCN(C2)C(=O)C3=CC=CC=C3)C4=CC=C(Cl)C(Cl)=C4)CC1)C5=CC=CC=C5,-7.031605787340429,Osanetant,Tachykinin NK3 Antagonist,NCGC00016268-09,OC(=O)C1=CC=CN=C1,-5.581605560846199,Niacin,Nicotinic acid,0.989055,0
NCGC00386226-04,NC1=NC(N)=C2N=C(CC(CC#C)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=NC2=N1,-7.274421616144317,Pralatrexate,Dihydrofolate Reductase (DHFR) Inhibitors,NCGC00346969-01,CCOC(=O)N1CCN(CC1)[N+](\[O-])=N\OC2=CC=C(C=C2C#N)[N+]([O-])=O,-5.981605362312015,JS-59-4,nitric oxide donors,1.10962,0
NCGC00347952-11,C\C(=N/NC(=S)N1CCC1)C2=NC=CC=C2,-8.731656086048936,NSC-319726,Mutant p53 Activator,NCGC00346969-01,CCOC(=O)N1CCN(CC1)[N+](\[O-])=N\OC2=CC=C(C=C2C#N)[N+]([O-])=O,-5.981605362312015,JS-59-4,nitric oxide donors,0.87156,1
NCGC00386226-04,NC1=NC(N)=C2N=C(CC(CC#C)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=NC2=N1,-7.274421616144317,Pralatrexate,Dihydrofolate Reductase (DHFR) Inhibitors,NCGC00253438-01,CC[C@H]1N(C2CCCC2)C3=NC(NC4=CC=C(C=C4OC)C(=O)NC5CCN(C)CC5)=NC=C3N(C)C1=O,-7.4816045202261074,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,1.34995,0
NCGC00345809-03,CC(C)C1=NN(C2=C1C(=O)NC(CC3=CC=C(OCCO)C=C3)=N2)C4=C(Cl)C=CC=C4Cl,-7.18160253455865,RGB-286147,CDK1/2/3/7/9 Inhibitor,NCGC00253438-01,CC[C@H]1N(C2CCCC2)C3=NC(NC4=CC=C(C=C4OC)C(=O)NC5CCN(C)CC5)=NC=C3N(C)C1=O,-7.4816045202261074,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,0.8549900000000001,1
NCGC00345782-02,ClC1=CC=C(OCCCCCCN\C(NC2=CC=NC=C2)=N/C#N)C=C1,-8.331614083309999,GMX-1778,IKK beta Inhibitor,NCGC00253438-01,CC[C@H]1N(C2CCCC2)C3=NC(NC4=CC=C(C=C4OC)C(=O)NC5CCN(C)CC5)=NC=C3N(C)C1=O,-7.4816045202261074,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,1.05422,0
NCGC00346644-04,O=C(CC1=CC=C(C=N1)C2=CC=C(OCCN3CCOCC3)C=C2)NCC4=CC=CC=C4,-7.43161051350816,KX-01,Src Kinase Inhibitor,NCGC00253438-01,CC[C@H]1N(C2CCCC2)C3=NC(NC4=CC=C(C=C4OC)C(=O)NC5CCN(C)CC5)=NC=C3N(C)C1=O,-7.4816045202261074,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,0.864795,1
NCGC00263017-01,COC1=C(OC)C=C2C(NCCN3CCOCC3)=NC(=NC2=C1)C4=CC=C(C=C4)N5CCN(C)CC5,-7.731609264370069,CPG-52364,"TLR 7, 8 and 9 Antagonist",NCGC00253438-01,CC[C@H]1N(C2CCCC2)C3=NC(NC4=CC=C(C=C4OC)C(=O)NC5CCN(C)CC5)=NC=C3N(C)C1=O,-7.4816045202261074,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,0.8709450000000001,1
NCGC00346962-02,CN1C=C(C=N1)C2=CC=C3N=CC4=C(N(C(=O)C=C4)C5=CC6=C(CCN6C(=O)C=C)C=C5)C3=C2,-6.031605320261941,HMSL10077,BTK Inhibitor,NCGC00253438-01,CC[C@H]1N(C2CCCC2)C3=NC(NC4=CC=C(C=C4OC)C(=O)NC5CCN(C)CC5)=NC=C3N(C)C1=O,-7.4816045202261074,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,0.80751,1
NCGC00346656-03,CCC1=C2N=C(C=C(NCC3=CC=C[N+]([O-])=C3)N2N=C1)N4CCCC[C@H]4CCO,-7.18160253455865,Dinaciclib (SCH727965),CDK1/2/5/9 Inhibitor,NCGC00253438-01,CC[C@H]1N(C2CCCC2)C3=NC(NC4=CC=C(C=C4OC)C(=O)NC5CCN(C)CC5)=NC=C3N(C)C1=O,-7.4816045202261074,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,0.700025,1
NCGC00263183-11,CN1CCN(CC1)C2=CC=C(NC3=NC=C4C(=O)N(CC=C)N(C4=N3)C5=CC=CC(=N5)C(C)(C)O)C=C2,-5.881605633370822,MK-1775,Wee1 Kinase Inhibitor,NCGC00253438-01,CC[C@H]1N(C2CCCC2)C3=NC(NC4=CC=C(C=C4OC)C(=O)NC5CCN(C)CC5)=NC=C3N(C)C1=O,-7.4816045202261074,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,0.8190149999999999,1
NCGC00263117-17,CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C3=CC=CC=C3N1,-6.231605379060391,Panobinostat,HDAC Inhibitor,NCGC00253438-01,CC[C@H]1N(C2CCCC2)C3=NC(NC4=CC=C(C=C4OC)C(=O)NC5CCN(C)CC5)=NC=C3N(C)C1=O,-7.4816045202261074,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,0.93601,1
NCGC00346951-03,O=C1C2=CC=CC=C2[N+]3=C1C4=C(C=C3)C5=CC=CC=C5N4,-5.931605578511759,Fascaplysin,CDK4/6 Inhibitor,NCGC00253438-01,CC[C@H]1N(C2CCCC2)C3=NC(NC4=CC=C(C=C4OC)C(=O)NC5CCN(C)CC5)=NC=C3N(C)C1=O,-7.4816045202261074,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,0.90006,1
NCGC00345799-07,COC[C@H](NC(=O)[C@H](COC)NC(=O)C1=CN=C(C)S1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)[C@@]3(C)CO3,-6.8316056515638195,Oprozomib,Proteasome Inhibitor,NCGC00253438-01,CC[C@H]1N(C2CCCC2)C3=NC(NC4=CC=C(C=C4OC)C(=O)NC5CCN(C)CC5)=NC=C3N(C)C1=O,-7.4816045202261074,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,0.9759800000000001,0
NCGC00263222-02,CC1(C)OC2=C([C@H](NCC3=CC=CC=C3)[C@@H]1O)C(=O)C4=CC=CC=C4C2=O,-5.481605573349707,CAY-10581,IDO Inhibitor,NCGC00253438-01,CC[C@H]1N(C2CCCC2)C3=NC(NC4=CC=C(C=C4OC)C(=O)NC5CCN(C)CC5)=NC=C3N(C)C1=O,-7.4816045202261074,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,1.0286149999999998,0
NCGC00347952-11,C\C(=N/NC(=S)N1CCC1)C2=NC=CC=C2,-8.731656086048936,NSC-319726,Mutant p53 Activator,NCGC00253438-01,CC[C@H]1N(C2CCCC2)C3=NC(NC4=CC=C(C=C4OC)C(=O)NC5CCN(C)CC5)=NC=C3N(C)C1=O,-7.4816045202261074,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,0.926755,1
NCGC00346535-01,COC1=CC=C(C=C1)[S+]([O-])(=O)N(C(C)=O)C2=C(\C=C\C3=CC=N(=O)C=C3)C=CC=C2,-6.081605805570835,IVX-214,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00253438-01,CC[C@H]1N(C2CCCC2)C3=NC(NC4=CC=C(C=C4OC)C(=O)NC5CCN(C)CC5)=NC=C3N(C)C1=O,-7.4816045202261074,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,1.106395,0
NCGC00345825-01,FC(F)C1=NN(C(=C1)C2=CN=C(NC(=O)C3CC3)S2)C4=C(Cl)C=CC=C4Cl,-5.931605578511759,BMS-3,LIMK Inhibitor,NCGC00253438-01,CC[C@H]1N(C2CCCC2)C3=NC(NC4=CC=C(C=C4OC)C(=O)NC5CCN(C)CC5)=NC=C3N(C)C1=O,-7.4816045202261074,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,1.2917999999999998,0
NCGC00345852-02,CC(C)C1=C2N=C(N[C@@H](CO)[C@H](O)CO)C=C(NCC3=CC=CC=C3)N2N=C1,-6.231605379060391,BS-194,CDK1/2/5/9 Inhibitor,NCGC00253438-01,CC[C@H]1N(C2CCCC2)C3=NC(NC4=CC=C(C=C4OC)C(=O)NC5CCN(C)CC5)=NC=C3N(C)C1=O,-7.4816045202261074,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,0.80193,1
NCGC00345823-01,CC(C)(N)C1=CC=C(C=C1)C2=NC3=C(C=CC=C3)N=C2C4=CC=CC=C4,-6.531605402012491,"Akt-I-1,2",AKT Inhibitor,NCGC00253438-01,CC[C@H]1N(C2CCCC2)C3=NC(NC4=CC=C(C=C4OC)C(=O)NC5CCN(C)CC5)=NC=C3N(C)C1=O,-7.4816045202261074,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,0.67461,1
NCGC00263087-15,CC[C@H]1N(C(C)C)C2=NC(NC3=CC=C(C=C3OC)C(=O)NC4CCC(CC4)N5CCN(CC6CC6)CC5)=NC=C2N(C)C1=O,-6.981607443736785,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00253438-01,CC[C@H]1N(C2CCCC2)C3=NC(NC4=CC=C(C=C4OC)C(=O)NC5CCN(C)CC5)=NC=C3N(C)C1=O,-7.4816045202261074,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,0.8864150000000001,1
NCGC00346969-01,CCOC(=O)N1CCN(CC1)[N+](\[O-])=N\OC2=CC=C(C=C2C#N)[N+]([O-])=O,-5.981605362312015,JS-59-4,nitric oxide donors,NCGC00253438-01,CC[C@H]1N(C2CCCC2)C3=NC(NC4=CC=C(C=C4OC)C(=O)NC5CCN(C)CC5)=NC=C3N(C)C1=O,-7.4816045202261074,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,0.9529400000000001,0
NCGC00346449-01,ClC1=CC=C(CCCOC2=NNC(=O)C(Br)=C2NCC3=CN=CC=C3)C=C1,-6.231605379060391,Parogrelil,Phosphodiesterase III/Va (PDE) Inhibitor,NCGC00253438-01,CC[C@H]1N(C2CCCC2)C3=NC(NC4=CC=C(C=C4OC)C(=O)NC5CCN(C)CC5)=NC=C3N(C)C1=O,-7.4816045202261074,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,0.897705,1
NCGC00263112-06,C[C@@H](OC1=C(SC(=C1)N2C=NC3=C2C=C(CN4CCN(C)CC4)C=C3)C(N)=O)C5=CC=CC=C5C(F)(F)F,-7.281606275378642,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00253438-01,CC[C@H]1N(C2CCCC2)C3=NC(NC4=CC=C(C=C4OC)C(=O)NC5CCN(C)CC5)=NC=C3N(C)C1=O,-7.4816045202261074,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,0.9227650000000001,1
NCGC00263110-02,CN(C(C)=O)C1(CCN(CCC[C@@]2(CCCN(C2)C(=O)C3=CC=CC=C3)C4=CC=C(Cl)C(Cl)=C4)CC1)C5=CC=CC=C5,-7.031605787340429,Osanetant,Tachykinin NK3 Antagonist,NCGC00253438-01,CC[C@H]1N(C2CCCC2)C3=NC(NC4=CC=C(C=C4OC)C(=O)NC5CCN(C)CC5)=NC=C3N(C)C1=O,-7.4816045202261074,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,0.9054949999999999,1
NCGC00386226-04,NC1=NC(N)=C2N=C(CC(CC#C)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=NC2=N1,-7.274421616144317,Pralatrexate,Dihydrofolate Reductase (DHFR) Inhibitors,NCGC00346449-01,ClC1=CC=C(CCCOC2=NNC(=O)C(Br)=C2NCC3=CN=CC=C3)C=C1,-6.231605379060391,Parogrelil,Phosphodiesterase III/Va (PDE) Inhibitor,1.003395,0
NCGC00346644-04,O=C(CC1=CC=C(C=N1)C2=CC=C(OCCN3CCOCC3)C=C2)NCC4=CC=CC=C4,-7.43161051350816,KX-01,Src Kinase Inhibitor,NCGC00346449-01,ClC1=CC=C(CCCOC2=NNC(=O)C(Br)=C2NCC3=CN=CC=C3)C=C1,-6.231605379060391,Parogrelil,Phosphodiesterase III/Va (PDE) Inhibitor,0.972925,0
NCGC00346962-02,CN1C=C(C=N1)C2=CC=C3N=CC4=C(N(C(=O)C=C4)C5=CC6=C(CCN6C(=O)C=C)C=C5)C3=C2,-6.031605320261941,HMSL10077,BTK Inhibitor,NCGC00346449-01,ClC1=CC=C(CCCOC2=NNC(=O)C(Br)=C2NCC3=CN=CC=C3)C=C1,-6.231605379060391,Parogrelil,Phosphodiesterase III/Va (PDE) Inhibitor,1.001225,0
NCGC00346656-03,CCC1=C2N=C(C=C(NCC3=CC=C[N+]([O-])=C3)N2N=C1)N4CCCC[C@H]4CCO,-7.18160253455865,Dinaciclib (SCH727965),CDK1/2/5/9 Inhibitor,NCGC00346449-01,ClC1=CC=C(CCCOC2=NNC(=O)C(Br)=C2NCC3=CN=CC=C3)C=C1,-6.231605379060391,Parogrelil,Phosphodiesterase III/Va (PDE) Inhibitor,0.942505,1
NCGC00346951-03,O=C1C2=CC=CC=C2[N+]3=C1C4=C(C=C3)C5=CC=CC=C5N4,-5.931605578511759,Fascaplysin,CDK4/6 Inhibitor,NCGC00346449-01,ClC1=CC=C(CCCOC2=NNC(=O)C(Br)=C2NCC3=CN=CC=C3)C=C1,-6.231605379060391,Parogrelil,Phosphodiesterase III/Va (PDE) Inhibitor,1.003235,0
NCGC00347952-11,C\C(=N/NC(=S)N1CCC1)C2=NC=CC=C2,-8.731656086048936,NSC-319726,Mutant p53 Activator,NCGC00346449-01,ClC1=CC=C(CCCOC2=NNC(=O)C(Br)=C2NCC3=CN=CC=C3)C=C1,-6.231605379060391,Parogrelil,Phosphodiesterase III/Va (PDE) Inhibitor,0.9043100000000001,1
NCGC00346535-01,COC1=CC=C(C=C1)[S+]([O-])(=O)N(C(C)=O)C2=C(\C=C\C3=CC=N(=O)C=C3)C=CC=C2,-6.081605805570835,IVX-214,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00346449-01,ClC1=CC=C(CCCOC2=NNC(=O)C(Br)=C2NCC3=CN=CC=C3)C=C1,-6.231605379060391,Parogrelil,Phosphodiesterase III/Va (PDE) Inhibitor,0.960815,0
NCGC00346969-01,CCOC(=O)N1CCN(CC1)[N+](\[O-])=N\OC2=CC=C(C=C2C#N)[N+]([O-])=O,-5.981605362312015,JS-59-4,nitric oxide donors,NCGC00346449-01,ClC1=CC=C(CCCOC2=NNC(=O)C(Br)=C2NCC3=CN=CC=C3)C=C1,-6.231605379060391,Parogrelil,Phosphodiesterase III/Va (PDE) Inhibitor,1.00469,0
NCGC00386226-04,NC1=NC(N)=C2N=C(CC(CC#C)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=NC2=N1,-7.274421616144317,Pralatrexate,Dihydrofolate Reductase (DHFR) Inhibitors,NCGC00263112-06,C[C@@H](OC1=C(SC(=C1)N2C=NC3=C2C=C(CN4CCN(C)CC4)C=C3)C(N)=O)C5=CC=CC=C5C(F)(F)F,-7.281606275378642,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,1.00244,0
NCGC00345809-03,CC(C)C1=NN(C2=C1C(=O)NC(CC3=CC=C(OCCO)C=C3)=N2)C4=C(Cl)C=CC=C4Cl,-7.18160253455865,RGB-286147,CDK1/2/3/7/9 Inhibitor,NCGC00263112-06,C[C@@H](OC1=C(SC(=C1)N2C=NC3=C2C=C(CN4CCN(C)CC4)C=C3)C(N)=O)C5=CC=CC=C5C(F)(F)F,-7.281606275378642,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,0.72749,1
NCGC00345782-02,ClC1=CC=C(OCCCCCCN\C(NC2=CC=NC=C2)=N/C#N)C=C1,-8.331614083309999,GMX-1778,IKK beta Inhibitor,NCGC00263112-06,C[C@@H](OC1=C(SC(=C1)N2C=NC3=C2C=C(CN4CCN(C)CC4)C=C3)C(N)=O)C5=CC=CC=C5C(F)(F)F,-7.281606275378642,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,0.9018550000000001,1
NCGC00346644-04,O=C(CC1=CC=C(C=N1)C2=CC=C(OCCN3CCOCC3)C=C2)NCC4=CC=CC=C4,-7.43161051350816,KX-01,Src Kinase Inhibitor,NCGC00263112-06,C[C@@H](OC1=C(SC(=C1)N2C=NC3=C2C=C(CN4CCN(C)CC4)C=C3)C(N)=O)C5=CC=CC=C5C(F)(F)F,-7.281606275378642,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,1.170165,0
NCGC00346962-02,CN1C=C(C=N1)C2=CC=C3N=CC4=C(N(C(=O)C=C4)C5=CC6=C(CCN6C(=O)C=C)C=C5)C3=C2,-6.031605320261941,HMSL10077,BTK Inhibitor,NCGC00263112-06,C[C@@H](OC1=C(SC(=C1)N2C=NC3=C2C=C(CN4CCN(C)CC4)C=C3)C(N)=O)C5=CC=CC=C5C(F)(F)F,-7.281606275378642,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,0.916115,1
NCGC00346656-03,CCC1=C2N=C(C=C(NCC3=CC=C[N+]([O-])=C3)N2N=C1)N4CCCC[C@H]4CCO,-7.18160253455865,Dinaciclib (SCH727965),CDK1/2/5/9 Inhibitor,NCGC00263112-06,C[C@@H](OC1=C(SC(=C1)N2C=NC3=C2C=C(CN4CCN(C)CC4)C=C3)C(N)=O)C5=CC=CC=C5C(F)(F)F,-7.281606275378642,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,0.9265749999999999,1
NCGC00263183-11,CN1CCN(CC1)C2=CC=C(NC3=NC=C4C(=O)N(CC=C)N(C4=N3)C5=CC=CC(=N5)C(C)(C)O)C=C2,-5.881605633370822,MK-1775,Wee1 Kinase Inhibitor,NCGC00263112-06,C[C@@H](OC1=C(SC(=C1)N2C=NC3=C2C=C(CN4CCN(C)CC4)C=C3)C(N)=O)C5=CC=CC=C5C(F)(F)F,-7.281606275378642,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,0.94614,1
NCGC00263117-17,CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C3=CC=CC=C3N1,-6.231605379060391,Panobinostat,HDAC Inhibitor,NCGC00263112-06,C[C@@H](OC1=C(SC(=C1)N2C=NC3=C2C=C(CN4CCN(C)CC4)C=C3)C(N)=O)C5=CC=CC=C5C(F)(F)F,-7.281606275378642,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,0.9699949999999999,0
NCGC00346951-03,O=C1C2=CC=CC=C2[N+]3=C1C4=C(C=C3)C5=CC=CC=C5N4,-5.931605578511759,Fascaplysin,CDK4/6 Inhibitor,NCGC00263112-06,C[C@@H](OC1=C(SC(=C1)N2C=NC3=C2C=C(CN4CCN(C)CC4)C=C3)C(N)=O)C5=CC=CC=C5C(F)(F)F,-7.281606275378642,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,1.08407,0
NCGC00345799-07,COC[C@H](NC(=O)[C@H](COC)NC(=O)C1=CN=C(C)S1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)[C@@]3(C)CO3,-6.8316056515638195,Oprozomib,Proteasome Inhibitor,NCGC00263112-06,C[C@@H](OC1=C(SC(=C1)N2C=NC3=C2C=C(CN4CCN(C)CC4)C=C3)C(N)=O)C5=CC=CC=C5C(F)(F)F,-7.281606275378642,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,0.967215,0
NCGC00263222-02,CC1(C)OC2=C([C@H](NCC3=CC=CC=C3)[C@@H]1O)C(=O)C4=CC=CC=C4C2=O,-5.481605573349707,CAY-10581,IDO Inhibitor,NCGC00263112-06,C[C@@H](OC1=C(SC(=C1)N2C=NC3=C2C=C(CN4CCN(C)CC4)C=C3)C(N)=O)C5=CC=CC=C5C(F)(F)F,-7.281606275378642,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,0.78145,1
NCGC00347952-11,C\C(=N/NC(=S)N1CCC1)C2=NC=CC=C2,-8.731656086048936,NSC-319726,Mutant p53 Activator,NCGC00263112-06,C[C@@H](OC1=C(SC(=C1)N2C=NC3=C2C=C(CN4CCN(C)CC4)C=C3)C(N)=O)C5=CC=CC=C5C(F)(F)F,-7.281606275378642,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,0.77224,1
NCGC00346535-01,COC1=CC=C(C=C1)[S+]([O-])(=O)N(C(C)=O)C2=C(\C=C\C3=CC=N(=O)C=C3)C=CC=C2,-6.081605805570835,IVX-214,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00263112-06,C[C@@H](OC1=C(SC(=C1)N2C=NC3=C2C=C(CN4CCN(C)CC4)C=C3)C(N)=O)C5=CC=CC=C5C(F)(F)F,-7.281606275378642,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,0.9506100000000001,0
NCGC00345825-01,FC(F)C1=NN(C(=C1)C2=CN=C(NC(=O)C3CC3)S2)C4=C(Cl)C=CC=C4Cl,-5.931605578511759,BMS-3,LIMK Inhibitor,NCGC00263112-06,C[C@@H](OC1=C(SC(=C1)N2C=NC3=C2C=C(CN4CCN(C)CC4)C=C3)C(N)=O)C5=CC=CC=C5C(F)(F)F,-7.281606275378642,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,1.20371,0
NCGC00345852-02,CC(C)C1=C2N=C(N[C@@H](CO)[C@H](O)CO)C=C(NCC3=CC=CC=C3)N2N=C1,-6.231605379060391,BS-194,CDK1/2/5/9 Inhibitor,NCGC00263112-06,C[C@@H](OC1=C(SC(=C1)N2C=NC3=C2C=C(CN4CCN(C)CC4)C=C3)C(N)=O)C5=CC=CC=C5C(F)(F)F,-7.281606275378642,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,1.00264,0
NCGC00345823-01,CC(C)(N)C1=CC=C(C=C1)C2=NC3=C(C=CC=C3)N=C2C4=CC=CC=C4,-6.531605402012491,"Akt-I-1,2",AKT Inhibitor,NCGC00263112-06,C[C@@H](OC1=C(SC(=C1)N2C=NC3=C2C=C(CN4CCN(C)CC4)C=C3)C(N)=O)C5=CC=CC=C5C(F)(F)F,-7.281606275378642,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,1.02074,0
NCGC00346969-01,CCOC(=O)N1CCN(CC1)[N+](\[O-])=N\OC2=CC=C(C=C2C#N)[N+]([O-])=O,-5.981605362312015,JS-59-4,nitric oxide donors,NCGC00263112-06,C[C@@H](OC1=C(SC(=C1)N2C=NC3=C2C=C(CN4CCN(C)CC4)C=C3)C(N)=O)C5=CC=CC=C5C(F)(F)F,-7.281606275378642,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,1.221825,0
NCGC00346449-01,ClC1=CC=C(CCCOC2=NNC(=O)C(Br)=C2NCC3=CN=CC=C3)C=C1,-6.231605379060391,Parogrelil,Phosphodiesterase III/Va (PDE) Inhibitor,NCGC00263112-06,C[C@@H](OC1=C(SC(=C1)N2C=NC3=C2C=C(CN4CCN(C)CC4)C=C3)C(N)=O)C5=CC=CC=C5C(F)(F)F,-7.281606275378642,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,1.1396000000000002,0
NCGC00386226-04,NC1=NC(N)=C2N=C(CC(CC#C)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=NC2=N1,-7.274421616144317,Pralatrexate,Dihydrofolate Reductase (DHFR) Inhibitors,NCGC00263110-02,CN(C(C)=O)C1(CCN(CCC[C@@]2(CCCN(C2)C(=O)C3=CC=CC=C3)C4=CC=C(Cl)C(Cl)=C4)CC1)C5=CC=CC=C5,-7.031605787340429,Osanetant,Tachykinin NK3 Antagonist,1.00438,0
NCGC00345809-03,CC(C)C1=NN(C2=C1C(=O)NC(CC3=CC=C(OCCO)C=C3)=N2)C4=C(Cl)C=CC=C4Cl,-7.18160253455865,RGB-286147,CDK1/2/3/7/9 Inhibitor,NCGC00263110-02,CN(C(C)=O)C1(CCN(CCC[C@@]2(CCCN(C2)C(=O)C3=CC=CC=C3)C4=CC=C(Cl)C(Cl)=C4)CC1)C5=CC=CC=C5,-7.031605787340429,Osanetant,Tachykinin NK3 Antagonist,1.008985,0
NCGC00345782-02,ClC1=CC=C(OCCCCCCN\C(NC2=CC=NC=C2)=N/C#N)C=C1,-8.331614083309999,GMX-1778,IKK beta Inhibitor,NCGC00263110-02,CN(C(C)=O)C1(CCN(CCC[C@@]2(CCCN(C2)C(=O)C3=CC=CC=C3)C4=CC=C(Cl)C(Cl)=C4)CC1)C5=CC=CC=C5,-7.031605787340429,Osanetant,Tachykinin NK3 Antagonist,0.8008299999999999,1
NCGC00346644-04,O=C(CC1=CC=C(C=N1)C2=CC=C(OCCN3CCOCC3)C=C2)NCC4=CC=CC=C4,-7.43161051350816,KX-01,Src Kinase Inhibitor,NCGC00263110-02,CN(C(C)=O)C1(CCN(CCC[C@@]2(CCCN(C2)C(=O)C3=CC=CC=C3)C4=CC=C(Cl)C(Cl)=C4)CC1)C5=CC=CC=C5,-7.031605787340429,Osanetant,Tachykinin NK3 Antagonist,0.9575549999999999,0
NCGC00346962-02,CN1C=C(C=N1)C2=CC=C3N=CC4=C(N(C(=O)C=C4)C5=CC6=C(CCN6C(=O)C=C)C=C5)C3=C2,-6.031605320261941,HMSL10077,BTK Inhibitor,NCGC00263110-02,CN(C(C)=O)C1(CCN(CCC[C@@]2(CCCN(C2)C(=O)C3=CC=CC=C3)C4=CC=C(Cl)C(Cl)=C4)CC1)C5=CC=CC=C5,-7.031605787340429,Osanetant,Tachykinin NK3 Antagonist,0.96069,0
NCGC00346656-03,CCC1=C2N=C(C=C(NCC3=CC=C[N+]([O-])=C3)N2N=C1)N4CCCC[C@H]4CCO,-7.18160253455865,Dinaciclib (SCH727965),CDK1/2/5/9 Inhibitor,NCGC00263110-02,CN(C(C)=O)C1(CCN(CCC[C@@]2(CCCN(C2)C(=O)C3=CC=CC=C3)C4=CC=C(Cl)C(Cl)=C4)CC1)C5=CC=CC=C5,-7.031605787340429,Osanetant,Tachykinin NK3 Antagonist,0.93318,1
NCGC00263183-11,CN1CCN(CC1)C2=CC=C(NC3=NC=C4C(=O)N(CC=C)N(C4=N3)C5=CC=CC(=N5)C(C)(C)O)C=C2,-5.881605633370822,MK-1775,Wee1 Kinase Inhibitor,NCGC00263110-02,CN(C(C)=O)C1(CCN(CCC[C@@]2(CCCN(C2)C(=O)C3=CC=CC=C3)C4=CC=C(Cl)C(Cl)=C4)CC1)C5=CC=CC=C5,-7.031605787340429,Osanetant,Tachykinin NK3 Antagonist,0.96299,0
NCGC00263117-17,CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C3=CC=CC=C3N1,-6.231605379060391,Panobinostat,HDAC Inhibitor,NCGC00263110-02,CN(C(C)=O)C1(CCN(CCC[C@@]2(CCCN(C2)C(=O)C3=CC=CC=C3)C4=CC=C(Cl)C(Cl)=C4)CC1)C5=CC=CC=C5,-7.031605787340429,Osanetant,Tachykinin NK3 Antagonist,0.92793,1
NCGC00346951-03,O=C1C2=CC=CC=C2[N+]3=C1C4=C(C=C3)C5=CC=CC=C5N4,-5.931605578511759,Fascaplysin,CDK4/6 Inhibitor,NCGC00263110-02,CN(C(C)=O)C1(CCN(CCC[C@@]2(CCCN(C2)C(=O)C3=CC=CC=C3)C4=CC=C(Cl)C(Cl)=C4)CC1)C5=CC=CC=C5,-7.031605787340429,Osanetant,Tachykinin NK3 Antagonist,0.951675,0
NCGC00345799-07,COC[C@H](NC(=O)[C@H](COC)NC(=O)C1=CN=C(C)S1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)[C@@]3(C)CO3,-6.8316056515638195,Oprozomib,Proteasome Inhibitor,NCGC00263110-02,CN(C(C)=O)C1(CCN(CCC[C@@]2(CCCN(C2)C(=O)C3=CC=CC=C3)C4=CC=C(Cl)C(Cl)=C4)CC1)C5=CC=CC=C5,-7.031605787340429,Osanetant,Tachykinin NK3 Antagonist,0.88196,1
NCGC00263222-02,CC1(C)OC2=C([C@H](NCC3=CC=CC=C3)[C@@H]1O)C(=O)C4=CC=CC=C4C2=O,-5.481605573349707,CAY-10581,IDO Inhibitor,NCGC00263110-02,CN(C(C)=O)C1(CCN(CCC[C@@]2(CCCN(C2)C(=O)C3=CC=CC=C3)C4=CC=C(Cl)C(Cl)=C4)CC1)C5=CC=CC=C5,-7.031605787340429,Osanetant,Tachykinin NK3 Antagonist,1.027625,0
NCGC00347952-11,C\C(=N/NC(=S)N1CCC1)C2=NC=CC=C2,-8.731656086048936,NSC-319726,Mutant p53 Activator,NCGC00263110-02,CN(C(C)=O)C1(CCN(CCC[C@@]2(CCCN(C2)C(=O)C3=CC=CC=C3)C4=CC=C(Cl)C(Cl)=C4)CC1)C5=CC=CC=C5,-7.031605787340429,Osanetant,Tachykinin NK3 Antagonist,0.9026449999999999,1
NCGC00346535-01,COC1=CC=C(C=C1)[S+]([O-])(=O)N(C(C)=O)C2=C(\C=C\C3=CC=N(=O)C=C3)C=CC=C2,-6.081605805570835,IVX-214,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00263110-02,CN(C(C)=O)C1(CCN(CCC[C@@]2(CCCN(C2)C(=O)C3=CC=CC=C3)C4=CC=C(Cl)C(Cl)=C4)CC1)C5=CC=CC=C5,-7.031605787340429,Osanetant,Tachykinin NK3 Antagonist,0.9944000000000001,0
NCGC00345825-01,FC(F)C1=NN(C(=C1)C2=CN=C(NC(=O)C3CC3)S2)C4=C(Cl)C=CC=C4Cl,-5.931605578511759,BMS-3,LIMK Inhibitor,NCGC00263110-02,CN(C(C)=O)C1(CCN(CCC[C@@]2(CCCN(C2)C(=O)C3=CC=CC=C3)C4=CC=C(Cl)C(Cl)=C4)CC1)C5=CC=CC=C5,-7.031605787340429,Osanetant,Tachykinin NK3 Antagonist,0.9924649999999999,0
NCGC00345852-02,CC(C)C1=C2N=C(N[C@@H](CO)[C@H](O)CO)C=C(NCC3=CC=CC=C3)N2N=C1,-6.231605379060391,BS-194,CDK1/2/5/9 Inhibitor,NCGC00263110-02,CN(C(C)=O)C1(CCN(CCC[C@@]2(CCCN(C2)C(=O)C3=CC=CC=C3)C4=CC=C(Cl)C(Cl)=C4)CC1)C5=CC=CC=C5,-7.031605787340429,Osanetant,Tachykinin NK3 Antagonist,0.9897499999999999,0
NCGC00345823-01,CC(C)(N)C1=CC=C(C=C1)C2=NC3=C(C=CC=C3)N=C2C4=CC=CC=C4,-6.531605402012491,"Akt-I-1,2",AKT Inhibitor,NCGC00263110-02,CN(C(C)=O)C1(CCN(CCC[C@@]2(CCCN(C2)C(=O)C3=CC=CC=C3)C4=CC=C(Cl)C(Cl)=C4)CC1)C5=CC=CC=C5,-7.031605787340429,Osanetant,Tachykinin NK3 Antagonist,0.978005,0
NCGC00346969-01,CCOC(=O)N1CCN(CC1)[N+](\[O-])=N\OC2=CC=C(C=C2C#N)[N+]([O-])=O,-5.981605362312015,JS-59-4,nitric oxide donors,NCGC00263110-02,CN(C(C)=O)C1(CCN(CCC[C@@]2(CCCN(C2)C(=O)C3=CC=CC=C3)C4=CC=C(Cl)C(Cl)=C4)CC1)C5=CC=CC=C5,-7.031605787340429,Osanetant,Tachykinin NK3 Antagonist,0.965565,0
NCGC00346449-01,ClC1=CC=C(CCCOC2=NNC(=O)C(Br)=C2NCC3=CN=CC=C3)C=C1,-6.231605379060391,Parogrelil,Phosphodiesterase III/Va (PDE) Inhibitor,NCGC00263110-02,CN(C(C)=O)C1(CCN(CCC[C@@]2(CCCN(C2)C(=O)C3=CC=CC=C3)C4=CC=C(Cl)C(Cl)=C4)CC1)C5=CC=CC=C5,-7.031605787340429,Osanetant,Tachykinin NK3 Antagonist,0.977535,0
NCGC00263112-06,C[C@@H](OC1=C(SC(=C1)N2C=NC3=C2C=C(CN4CCN(C)CC4)C=C3)C(N)=O)C5=CC=CC=C5C(F)(F)F,-7.281606275378642,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00263110-02,CN(C(C)=O)C1(CCN(CCC[C@@]2(CCCN(C2)C(=O)C3=CC=CC=C3)C4=CC=C(Cl)C(Cl)=C4)CC1)C5=CC=CC=C5,-7.031605787340429,Osanetant,Tachykinin NK3 Antagonist,1.12517,0
